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1 Abstract 
Introduction: Cardiac disease is a major cause of morbidity and mortality worldwide and 
therapeutic advances continue to be made. Improved accuracy of diagnosis and risk 
stratification is therefore important. Advanced imaging using contrast enhanced magnetic 
imaging ( ceMRI) is under investigation for assessment of myocardial necrosis in both acute 
and chronic settings due to ischaemic and non -ischaemic aetiologies. Consecutive patients with 
an incident episode of chest pain necessitating hospital admission were recruited and 
underwent ceMRI. CeMRI was considered the gold standard for determining presence of 
ischaemic myocardial necrosis and used to evaluate current ECG guidelines in acute chest pain 
syndromes. ST segment elevation on the presenting ECG determines the acute reperfusion 
strategy but will not detect all infarcts and additional consideration of ST depression termed, 
"STEMI equivalent" may reduce the burden of missed AMI. Infarct size (IS) was measured by 
manual planimetry of regions of delayed hyperenhancement (DE) and then correlated with 
routinely available biochemical and bioelectrical markers. The evolution of infarct size and 
characteristics were then followed using at ceMRI at 4 time points out to 1 year. The role of 
inflammation in MI using CRP as the marker was also investigated. Finally, additional clinical 




Coronary heart disease is a major cause of morbidity and mortality in the Western world with 
Scotland, Glasgow in particular, near the top of the MONICA league tables (1). The ultimate 
consequence of coronary heart disease is myocardial infarction so it is important to make an 
accurate diagnosis for physical, psychological and social reasons. Diagnostic criteria have been 
evolving since the World Health Organisation published the first guidelines in 1994 (2). These 
relied on the patient meeting two out of three from: typical chest pain; typical appearances on 
the 12 -lead ECG; and a rise and fall of cardiac biomarkers. The introduction of assays to 
measure serum troponin meant that it assumed a central role when the joint European Society 
and American College of Cardiology published updated guidelines in 2000 (3) almost rendering 
the ECG and patient symptoms superfluous. By the time of discharge most patients admitted 
with chest pain will have a clear diagnosis using these basic tools. There a number of patients 
that would benefit from a more comprehensive examination of left ventricular function, infarct 
size and infarct characteristics. 
An accurate, reproducible and safe method that would perform all these tasks at a single time 
point is desirable. Advanced imaging is therefore under investigation to improve the diagnosis 
of ischaemic heart disease at all stages of disease progression, but the first priority must be 
once it has become manifest. Contrast enhanced cardiac Magnetic Resonance Imaging 
(ceMRI) is non invasive and uses no radiation making it a very safe procedure to perform. 
CeMRI provides three dimensional cinematographic images allowing accurate and 
reproducible assessment of left ventricular mass, function and volumes. The addition of 
contrast agents such as Gadolinium -DTPA (Gd- DT PA) enables direct identification of 
-6- 
irreversible ischaemic injury. It is therefore possible to determine infarct size, location, 
transmurality and endocardial extent. It is also possible to visualise infarct characteristics, such 
as the presence of microvascular obstruction, that are associated with additional adverse 
prognosis. ceMRI seems likely to become the gold standard reference imaging modality for 
myocardial infarction size but further work is still required. The ceMRI set up and running 
costs are high and it is not yet readily available in all hospitals so any additional roles it may 
play in Acute Coronary Syndromes (ACS) still require to be validated. 
The hypothesis of this thesis is that quantitative and qualitative electrocardiographic and 
biochemical markers of myocardial necrosis, inflammation and remodelling in patients 
following their first myocardial infarction will correlate with infarct size as measured by ceMRI. 
In addition, ceMRI may provide information on those patients admitted with a chest pain 




Every year in the United Kingdom, around one million patients are admitted to hospital as an 
emergency with a chest pain syndrome. In 2004 the diagnosis of acute myocardial infarction 
(AMI) was made in 230 000 patients. The mortality from coronary heart disease was 105 000 
accounting for 21% of male and 15% of female deaths. In 2006 the total annual cost to the 
UK economy of coronary heart disease was £7900 million, £3500 million was attributable to 
hospital care and £4400 million to work days lost and informal care (4). 
Coronary heart disease forms a major part of the work of NHS Scotland accounting for 4% of 
all hospital discharges. For the year ending March 31st 2006 there were 48 962 hospital 
discharges for coronary heart disease, 16 320 of whom were diagnosed with acute myocardial 
infarction. 
Within the greater Glasgow Health Board area, for the 2 years that covered this study's 
recruitment period (2002 and 2003), the crude annual rate for AMI per 100 000 population 
was 276.8 and 273.1 respectively (5). Patients enrolled in this study were recruited from the 
population of 1278 patients admitted to the Western Infirmary, Glasgow to rule out AMI 
between August 2002 and May 2003. Five hundred and nineteen (41 %) had a discharge 
diagnosis of ACS. 
Patients are encouraged to attend hospital as an emergency if they experience chest pain of 
greater than 20 minutes duration. Not all patients have typical symptoms; some have none that 
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can be recognised as indicative of ischaemic heart disease. It is important to achieve a rapid 
and accurate diagnosis regarding AMI in patients with suggestive symptoms so that prompt 
reperfusion therapy may be administered. Cardiac biomarkers such as troponin are sensitive 
but the infarct process is near completion by the time they are available. The initial ECG is 
therefore the cornerstone of determining the initial management. Those patients with ST 
elevation (STEMI) will receive prompt reperfusion therapy with either thrombolysis (the 
primary method in this study) or percutaneous intervention (PCI). The remaining patients 
(Non -STEMI) may not. 
The aim of acute reperfusion therapy is to restore blood flow through an open epicardial artery 
and to limit final infarct size. However, it is well recognised that an open artery does not 
necessarily equate to perfusion at the tissue level due to microvascular obstruction (MVO) (6- 
8). In addition, any area that is reperfused will include both infarcted and stunned myocardium, 
so reperfusion itself can adversely affect infarct size. Final infarct size is determined by a 
number of factors including the amount of tissue perfused by the occluded artery, the duration 
of occlusion, quality of reperfusion, perfusion by collaterals, and ischaemic preconditioning. 
It is of clinical importance to make an accurate estimate of infarct size in vivo as the extent of 
damage is closely related to a patient's prognosis (9 -11). Knowledge of infarct size will improve 
risk assessment and guidance of future management. It also serves as an end point in the 
evaluation of current and future reperfusion therapies. The evolution of the myocardial scar 
with time may also be of clinical importance. Infarct healing is an ongoing process with initial 
infarct expansion due to oedema and haemorrhage followed by resorption and collagen 
formation. To be able to document the natural history of infarct healing will be of benefit in 
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future therapeutic trials such as rebuilding myocardial tissue at the infarct site using stem cell 
therapy. 
The current estimates of infarct size are limited to cardiac biomarkers, the ECG and 
echocardiography in clinical practice. 
The initial and most validated biomarker was the cytoplasmic enzyme creatine kinase (CK) 
(12;13). It's release is affected by reperfusion, requires serial measurements and lacks 
cardiospecificity although the latter was improved by the MB fraction (CK -MB) (14). CK has 
largely been superseded by measurement of troponins (T and I), the structural protein of the 
myofilament exclusively expressed in cardiomyocytes. The release ratio of troponin is unclear 
and values remain elevated for up to two weeks. Previous correlations with infarct size have 
shown it to be superior to CK or CKMB (15;16). 
The standard 12 lead ECG is widely available and has been used for many decades as a guide 
to the extent of threatened or damaged myocardium in acute and chronic myocardial 
infarction. Selvester et al (17) developed a 31 point quantitative QRS scoring system to be 
applied to the standard 12 lead ECG for the estimation of MI size and location. This score was 
devised in the pre reperfusion era of the early 1980s using autopsy samples. It is testament to 
the score that it has only undergone minor adjustments since, although validation has so far 
been limited to comparison with indirect measurements (18 -20) in vivo or histopathology ex 
vivo(21;22). 
Trans thoracic echocardiography (TTE) is able to assess global and regional wall function but 
these measurements of infarct size are indirect and influenced by image quality, the presence of 
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arrhythmias, cardiomyopathies, valvular heart disease and ventricular loading conditions (23). 
TTE can also overlook small subendocardial infarcts and its sensitivity is reduced in the acute 
setting due to stunning or hibernation. There will be no formal comparisons made between 
TTE and ceMRI in this study. 
Gibbons et al in 2004 reviewed the potential value of many clinical methods for 
"quantification of infarct size "; and concluded that "on the basis of existing evidence single 
photon emission computed tomography (SPECT) sestamibi imaging is currently the best 
technique available to meet this challenge" (24). A number of animal and clinical studies have 
been conducted using SPECT. The technique is well validated in the determination of final 
infarct size (25 -28) and there is comparability between multiple centres(29) but it is not 
routinely used acutely in the UK. SPECT has the major disadvantage that radiation is required. 
CeMRI, as a contender to the status of new gold standard has been compared with SPECT 
imaging (30 -32). The main conclusions are that ceMRI and SPECT are equivalent for infarct 
size quantification but that ceMRI has additional advantages in spatial resolution and lack of 
radiation. CeMRI provides the first clinical method to directly image the infarcted myocardium 
(33) making it possible to comment on certain characteristics of the infarct. 
A systemic inflammatory response has been demonstrated across the spectrum of ACS and C 
Reactive Protein (CRP) is the most widely studied and readily available marker. The source of 
CRP is not clear and it is uncertain whether CRP is the cart, the horse or both in AMI (34). 
CRP has been implicated in microvascular obstruction (35), so may have the ability to 
differentiate infarct characteristics that would provide an explanation for its additional 
prognostic information. 
Several matrix metalloproteinases are expressed in the myocardium and may play a role in 
pathogenesis of LV remodelling after AMI by degrading myocardial collagen. MMP -1 
transcription is increased post AMI which may be due to a functionally specific polymorphism 
in the promoter sequence. It would be possible to measure the phenotype using ceMRI due to 
its accuracy and reproducibility at measuring LV dimensions. 
By the time of discharge most patients will have a correct diagnosis of AMI or unstable angina 
and the subsequent management plan is dependent on a sound assessment of the patient's 
prognosis (36). The label of myocardial infarction has been redefined since the introduction of 
troponin (37) but this only provides information on at most a 2 week window. Missing the 
diagnosis of current (or prior) MI deprives patients of the proven benefits of secondary 
prevention medical therapy, let alone revascularisation. On the other hand, a mis- diagnosis of 
MI will have implications including lifelong drug treatment and raised insurance premiums. 
Women in particular present with atypical symptoms of AMI and would be more likely to be 
unrecognised than in men (38;39). It has been shown that, by the presence of pathological Q 
waves, up to 25% of myocardial infarctions are silent (40) and that the true prevalence may be 
even higher due to its insensivity (41). 
Acute coronary occlusion is not the sole cause of myocyte necrosis and there are other acute 
medical disorders that are associated with a positive troponin. In many patients the diagnosis is 
clear from the routine clinical history and investigations performed in the acute medical ward. 
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Not all patients are discharged with a clear diagnosis and, "chest pain, unknown cause" is the 
label often (mis)used. 
CeMRI is an advanced imaging tool that can be used to accurately measure LV dimensions and 
to diagnose, quantify and characterise myocardial infarction both on admission and on serial 
examinations. This allows novel markers of remodelling to be assessed and comparisons to be 
made with the current biochemical and bioelectrical measures of infarct presence and size. It 
will enable investigation into the relationship of CRP to infarct size and microvascular 
obstruction. Finally, for those patients admitted with chest pain who do not meet the current 
criteria for AMI, ceMRI will describe the myocardial structure and function in more detail that 
may provide additional diagnostic information. 
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3.2 Contrast enhanced cardiac Magnetic Resonance Imaging in 
acute and chronic myocardial infarction 
Cardiac magnetic resonance imaging allows accurate and reproducible three dimensional 
quantification of cardiac structure and function, in particular the left ventricle (LV) (42). With 
the addition of the extracellular contrast agent Gadolinium diethylenetriamine pentaacetic acid 
(Gd- DTPA), direct visualisation of myocardial damage with high spatial resolution is possible 
as delayed hyperenhancement (DE). CeMRI therefore provides a unique gold standard for 
evaluation of more universally available diagnostic methods (43). 
LV mass and function 
CeMRI offers accurate and reproducible measurements of the routine parameters of global 
cardiac function with several advantages over TTE. There is excellent delineation of both 
endocardial and epicardial borders and a user defined choice of imaging plane. A three 
dimensional cinematographic image of the LV for measurement comprises a stack of short 
axis (SA) slices so no geometrical assumptions are required. There are analysable images in the 
vast majority of patients, which compares favourably to TTE where up to 30% of images are 
of too poor quality to measure LV function and dimensions objectively. The standard global 
measurements are: LV ejection fraction (LVEF), LV end diastolic volume (LVEDV), LV end 
systolic volume (LVSEV) and LV mass (LVM). LVEF is the universal parameter for LV 
performance and is a function of the dimensions LVEDV and LVESV whose change over 
time have prognostic significance, a process known as remodelling. 
Other measurements that would be possible using the dataset acquired include diastolic 
function, myocardial viability and RV structure and function. Due to the additional time and 
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software required this information will not form part of the thesis. The raw data is available 
and could still be analysed for future studies. 
Stress ceMRI was not performed in the Glasgow Cardiac Magnetic Resonance Unit (GCMRU) 
at the time of this study so there will be no data on this. It will be possible to provide resting 
viability information on these patients at a later date but no such data on will be presented in 
this thesis. 
In summary the global LV structure and function was measured in all patients at all visits. The 
global LV function is part of a routine ceMRI scan and forms part of the secondary analysis in 
this study. 
Contrast enhanced cardiac magnetic resonance imaging 
To achieve image contrast in ceMRI, T1 weighted images were used to show the difference in 
longitudinal relaxation times between adjacent pixels. The contrast agents used work by 
shortening the T1 relaxation time in the contrast -rich tissue so the measured signal after the 
second radiofrequency pulse is greater than that of the contrast -poor tissue. Using gadolinium 
based contrast agents and ECG gated spin echo sequences, it was noticed that the image 
intensity of myocardial infarction was particularly strong (hyperenhanced or bright white) 
when obtained >10 minutes after injection. There was a major problem with image quality 
because only one line of k space was filled per cardiac cycle. Each scan had a very long 
acquisition time (minutes) leading to respiratory motion artifacts. 
There were two breakthroughs in the 1990's. The first was the ability to use segmented k space 
so that multiple lines could be acquired during each cardiac cycle thereby greatly reducing the 
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imaging time (44). The entire image could now be acquired in around 10 seconds or a single 
breath -hold. The second innovation was the use of an inversion recovery pre -pulse which 
increased the T1 weighting of images even further (45). For infarct imaging, the inversion time 
is set to null (black) normal myocardium thus further improving the differential by a factor of 
up to 500 %. Waiting for 20 -40 minutes after the injection of contrast and visualising infarction 
as a bright white area gave rise to the term delayed hyperenhancement (DE) which has 
emerged as a new reference method for infarct characterisation in vivo (46 -50). 
The area of DE accurately depicts infarction in animal models by comparison with 
triphenyltetrazolium chloride (TTC) stained gross histological slices of the heart, but no such 
studies have been performed in humans (51 -54). Research in humans revealed that the 
transmural extent of hyperenhanced myocardium correlates with the probability, magnitude 
and timing of functional recovery after reperfusion in acute MI and chronic ischemic heart 
disease (48;55). 
The mechanism for the different Gd -DTPA wash -in /wash -out profiles of necrotic and viable 
myocardium is under ongoing investigation. Current theories include: an increased distribution 
volume in the area of necrosis caused by loss of myocyte integrity and oedema in AMI; and 
scar tissue replacement in chronic MI (33;56 -61). By using the ceMRI technique early after 
AMI the region of DE had been thought to overestimate the actual MI size because of the 
increased distribution volume of contrast due to acute oedema in the peri infarction zone (62). 
Detailed histological studies have since confirmed that the presence of hyperenhancement is 
strongly associated with infarct size by TTC staining in both acute and chronic infarcts (63). 
Pathologically, the initial infarct expansion during week 1 is due to oedema and haemorrhage 
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within the infarct zone followed by resorption up to 28 days and collagen formation until 6 
months. To be able to document the natural history of infarct healing in vivo will be of benefit 
as an end point in future therapeutic trials that aim to influence infarct sizes. Serial ceMRI was 
performed on patients with first presentation of AMI at 4 time points associated with the 
major histopathological landmarks to determine the absolute and rate of change in infarct size 
and morphology. 
Myocardial infarct characteristics 
It is not only possible to determine infarct size but qualitative information is available on 
different characteristics that have also been shown to influence prognosis (64 -67). These 
characteristics include infarct location, transmurality and MVO (31;68;69). 
(i) Location 
The definition of infarct location was standardised in 2002 and the guidelines were released as 
a Scientific Statement by the American Heart Association (70). The aim was to use precise 
anatomic landmarks to divide the LV into segments that would correspond to standard 
coronary artery territories. There are 17 segments in this model and the 3 vessel territories are: 
left anterior descending artery (LAD), left circumflex artery (LCx) and right coronary artery 
(RCA). 
(ii) Transmurality 
As a consequence of the high spatial resolution of ceMRT images it is possible to detect 
infarcts that are <1% total LV mass meaning that the transmural extent can be expressed as a 
proportion of myocardial wall thickness (43;60). This is a major advantage over SPECT 
imaging that can miss subendocardial infarcts (71). It allows differentiation between ischaemic 
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(involving the subendocardium) and non ischaemic (sparing the subendocardium) patterns of 
myocyte necrosis (72). The presence of DE is not specific to myocardial infarction; but when 
infarction is the cause, there is always involvement of the subendocardial layer. When there is 
DE that does not involve the subendocardium then different non ischaemic aetiologies have 
to be considered such as myocarditis, sarcoidosis, cardiomyopathy and iatrogenic scars. 
There has been much debate about what constitutes a transmural infarct. Myocardial infarcts 
are a complex shape and within the same infarct there will be varying degrees of transmurality 
rendering the binary allocation over simplistic. The degree of transmurality has been shown to 
be inversely proportional to recovery of segmental function. The best recovery of global 
function was in those patients with no infarct or <259/e transmurality and over 90% of akinetic 
or dyskinetic segments have a transmurality score of >50% (73 -75). There are many ways of 
scoring transmurality and with continued improvement in post processing software including 
automated programmes any degree of precision is possible once the endocardial and epicardial 
contours have been delineated. At the time of this study it was only possible to visually score 
the extent of transmurality and good agreement has been shown with automated systems (74). 
Thus assessment of degree of transmurality and recognition of a subendocardial sparing 
pattern of DE is important in future clinical decision making. 
(ill) Endocardial extent 
It had not been possible to measure endocardial extent with any accuracy in vivo until the 
development of ceMRI. Myocardial infarct size is a function of its transmurality and 
endocardial extent so one should not be considered without the other. Endocardial extent has 
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been shown to be more predictive of pathological Q waves than transmural extent in a small 
study of first time reperfused myocardial infarcts using ceMRT (76). 
(iv) Micro vascular obstruction 
MVO leads to inadequate myocardial tissue perfusion in an area subtended by an 
angiographically open coronary artery (6;8). MVO can occur in over 30% of patients after 
acute reperfusion therapy for AMI and is associated with poor functional and clinical 
outcomes when compared to patients with reflow post reperfusion (77;78). MVO arises due to 
platelet microembolism, thrombosis, neutrophil plugging, free radical release, endothelial 
dysfunction and microvascular constriction (79 -83). The white cell count is an independent 
risk factor for, and correlates with extent of, coronary disease and the risk of reinfarction (84- 
86). 
Lima et al. noticed that during ceMRI there was often a region of hypoenhancement at the 
core of the hyperenhancement which they described as regional heterogeneity (87). Some basic 
animal research has confirmed that these areas of hypoenhancement represent MVO by 
showing negative staining for thioflavin -S in histological photography under ultra violet light 
(54). MVO seen <5 minutes following GdDTPA injection shall be termed "early MVO" and 
has been shown to be associated with an adverse prognosis and reduced late functional 
recovery (65;88). By considering the images as part of the delayed enhancement (DE) protocol 
an improved distinction between hypo- and hyper- enhanced areas is achieved and will 
delineate areas with more profound microvascular damage, termed "late MVO" (67). Late 
MVO has been shown to be a more powerful predictor of major adverse clinical events than 
LV ejection fraction, infarct size and end diastolic volume (67). 
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MVO by ceMRI correlates with both standard measures of infarct size (CK) and inflammatory 
status as assessed by leucocytes and CRP in patients with STEMI treated with primary PCI 
(89). In the current study NSTEMI patients are also included and the primary acute 
reperfusion therapy was thrombolysis. Both early and late MVO are considered. 
There is no doubt that MVO is a major hindrance to the success of reperfusion and specific 
therapies are limited. There is evidence for a central role of inflammation in ACS so the 
interactions between MVO and inflammation, infarct size and infarct healing were studied. 
The incidence, natural history and interactions of both early and late MVO identified by 
ceMRI are also described. 
(y) CeMRllimitations 
There are a number of limitations to the routine performance of ceMRI in all patients admitted 
with acute chest pain to rule out myocardial infarction in addition to the cost and limited 
portability. The absolute contraindications to ceMRI scanning are covered in 
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MRI safety Questionnaire, 12.4. The patient factors include claustrophobia, which accounted 
for 5.7% of patients eligible for this study, and inability to lie flat for the scan duration (mean 
40 minutes). Image quality is strongly affected by patient movement so their cooperation is 
required and they must be able to hold their breath for approximately 10 seconds. Images for 
DE are acquired during diastole, triggered by the ECG and reliant on a regular R -R interval so 
dysrhythmias including atrial fibrillation can affect image quality. The protocol for acquisition 
of images is standardised but significant adjustments are required to be made by the operator. 
The scans for this study were performed by one of 3 operators (TNM, TS, BAG) with 9 
months of full time training prior to the first patient scan. A major limitation of ceMRI at the 
time of the study was the ability to determine the age of the myocardial damage although there 
have since been some promising studies in the use of T2- weighted imaging (90). 
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3.3 ST segment deviation and QRS complex patterns on the 
ECG in acute myocardial infarction 
This section describes the current use of the ST segment on the admission ECG in the triage 
of patients with chest pain. The Selvester score utilising the QRS complex is described in the 
estimation of infarct size and previous studies using ceMRI are reviewed. 
The admission ECG, particularly ST segment deviation, is used in the triage of patients but is 
only a snap shot of a short period of time. It is generally the gatekeeper to reperfusion therapy 
and Coronary Care Units, but up to 28% of patients with normal admission ECG are 
subsequently ruled in for MI (91). Missing the diagnosis of AMI on admission doubles the risk 
adjusted mortality and the ten year mortality from unrecognised MI has been estimated to be 
45 to 55% (92;93). 
Clinical decisions for initiating reperfusion therapy are typically based on criteria developed in 
the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
Arteries (GUSTO) series of trials (94). Slightly revised criteria have since been introduced by 
the American College of Cardiology and European Society of Cardiology (ACC /ESC) joint 
committee (95). It is well recognised that the sensitivities of these sets of ECG criteria are 
suboptimal (96;97) An example of this deficiency is the routine under detection of acute 
posterolateral myocardial infarction that is the typical result of occlusion of the left circumflex 
coronary artery (LCx) (98). The adverse risk associated with non -ST segment elevation 
myocardial infarction (NSTEMI) is well documented (99), but many trials have failed to 
demonstrate the benefits of thrombolysis on the basis of alternative non -ST segment elevation 
criteria (100 -103). With the emergence of more targeted treatments whose benefits remain 
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time dependent, such as percutaneous coronary intervention, the role of the admission ECG 
as a triage tool is increased. 
Acute transmural ischemia caused by occlusion of a major coronary artery produces an 
epicardial injury current that can be detected as a deviation of the ST- segment toward the 
involved myocardial region(104). This deviation is ST segment elevation when a region is 
"viewed" by the positive pole of an ECG lead but ST- segment depression when "viewed" by 
the negative pole. Acute occlusion of the left anterior descending (LAD) or the right coronary 
artery (RCA) therefore typically causes ST- segment elevation in chest leads V1 to V4 or in limb 
leads II, aVF, and III, respectively, and therefore the resulting myocardial infarcts are termed 
STEMI. However, acute occlusion of the non dominant LCx typically produces only ST- 
segment depression in the 12 standard ECG leads, and therefore, the resulting myocardial 
infarcts could be termed "STEMI equivalent" (105). This ST- segment depression in the 
standard leads would appear as ST- segment elevation in the negative counterparts of these 
leads (97;106) Figure 3 -1. 
Whilst ST segment deviation is useful in the acute setting and has been used to predict 
myocardium at risk (107) it is the QRS segment that provides information on the final infarct 
size. An area of myocardial infarction results in loss of local electrical sources resulting in a 
reduction in the QRS and STT potentials for that area. Therefore the ECG has the ability to 
identify, localise and quantify this important event. The amplitude and duration of these 
deformities in ECG leads perpendicular to the pre -existing local electrical fields are 
proportional to the amount of myocardium removed by the infarction. In order to use this 
information to determine infarct size the eponymous scoring system derived by Ronald 
- 23 - 
Figure 3 -1: ECG recording from a patient during balloon inflation in the LCx with ST 
depression in V1 - V5 appearing as elevation in the negative counterparts 
Selvester (108 -112). This was validated by histopathology for different MI locations in the 
chronic phase of infarction prior to the reperfusion era. The Selvester QRS scoring system is 
weighted and considers not only Q waves but also other infarct related deformities in the QRS 
complex such as changes in the R wave and S wave amplitudes and durations. The ratios of 
R:Q and R:S are also considered Appendix 12.1 Selvester Score. Previous studies have 
documented the clinical use of the Selvester score in predicting prognosis(113). 
Further development of ECG criteria requires valid non -ECG methods to define the size of 
the initial myocardium at risk, the final infarct size and the function of the salvaged 
myocardium. Several studies have confirmed that the Q wave is a marker of infarct size rather 
that transmural extent using ceMRI as a gold standard (114). In the acute setting of reperfused 
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first time Ai\1I the global QRS score at one week has been shown to correlate with MI size, MI 
transmurality and MI endocardial extent (76;115). The Selvester QRS scoring system has been 
validated in chronic anterior myocardial infarctions using a ceMRI gold standard and the 
correlation is particularly strong in the mid ventricular segments (116). 
The concept of ceMRI as a gold standard in the validation of ECG scoring systems is relatively 
unique. Based on the data from this thesis a group was set up in conjunction with Duke 
University ECG core lab in 2002 to examine the issues of Magnetic And eLectrical 
Technologies (MALT). Some of the initial findings are presented here. The priority issue that 
has been uncovered is that images produced using ceMRI to determine infarct size will have to 
undergo a rigorous process of validation to ensure global agreement regarding the image 
acquisition and post processing. A similar situation that automated ECG analysis was at 30 
years ago and addressed by the Common Standards for quantitative Electrocardiography 
(CSE) (117). Ultimately, rather than validation of ECG scoring systems, the role of ceMRI will 
be to revise ECG criteria. 
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3.4 Cardiac biomarkers in acute myocardial infarction 
This section describes the evolution of biomarkers in assessment of myocardial infarct size 
from CK, CK -MB to TnI and previous studies using ceMRI are highlighted. The role of CRP 
in AMI is discussed and the potential contribution of ceMRI suggested. 
Creatine kinase 
Serum biomarkers were the first in vivo measures of infarct size and developed once it was 
realised that the evolution of myocardial infarction was dynamic and could be modified. The 
first to be used was creatine kinase (CK) and specificity was improved by measurement of the 
MB fraction (CK -MB). The release characteristics of these biomarkers were then studied to 
determine the optimal sampling time and frequency using a gold standard for infarct size. 
These gold standards lacked precision and included the ECG, LV ejection fraction, 
haemodynamics, arrhythmias and prognosis. In animal studies it was possible to make direct 
measurements at autopsy. Sampling methods used were total enzyme released, peak levels and 
area under the curve. This intensity is possible in animal studies and clinical trials but 
translation into clinical practice is difficult because of the time delays intrinsic to each patient's 
presentation and the impracticalities of frequent sampling. 
It was noted that the kinetics of release were altered by reperfusion. A greater peak and more 
rapid decline makes comparison of reperfused with non -reperfused infarcts problematic. 
Regardless of formal reperfusion status; there will be differences in many other aspects 
including spontaneous occlusion and reperfusion, subtotal occlusions, collateral flow, infarct 
haemorrhage, oedema and degree of ischaemic preconditioning. 
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Troponin 
Troponins (T or I) are very sensitive markers for the detection of myocvte necrosis and 
therefore AMI. With the publication of the ACC/ ESC guidelines in 2000, troponin 
measurement became central to the redefinition of myocardial infarction with less emphasis on 
corroborative evidence from the history and ECG (118;119). The measurement of serum 
troponin is now part of routine clinical practice in the diagnosis of patients with symptoms 
suggesting ACS. However, the infarction is in progress by the time the current routine 
biomarkers are detectable in venous blood and the non cardiac causes for troponin release are 
well documented. These include acute myocarditis and cardiomyopathies such as Takotsubo, 
pulmonary embolism, chronic renal failure and sepsis (120). Total troponin released would be 
the ideal marker for infarct size but is impractical as it remains elevated for up to 2 weeks, so 
fixed time points have been explored. There is an excellent correlation between troponin and 
infarct size by ceMRI and SPECT at 72 and 96 hours (15;16). The clinical reality is that 
patients will get a single troponin checked at between 8 and 12 hours enabling early risk 
stratification, for example to determine suitability for inpatient coronary angiography. It would 
therefore be more clinically relevant to study the association with infarct size at this single time 
point. 
Cardiac biomarkers are sensitive in the detection of acute myocardial necrosis but are not 
necessarily specific to ischaemic aetiology. Patients who are troponin positive have been 
observed to have minimal coronary artery disease at angiography (121 -123). There is debate 
whether this represents a "false positive" and speculation as to the potential coronary causes 
such as spasm or embolus. These patients have been shown to be at increased risk of death or 
MI, although the mechanism underlying this adverse outcome is unclear (124). The more likely 
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explanation is that troponin is not "false positive" for myocardial necrosis, rather not as 
specific for the aetiology of necrosis as was first thought. 
Since this study was initiated, both peak CK and troponin have been tested against ceMRI for 
assessment of infarct size (125). There is generally a good correlation with these biomarkers 
and reperfused infarcts. The correlation in non -reperfused infarcts is not as strong and in some 
cases does not reach significance. The additional information that will be provided in this study 
is the assessment of the clinically used troponin sampling point in those patients with single 
acute MI. The study population includes patients admitted with chest pain syndrome so 
additional information on the aetiology of troponin release was investigated. CeMRI can also 
detect episodes of previous myocardial damage that would be out-with the biomarker radar. In 
those patients with chest pain but a normal troponin ceMRI will provide information on 
previous "silent" ischaemic or non-ischaemic damage. 
C reactive protein 
Early in the atherogenesis process there is involvement of inflammatory cells such as 
leucocytes in response to triggers such as infection, injury and oxidised lipids. The migration of 
these inflammatory cells into the subendothelial space is induced by several adhesion 
molecules. Thus begins the formation of foam cells, fatty streaks and the atheromatous lesion 
with fibrous cap. Local smooth muscle cells in the artery wall continue to promote 
inflammation by triggering the release of cytokines (particularly IL -6), chemokines and growth 
factors. These have a local regulatory role but also induce the production of liver derived acute 
phase proteins such as CRP. CRP may then itself play an active role in atherogenesis by 
mediating LDL uptake by macrophages, stimulating monocyte release of cytokines, 
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modulating monocyte chemotactic protein -1 induction in endothelial cells and exerting a 
direct effect on endothelial cells to express adhesion molecules (126 -129). CRP is the most 
widely studied marker of inflammation and has been shown to provide independent 
prediction of cardiovascular risk for both primary and secondan, prevention (130 -133). 
CRP is also implicated in the ultimate stage of coronary atherosclerosis that is myocardial 
infarction. It has been shown to be elevated within 6 hours of onset of AMI and peaks at 50 
hours (134;135). A CRP measurement will provide information on cardiovascular risk (death, 
MI) early post MI (133;136), at 6 months using a cut off of 10mg /L (137) and at 5 years (138). 
In each of these studies CRP provided additive information to serum troponin. 
The exact source for CRP in ACS remains unclear and it seems likely that plaque rupture and 
myocyte necrosis are the main contributors. A CRP >3 mg /L is associated with a plaque 
rupture lesion and <3 mg /L with a plaque erosion lesion (139). In unstable angina an 
intracardiac inflammatory process appears to be the result of myocyte necrosis (140). CRP has 
been associated with infarct size when estimated using CK, CKMB and SPECT (141). An 
elevated CRP has been shown to predict infarct expansion and cardiac rupture in patients with 
their first Q wave myocardial infarction (136). Some models of reperfusion injury suggest that 
neutrophil accumulation plays a key role and in animal studies leukocyte depletion leads to a 
reduction in the no reflow phenomenon (142;143). More evidence is emerging that implicates 
CRP in MVO due to its effects on endothelial function, cell adhesiveness and cytokine release 
(144 -146). In a rat model Griselli et al. demonstrated that injection of human CRP is associated 
with increased infarct size (147). 
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3.5 Matrix metalloproteinase -1 and left ventricular remodelling 
post acute myocardial infarction 
Matrix metalloproteinases (MMPs) are a family of enzymes responsible for the degradation of 
the extracellular matrix. Several MMPs are expressed in human myocardium and play an 
important role in left ventricular (LV) remodelling after AMI (148;149). The principal structural 
protein in the human myocardium is type I collagen, with a lesser contribution from type III 
collagen (150). These fibrillar collagens can be degraded only by MMP -1 and membrane -type 
MMP -1, suggesting that these enzymes must play a pivotal role in LV remodelling. Supportive 
evidence for the importance of MMP -1 in this process comes from animal models and from 
human studies demonstrating increased myocardial enzyme and messenger ribonucleic acid 
expression and elevated circulating levels after AMI (150 -155). 
MMPs are regulated at 3 levels: gene transcription, the activation of latent enzymes, and 
inhibition by tissue inhibitors of metalloproteinases (148;156). For most MMPs (with the 
exception of MMP -2), transcription is the key regulatory step (156). This in turn is influenced 
by promoter sequences that exhibit deoxyribonucleic acid polymorphisms, some of which 
exert allele- specific effects on gene transcription. Functionally significant polymorphisms have 
been identified in the promoter sequence of MMP -1. Specifically, a guanine (G) addition, 
creating a GG allele, increases enzyme production (156;157). It was hypothesised that patients 
with the GG allele might be predisposed to increased remodelling after AMI. 
- 30 - 
3.6 Aims 
Bioelectrical markers 
To demonstrate that on the presenting ECG, the currently accepted GUSTO and ACC /ESC 
ST segment elevation criteria have high specificity but low sensitivity for the diagnosis of acute 
myocardial infarcts 
To investigate the diagnostic benefits of considering STEMI -equivalent ST- segment 
depression criteria. 
Biochemical markers 
To determine the incidence and extent of infarcts meeting ACC /ESC biochemical marker, i.e. 
troponin positive, criteria that are not detected by ceMRI and so define minimal myocyte 
necrosis. 
To describe the ceMRI findings in patients with positive troponin but negative coronary 
angiography. 
To assess the diagnostic ability of CRP in acute chest pain syndromes both linearly and using a 
cut off of 10 mg /L. 
To assess the correlation between CRP and infarct size by ceMRI in both reperfused and non- 
reperfused infarcts. 
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Infarct size 
To compare infarct size by CK, CKMB, TnI and Selvester score with ceMRI and to assess the 
relationship between the Selvester score, Tnl and ceMRI as measures of acute reperfused and 
non- reperfused infarct size. 
To investigate if there is an improved correlation with these same markers and final infarct size 
by ceMRI at a mean of 38 days. 
To investigate whether the combination of Selvester scores added to TnI will improve the 
correlation with acute infarct size by ceMRI. 
To document the change and rate of change in infarct size over a 1 year period by imaging at 
the routinely used follow up time points of 28 days, 6 months and 1 year. 
MVO 
To define early and late MVO and their incidences. 
To document the change and rate of change in early and late MVO and to examine their role 
in infarct healing. 
To assess the sensitivity and specificity of CRP in its ability to identify both early and late 
microvascular obstruction using the pre- specified cut off points of 3 and 10 mg /L and define a 
new cut off for the detection of early and late MVO. 
LV remodelling 
To document change and rate of change of LV dimensions over 1 year using the above time 
points. 
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To assess the relationship between matrix metalloproteinase -1 promoter genotypes and 
remodelling in patients after their first acute myocardial infarction. 
Additional findings 
To describe those findings by ceMRI seen in patients presenting with their first episode of 
ischaemic chest pain without the `sine qua non' diagnosis of single AMI. The initial and follow 
up findings for the 63% of patients who do not have single AMI by strict biomarker, ECG and 
ceMRI criteria are described. 
To document the incidence of common complications of AMI such as RV infarction and LV 
thrombus and compare the diagnostic capabilities with standard practice. 
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4 Methods 
4.1 Patient recruitment 
One thousand two hundred and seventy eight consecutive patients admitted to the Western 
Infirmary, Glasgow with symptoms suggesting an ACS between August 2002 and May 2003 
were screened for this study. This hospital is the primary medical centre for a population of 
300 000 located in a metropolitan area in a surrounding mixed suburban /rural region in 
Western Scotland. For each patient there was an initial case note review performed the 
morning after admission to assess suitability for the study. Basic demographic data including 
diagnosis and reason for exclusion were recorded. Patients were excluded if they: had a past 
medical history of angina; had significant comorbidity; were unable or refused to consent for 
the study; were transferred from another hospital; or had contraindications to ceMRI (ferrous 
implants, severe claustrophobia, pregnancy and unable to remain supine for ?45 min). Patients 
that met the inclusion criteria were then interviewed, the study discussed and approved 
information sheet distributed Information sheet for patients/ volunteers in clinical 
research project, 12.2 below. Once consent was obtained patients were asked to complete a 
patient information questionnaire Personal Health Record, 12.3 below and were listed for 
the next available ceMRl slot. 
The study of the remaining 153 patients complies with the declaration of Helsinki . The West 
Ethics committee of North Glasgow University Hospitals Trust approved the protocol for the 
study and all participants gave their written infromed consent (R &D reference no: 02 
CA0I2VRW). 
-34- 
The aim for this study was to scan patients as soon as practically possible following chest pain 
onset. After clinical stabilisation 153 patients were studied with ceMRI at mean (SD) 55 (32) 
hours. Delays included weekends and the clinical protocol mandated 48 hours in CCU for all 
STEMI patients. The study did not interfere with routine clinical care and the primary means 
of restoring coronary artery patency at the time of the study was intravenous thrombolysis. 
Information gathered in conjunction with routine clinical practice was at the following time 
points: in Accident in Emergency (presentation), 8 -12 hours after chest pain and at the time of 
each ceMRT scan. Data collected included: additional blood sampling for troponin (including 
dilutional analysis), CK/ CKMB, CRP and ECG recording. The results of the ceMRT scan 
were made available to the clinician in charge of the patients care in the form of a subjective 
report. Final discharge diagnosis as presented in this study was determined by the clinical 
judgment of the physician in charge of the patient's care. Infarct acuteness was defined by a 
rise and fall of TnI ( >0.02ng /ml) during 3 serial measurements, absence of ECG evidence of 
prior MI and the presence of single region of DE at ceMRI. 
At each visit, all patients underwent a clinical evaluation, ceMRI, ECG and blood testing. 
The planned study schedule and follow up was based on the initial ceMRI scan and three 
follow up visits at 28 days, 6 months and 1 year. 
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1. During initial hospital admission number= 153, at mean (SD) 2.28 (1.3) days 
2. 28 days n= 122, at 39 (17) days 
3. 6 months n= 105, at 205 (34) days 
4. 1 year n = 8C), at 389 (46) days 
The study design complies with the Declaration of Helsinki. The Ethics Committee of the 
North Glasgow University Hospitals NHS Trust approved the protocol for study. All 
participants gave their written informed consent. 
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4.2 Specific study inclusion/ exclusion criteria 
For the studies of ST deviation on admission ECG, myocardial infarction size and 
characteristics by ceMRI, further exclusion criteria were applied to the 153 patients determined 
by each research question. Specific study criteria are outlined below. 
ST- segment deviation analysis of the admission 12 -Lead ECG as an aid to 
early diagnosis of AMI with a ceMRI gold standard 
Thirty -five patients (23 %) were excluded from this study because of confounding factors in 
the admission ECG. These ECG factors include diagnostic evidence of prior AMI (n = 17); 
left ventricular (LV) hypertrophy (n = 9); atrial fibrillation with high ventricular rate (n = 1); 
Wolff- Parkinson -White syndrome (n = 1); bundle branch block (n = 5); right ventricular 
hypertrophy (n = 1); and excessive artifacts (n = 1). The study was of the remaining 116 
patients. The diagnosis of STEMI for the final analysis was made according to the stated 
criteria on the basis of the findings of the ECG core lab. The diagnosis of NSTEMI included 
all those patients with evidence of myocardial infarction as defined by the presence of DE 
rather than by biomarkers alone. All STEMI and NSTEMI patients, except 4, had positive 
biomarkers and a rise and fall over three separate time points (admission, 12 h, and at the time 
of ceMRI). Of the 4 with negative biomarkers (false positive by ceMRI for AMI), 3 did not 
have ST segment deviation on the admission ECG. The 4th patient met the STEMI -equivalent 
criteria (ST- segment depression had resolved on the repeat ECG the following day) and had a 
diffuse pattern of DE associated with an inferior and posterolateral hypokinetic regional wall 
motion abnormality. Coronary angiography was not performed in this patient. 
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Validation of electrocardiographic and biochemical estimates of first MI 
size using ceMRI 
Eighty (52°ío) patients had acute myocardial necrosis by a rise and fall of TnI. Four were 
excluded on the basis of ECG evidence of prior MI. Myocardial infarction was defined as the 
presence of DE in a subendocardial distribution and in a single coronary artery territory (LAD, 
LCx or RCA) by the AHA 17 segment model (70). Once ceMRI was performed there had to 
be a single infarct location only, if greater than one then one of the infarcts was assumed to be 
old. Nineteen patients were excluded from this study population based on their ceMRI 
findings. Seven patients had evidence of myocardial infarction in greater than one separate 
coronary artery territories (six with at least anterior involvement), four patients had 
subendocardial sparing as the pattern of hyperenhancement in keeping with non ischaemic 
fibrosis and eight patients had no evidence of hyperenhancement and therefore labeled as 
minimal myocyte necrosis. 
The study was of the remaining 57 patients, 31 (54 %) of whom received IV thrombolysis 
(STEMI). Patients were assessed for reperfusion at 90 minutes by repeat ECG. In 6 patients 
there was ongoing chest pain and less than 50% ST resolution so rescue PCI was performed. 
The 26 (46 %) patients with diagnosis of NSTEMI were managed conservatively on the acute 
medical ward until biomarkers available at 8 -12 hours. 
Serial assessment of myocardial infarction size and characteristics using 
ceMRI 
Patients with single AMI, as defined above, were included in the analysis for this study and 
information from all four time points included in the analysis. 
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Usefulness of CRP in detecting higher risk patterns of MI defined by ceMRI 
Subgroup analysis was performed in 2 groups. The first was defined by ceMRI and consisted 
of the 57 patients who had acute myocardial ischaernia as above. These patients were used in 
the assessment of the correlation of CRP with acute and final infarct size and LV remodelling 
by reperfusion status. In the second group the sensitivity and specificity of CRP in the 
detection of microvascular obstruction was tested in the 80 patients that were troponin 
positive. 
Matrix Metalloproteinase -1 Promoter Polymorphisms and Changes in Left 
Ventricular Volume Following Acute Myocardial Infarction 
Of the 68 patients with acute MI (TnI positive and subendocardial DE), 42 underwent further 
study to investigate MMP -1 promoter polymorphisms in LV remodelling. The reason for 
exclusion of 26 samples was that they were unsuitable or insufficient for this analysis. 
Additional ceMRI findings in patients with first hospital admission to rule 
out MI 
Fifty seven (37 %) patients had the expected first presentation with single AMI defined by 
patient history, ECG, biomarkers and ceMRI. The ceMRI findings of the remaining 96 
patients, "non" single AMI, are described according to the following groups: minimal myocyte 
necrosis; chest pain, other; unstable angina; acute myocarditis; prior myocardial infarction; 
acute and prior myocardial infarction; prior non -ischaemic fibrosis, Figure 5 -4. 
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4.3 Contrast enhanced Cardiac Magnetic Resonance Imaging 
Cardiac and blood pressure monitoring using the Schiller (Schiller AG, Baar, Switzerland) 
monitoring equipment provided a continuous ECG trace and regular blood pressure recording 
similar to the level of monitoring in CCU. Every scan was supervised by at least one member 
of the medical staff experienced in Cardiology. CeMRI was performed on a 1.5 -T whole -body 
scanner (Siemens Sonata, Erlangen, Germany) with a phased -array chest coil as the receiver 
during breath hold and gated to the ECG. 
Table 4 -1: Preparation of patient for ceMRI 
1. Prepare 
a Syringe A: Gadolinium (Gd) -DTPA 
(Omniscan, Nycomed) dose = 0.2 mmol /kg 
b. Syringe B: 0.9% NaC1 solution as flush 
2. Enter patient data in scanner 
3. Place patient on table 
4. Attach Siemens active Brooker ECG electrodes 
5. Lead selection for optimal positive R -wave 
configuration 
6. Insertion of 20 GI.V. catheter in antecubital vein. 
Flush with 10 ml 0.9% NaC1 solution 
7. Place and align phased array chest coil (Siemens CP 
body array flex) 
8. Patient enters scanner 
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CeMRI image acquisition 
(i) LV structure and function 
1) Scout images 
Once the patient in the scanner a multi -slice breath -hold localiser scan was used. 
Protocol: Multi -slice single -shot breath -hold steady -state free precession (SSFP) or TrueFISP 
(Siemens) localiser with transversal, sagital and coronal slices. Field of view (FoV) = 360 mm, 
FoV phase = 81.3 %, slice thickness = 6 mm, repetition time (TR) =3.41 ms, echo time (TE) _ 
1.71 ms, flip angle (FA) = 600, averages = 1, measurements = 1, phase resolution = 80, phase 
oversampling = 0 %. 
2) Localiser images 
The best axial image that depicted the left ventricle and septum was used to plan 3 vertical long 
axis (LA) localisers along the long axis of the LV from the mid -point of the mitral valve to the 
apex. 
From the resulting vertical LA scan, 3 horizontal LA localisers were planned, again using the 
mid -point of the mitral valve and the apex of the left ventricle to prescribe the orientation. 
From the 3 horizontal LA slices produced, 3 SA localiser slices with orientation parallel to the 
mitral valve plane using the anatomical landmark of the atrio- ventricular groove were planned. 
The basal slice was positioned into the atria to depict the LV outflow. 
From the resulting SA images, three LA views were planned: the four- chamber (4CH); two - 
chamber (2CH); and LV out -flow tract (LVOT). Cinematographic (CINE) studies were then 
obtained. 
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SSFP CINE protocol: TrueFISP breath -hold CINE. FoV =340 mm, FoV phase = 81.3 %, Slice 
thickness =8 mm, TR =47.4 ms, TE =1.58 ms, averages =l, FA =60 °, measurements =l, phase 
resolution =65 %, phase oversampling =20 %, segments =15. 
3) Short axis CINE stack 
From the 4CH CINE, the SA CINE stack encompassing the entire left ventricle was planned. 
The first of these SA CINE slices was planned in an orientation across the mitral valve plane, 
again using the atrio- ventricular groove as an anatomical land -mark. The end -diastolic image 
from the 4CH CINE study was used to plan the first and most basal SA slice. 
The slice position was then incremented by 10 mm moving towards the apex region of the left 
ventricle and repeated until the left ventricle has been completely covered thus inter -slice gaps 
of 2 mm were used. 
(ii) Contrast enhanced cardiac MR imaging 
Contrast dose, time between injection of the contrast agent to image acquisition are important 
for accurate DE visualization and these were kept constant(158). Following SA image 
acquisition a single dose of 0.2mmol /kg Gd- DTPA -BMA (GE Healthcare, Waukesha, 
Wisconsin) was injected via an antecubital vein. CeMRI was performed with the single shot 
(159) and standard segmented gradient -echo inversion -recovery sequences (33;48;58). 
1) Early MVO imaging 
Image acquisition using the "single shot" inversion recovery SSFP was started 2 minutes 
following contrast injection using the same slice positions as for all SA CINE slices. No breath 
holding is necessary and imaging in a single heart beat is possible Figure 6 -1. 
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Protocol: ECG trigger, 100 lines field of view =270 x 360, slice thickness =8 mm, interslice 
gap = 2 mm, flip angle 30 degrees, TE 1.2 ms, TR 2.7ms, TI 200- 350ms, bandwidth/ pixel 980 
Hz, matrix 256. 
2) Delayed hyper- enhancement Gd -DTPA imaging (DE) 
Image acquisition using the inversion recovery fast gradient echo sequence was started 10 
minutes post Gd -DTPA injection to allow time for necessary adjustments before start of 
actual image acquisition at time = 15 minutes. Identical slice positions to SA CINE and early 
MVO images were used starting at the mitral valve plane as before. LVOT, 2CH- and 4CH LA 
slices were also acquired. 
Protocol: Breath -hold segmented rephased Turbo Flash (Siemens) sequence with non -selective 
inversion pulse with non -slice selective inversion -recovery Figure 4 -1. 
Constants: FoV =340 mm, FoV phase = 81.3 %, slice- thickness =8 mm, inter -slice gap =2mm, 
TE =4.3 ms, averages =2, flip- angle =30, phase -resolution =65 %, segments =25, trigger delay =0, 
trigger pulse= 2 but dependent on scan time (1 if bradycardic, >2 if tachycardic) to allow for 
sufficient longitudinal relaxation between inversion pulses. 
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Figure 4 -1: Segmented inversion -recovery turboFLASH sequence with TI set to null 
normal myocardium after contrast agent administration 
Variables: The acquisition window was set greater than RR- interval and TR just under to allow 
for diastolic imaging. Inversion time (TI) was 250 ms (for initial scan) and adjusted according 
to image quality by 10 ms steps to optimise image quality. Optimum TI and TR produced a 
diastolic image with black (nulled) myocardium and bright late enhancement area. Blood 
appeared with an intermediate intensity Figure 6 -2. 
Guide to adjustments used to improve image quality: 
TI too short: infarct nulled and normal myocardium bright white; 
TI too long: infarct may be white but normal myocardium grey (rather than black); 
TI close; infarct white, myocardium speckled change the TI by just 10 ms to attain optimal 
suppression of myocardium. 
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Dark signal at the endocardial boundary: the effective TI of the tissue at the blood- myocardial 
interface is often slightly shorter, due to mixing. This indicates that the inversion time is too 
short. Therefore, increase TI to obtain uniform suppression of the myocardium. 
Blood pool too dark: TI is too short, increase TI. 
Blood pool too bright: TI is too long, decrease TI. 
In order to decrease the dependence of optimal TI when acquiring DE -MRI images a phase 
sensitive acquisition technique was used (90). 
CeMRI Image Analysis 
A blind, random ordered analysis of all ceMRI examinations was undertaken by one observer 
in as few batches as possible once the study was completed. Image analysis was performed 
using Siemens Argus software for LV mass and function and CMR tools (Imperial College, 
London) for manual DE area planimetry. 
(i) Left ventricular structure and function analysis 
Measurement of LV mass and function was evaluated with manual planimetry on 
commercially available Argus software (Siemens, Erlangen). In each examination, the number 
of slices to be included in the covering of the left ventricle in end -diastole and end -systole were 
decided. End -systole was chosen at the point where the LV blood pool is smallest. On each 
end -diastolic and end -systolic frame, both endocardial and epicardial circumferences of the LV 
myocardium were manually planimetered and the corresponding areas calculated. The papillary 
muscles were included as part of the LV myocardium. Total volumes of the left ventricle were 
then calculated by simple addition of the individual SA slice areas in the stack slices covering 
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the left ventricle. In this manner, LV end -diastolic (LVEDV) and end -systolic (LVESV) 
volumes (ml) were determined and LV ejection fraction (LVEF, %) and LV myocardial mass 
(LVM, g) calculated. The latter calculation assumes a myocardial density factor of 1.05 g /ml. 
(ii) Delayed hyperenhancement (DE) analysis 
The ceMRI data were analysed with CMR Tools (Imperial College, London). There are a 
variety of commercially available post processing software programmes used to measure 
infarct size and even the simple choice of whether whole pixels are located within, on or 
outwith the perimeter varies between different software. The same software for all DE analysis 
was used. 
The high accuracy of the ceMRI technique for depicting areas of infarction shown in animal 
studies relies on quantification of hyperenhanced areas in high spatial resolution (0.5 x 0.5 x 0.5 
mm) ex vivo images. This high spatial resolution is not obtained when acquiring standard 
ceMRI images in routine clinical practice. The typical spatial resolution of a clinically acquired 
ceMRI image is 1.5 x 1.5 x 8 mm. Thus, the thickness of standard infarct MR images is 16 
times that of the high spatial resolution MR image acquired ex vivo. Consequently, the 
problem of partial volume arises in the clinical setting (33). Within the 8 mm thick image slice 
the infarcted myocardium can be very irregular, resulting in blunted infarct borders. In order to 
maintain objective consistency no allowance for partial volume was made in this study i.e. 
anything that was hyperenhanced was included. 
Relative contrast and brightness varies with different image display systems and can be 
manually altered to optimise visualisation of the infarcted myocardium. By doing so, the 
periphery of the hyperenhanced region is manipulated subjectively, which can affect the 
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assessment of M1 size in an unpredictable manner. In this study no manual adjustments to the 
image were used - planimetry was performed on the image as presented by the software, no 
"windowing" Figure 6 -2 and Figure 6 -3. 
The signal intensities of Gd- enhanced myocardium and normal myocardium were measured 
with computer -assisted planimetry and delineated manually. Delayed hyperenhancement that 
involves the subendocardial area was considered to represent an MI scar (72;160). 
Subendocardial sparing was identified visually and defined as DE that did not at any point 
extend to the subendocardium i.e. nulled myocardium was visible between the blood pool and 
region of DE on both long and short axes (72). The best quality images from the SA stack that 
contained DE were selected for analysis and for each SA slice the DE area was planimetered. 
A myocardial volume was calculated by the sum of each area. Infarct mass then calculated by 
multiplying the volume by a factor of 1.05 g /ml as above. 
All DE images from the admission ceMRI scan were analysed twice to measure intra observer 
variability calculated as part of quality control. The mean value of both images was used in the 
final analysis. All screenshots of DE planimetry were saved and one in five images were 
qualitatively assessed by a second observer (BAG). 
(iii) Infarct characteristics 
1) AMI location 
The AMI location was determined by the 17 segment AHA standardised myocardial 
segmentation model(70) into anterior, lateral and inferior. The location was defined as the 
region of the LV containing the highest percent infarction; patients were classified as having 
multiple infarcts if there were >1 separate areas of DE. In some cases it was not possible to 
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assign an infarct to one particular territory so a hybrid was used e.g. inferior and lateral Figure 
6 -4. 
2) Microvascular obstruction 
Microvascular obstruction (MVO) was considered present when at least one segment had a 
central core of hypoenhancement surrounded by hyperenhancement (161;162). Early MVO is 
seen between 1 and 5 minutes post contrast (87) and late (persistent) MVO when the 
appearance persists for ? 10 minutes(67). The region of hypoenhancement was manually 
planimetered as for DE images Figure 6 -5. 
3) Infarct transmurality 
Mean transmurality (TM) score was calculated by visually deciding the transmural extent per 
segment in quarters (1 - 1 -25 %, 2 - 26 -50 %, 3 - 51 -75 %, 4 - 76 -100 %) and calculating the 
mean. A myocardial infarct was labeled TM of mean score ? 3 (48). Figure 6 -4, left and right 
panels show an anterior and a lateral infarct both with mean TM score of ? 3, the middle 
panel shows an inferior infarct with a mean TM score < 3. 
4) Endocardial extent of infarct 
Endocardial extent was calculated by measuring the circumferential extent of the infarct at 
each of the SA slice used in the AHA segmentation model (70) and the mean value used in the 
analysis Figure 6 -6. 
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4.4 12 lead Electrocardiography 
All ECGs were quantitatively and qualitatively evaluated in the Duke University Medical centre 
ECG core laboratory (North Carolina, USA) by 2 investigators (GW, RS), who were blinded 
to all other study data. An ECG for analysis was recorded at presentation, at 8 -12 hours and at 
the time of each ceMRl scan. 
The ST- segment measurements were made at the J point to the nearest 0.05 mV, and all 
differences were adjudicated in conference. Regarding "contiguity," the 6 chest leads and the 
spatially based orderly sequence of the 6 standard limb leads were considered (163). 
The ECGs were classified according to the following 3 criteria: 
1. GUSTO STEMI: >_0.1 mV ST- segment elevation in ?2 anatomically contiguous 
standard limb leads (among I, II, III, aVL, and aVF) or ?0.2 mV in ?2 contiguous 
standard precordial leads (94). 
2. ACC /ESC STEMI: ?0.1 mV ST- segment elevation in? 2 anatomically contiguous 
standard limb leads (in their orderly sequence from aVL to III, including -aVR) or 
chest leads V4 to V6, or ?0.2 mV in chest leads V1 to V3 (164). 
3. STEMI equivalent: ?0.1 mV ST- segment depression in ?2 anatomically contiguous 
leads or in 1 lead that is anatomically contiguous to a lead with ST- segment elevation 
criteria (e.g., ST- segment elevation in lead aVL and ST- segment depression in lead III 
and vice versa). 
At the time of study recruitment acute reperfusion was based on the GUSTO set of criteria so 
this is the definition of STEMI for analysis i.e. the terms STEMI and "reperfused infarct" are 
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synonymous. The exception is the study entitled, "ST- Segment deviation analysis of the 
admission 12 -Lead ECG as an aid to early diagnosis of AMI with a ceMRI gold standard ". 
Patients defined as ST deviation were those with with either ST elevation or depression. "No 
ST deviation" includes those patients in whom nether of the above criteria were met. 
The complete 50- criteria, 31 point Selvester QRS scoring system (165) adapted from the 
original 54 criteria 32 point system(110) was performed contemporaneously with each ceMRI 
scan Selvester Score page 197. 
Pathological Q waves were defined as negative deflection in the first part of QRS complex of 
1 mm deep and ?2 mm wide in at least 2 contiguous leads. T wave inversion considered 
significant if 2mm below baseline. 
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4.5 Biomarkers 
Sample timing 
Troponin I and CK/ CKMB: at presentation, 8 -12 hours post chest pain onset as per clinical 
protocol, at the time of ceMRT scan 1. 
CRP: at the time of ceMRI scan 1. 
Renal function and full blood count: at presentation, 8 -12 hours post chest pain onset as per 
clinical protocol, at the time of ceMRT scan 1. 
Assays 
Troponin: Bayer Advia Centaur Immunoassay analyser (Bayer, Tarrytown, New York) which 
has a coefficient of 18% at the reference limit of 0.2 ng /ml and a 99`h percentile for normal 
controls of 0.16ng/m1(166). 
CK: Bayer Advia 1650 Random Access Analyser- colorimetric assay. 
CK -MB: Bayer Advia Centaur Immunoassay analyser 
CRP: Ultra sensitive double antibody sandwich ELISA (linear up to 5mg /L and logarithmic 
thereafter). The inter -assay coefficient of variation was less than 7% across the range of 
measured results. 
NtBNP: Roche diagnostics chemiluminescent kit on an Elecsys 2010 analyser. The coefficient 
of variation is < 5% 
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4.6 Matrix metalloproteinase -1 promoter polymorphisms 
Deoxyribonucleic acid samples were prepared from whole blood using a commercially 
available extraction kit (Tepnel Life Sciences PLC, Wythenshawe, United Kingdom). 
Polymerase chain reaction was used to amplify a region across the G insertion in position - 
1607, consisting of 317 or 318 base pairs (bp), depending on the presence or absence of the 
insertion. The sense primer for this amplification flanks the polymorphism at the site -1823 to 
-1802 bp (5'- CCCTCTAATATGAAGAGCCCC -3 ") and the antisense primer at -1506 to - 
1526 bp (5 TTCCTC- CCCTTATGGATTCC -3'). The polymerase chain reaction conditions 
were 35 cycles of 30 seconds at 94 °C, 30 seconds at 59 °C, and 30 seconds at 72 °C. A second 
nested mutagenesis polymerase chain reaction of this amplified sequence was then undertaken 
to create a GGATCC restriction site for the enzyme BamHI when adjacent to the GG 
polymorphism: sense 5'- GCTGGAGTCACTTCAGTGGC -3', antisense 5'- 
TATCTTGGATTGATTTGAGATAAGTCGGAT-3', 35 cycles of 30 seconds at 94 °C, 30 
seconds at 60 °C, and 30 seconds at 72 °C. These polymerase chain reaction products were then 
digested with BamHI and the products (defining genotype) separated by gel electrophoresis 
and visualised by ethidium bromide staining. All polymerase chain reaction reactions included 
negative controls, without deoxyribonucleic acid template, to exclude the amplification of 
contaminants. Repeat polymerase chain reaction of 20% of the samples confirmed consistent 
results. Patients were grouped according to their genotypes. 
Blood samples were tranferred to the Department of Cardiology, Aberdeen Royal Infirmary 
where all further sampling including PCR was undertaken as part of a collaboration with Dr. 
Graham Hillis (see acknowledgements). 
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4.7 Coronary Angiography 
Diagnostic coronary angiography and follow on percutaneous intervention was performed 
during admission at the discretion of the Cardiologist performing the procedure in the Western 
Infirmary. 
Qualitative analysis was performed by at least one experienced operator independent from this 
study. Significant stenosis is defined as >_ 70% luminal narrowing, moderate disease as 50 -70 %, 
mild disease as 25 -50% and classified as normal if <25% or plaque disease. 
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4.8 Statistics 
Statistical analyses were performed with SPSS for Windows (version 14. 2005. Chicago, 
Illinois, USA). 
Baseline demographic data and clinical characteristics for patient groups as stated in results 
section were compared with the 2- sample t test (or Wilcoxon rank sum test for skewed 
measurements) for continuous variables and the chi- square test for categorical variables (or 
Fisher Exact test if expected counts 5 5). Graphical procedures and the relation of the 
standard deviation (SD) to the mean were used to check whether the data were normally 
distributed. In each case the value for the SD was either greater or close to the mean value. 
Exact p values are reported where possible and the level of significance was set at p <_ 0.05. 
Summary statistics are presented as mean (SD) or median (IQR) for continuous variables and 
number ( %) for categorical variables. Analysis of variance using paired samples was used to 
compare change in infarct size with time and to compare the difference in change in infarct 
size between subgroups. 
The sensitivities and specificities of the GUSTO STEMI, ACC /ESC STEMI, and STEMI- 
equivalent criteria were compared with the ceMRI gold standard using the McNemar test. The 
95% confidence intervals (CI) were calculated for each statistic from the binomial distribution. 
Correlation was assessed by Spearman rank correlation coefficient for non parametric data. 
Multiple linear regression using ceMRI as the dependent variable and TnI then TnI plus 
Selvester score as fixed factors was used to assess any improvement in the correlation with 
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infarct size using the combination. For the multiple linear regression the Pearson correlation 
coefficient was used. 
Receiver operator curves (ROC) were used to assess diagnostic ability of CRP and to 
determine optimal levels for the detection of early and late MVO in the troponin positive 
patients. The sensitivities and specificities of the predefined cut offs of 3 and 10 mg /L and the 
ROC curve determined optimal cut off were compared to the ceMRI gold standard using the 
McNemar test. The 95% confidence intervals (CI) were calculated for each statistic from the 
binomial distribution. 
For MMP -1 and LV remodelling, it was prospectively defined that patients would be 
dichotomised and genotype frequencies compared on the basis of a <10% or >10% increase 
in LV volumes. It was estimated that to detect a 10 -m1 difference in LV volume, with a SD in 
measurement of 10 ml at a 2 -sided significance value of 0.05 and 80% power, a sample size of 
32 patients would be required, assuming approximately equal frequency of the 2 alleles. 
Genotype distributions were consistent with Hardy- Weinberg equilibrium. 
All ceMRI scans from visit 1 were assessed twice by the same observer and the coefficient of 
variation calculated to be 3.4 %. 
The Z test was used to compare 2 independent correlations when testing the improvements of 
Selvester score and TnI with final infarct size and final LVEF. 
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4.9 Definitions 
Cardiovascular risk factors 
Smoking: >10 pack years of tobacco use. Family history: >_ 2 first degree relatives with a 
history of premature cardiovascular disease (c 60 years). Hypertension: treated hypertension 
prior to hospital admission. Hypercholesterolaemia: lipid lowering therapy initiated prior to 
admission. Diabetes: grouped together as type I and type II requiring medical (oral and insulin) 
therapy. 
MACE (major adverse cardiovascular event) was defined as death, MI, emergency 
revascularisation, hospital admission with heart failure or stroke. Patients were followed up by 
case note review at 3 years. MACE was not a primary end point of this study. 
Definitions of Primary Discharge Diagnosis 
Final diagnosis is reached by a combination of clinical and ceMRI findings Figure 5 -4. 
(i) Single Acute Myocardial Infarction 
Patients that had a rise and fall of troponin over three sample points, no evidence of prior MI 
by ECG and subendocardial DE in single coronary artery territory. 
(ii) Prior myocardial infarction 
Patients that were TnI negative and subendocardial DE positive. 
(iii) Acute and prior myocardial infarction 
Patients that were TnI positive and had >1 region of subendocardial DE. 
(iv) Prior non -ischaemic fibrosis 
Patients that were TnI negative with subendocardial sparing of DE. 
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(v) Acute myocarditis 
Patients that were Tnl positive with subendocardial sparing of DE. 
(vi) Unstable angina 
Patients that were Tnl and DE negative but had ST deviation/ significant T wave inversion on 
the ECG and/ or significant coronary angiographic findings ( >70% stenosis), including 
coronary artery spasm. A positive exercise tolerance test is included if no subsequent coronary 
angiography performed. 
(vii) Chest pain, other 
Patients that were Tnl and DE negative for whom either an alternative diagnosis was made or 
there was no further objective evidence for ischaemic heart disease. There are 5 patients in this 
group who were labeled "unstable angina" without objective evidence and started on anti - 
ischaemic drug therapy. The clinical diagnosis of pericarditis was made in 2 patients with 
typical history and ECG findings. 
(viii) Minimal myocyte necrosis 
Patients that were TnI positive but DE negative (24). 
- 57 - 
5 Results 
5.1 Screening data 
One thousand two hundred and seventy eight patients were screened between 6th August 2001 
and 9" May 2002 Figure 5 -1. Eight hundred and ninety one (70 %) were admitted to the 
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Figure 5 -1: Cumulative screening data for all patients 
Three distinct gaps in the consecutive nature of screening can be seen. The first was due to 
MRI scanner disrepair, the second due to annual leave and the third due to an annual MRI 
scanner service. These match the gaps on the graph of cumulative recruitment rate shown in 
Figure 5 -2. The mean (SD) age of the screened population was 68 (15) years and 704 (55 %) 
were male. Eleven hundred and twenty five patients (88 %) were excluded from the study with 
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a mean (SD) age of 70 (15) years and 602/1125 (54 °') were male. For a total of 281 (22 %) 
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Figure 5 -2: Cumulative recruitment data for study population 
The reasons for exclusion of the 1125 patients are shown in Figure 5 -3. Eight hundred and 
twenty six (73 %) were excluded due to a past medical history of chest pain. Of these forty nine 
(6 %) had had Coronary Artery Bypass Graft surgery (CABG), 410 (50 %) had a history of 
angina (5 patients already in the study from previous admission), 106 (13 %) had a definite 
diagnosis of previous myocardial infarction, 261 (31 %) had a history of hospital admission for 
non specific chest pain. 
Forty two patients (4 %) were excluded due to significant comorbidity. Nine died, 12 were too 
unwell and 21 had a diagnosis of active cancer. 
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Figure 5 -3: Total exclusions from study by reason 
Sixty eight patients (6 %) were excluded for reasons of consent. Fifteen were unable due to 
dementia, learning difficulties or language issues. One was in police custody and 52 refused to 
take part in the study (9 took their own discharge). 
Thirty three (3 %) had one of the listed contraindications to ceMRI. Four had a pacemaker in 
place, 10 had a previous procedure and implant that was non -compatible. Sixteen stated that 
they were claustrophobic and two felt they would be unable to lie still due to back pain, one 
was too heavy. 
One hundred and three patients (9 %) were excluded due to reasons of geography, meaning 
that they were transferred from another hospital or on holiday and so presented too late or 
would not be able to return for follow up. The remaining 53 (5 %) are classified as other due 
to missing data. 
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5.2 Final study population 
One hundred and fifty three patients with a mean (SD) age 56 (13) years met the study criteria 
and were recruited between August 2002 and May 2003, 102/153 (67%) were male and 57 
(37 %) had a single acute MI by a combination of ceMRI and biomarkers, Table 5 -1. 
Cardiovascular risk profile was in keeping with previous studies on ACS: smokers = 103/153 
(67 %); positive family history = 70/153 (46 %); diabetes mellitus = 19/153 (12 °/o); hypertension 
= 53/153 (35 %); and hypercholesterolaemia = 33/153 (22 %). The mean (SD) TIMI risk score 
was 2.6 (1.2) with all patients scoring one point for chest pain. By presenting ECG; 37/153 
(24 %) had ST elevation and 26/153 (17 %) had ST depression. Seventy eight (52 %) went on to 
have inpatient diagnostic coronary angiography and 58 (38 %) had ? 1 region of significant 
stenosis. The total population had a mean BMI of 27 which would be classified as 
"overweight ". The mean serum cholesterol was greater than 5 mmol /I and over half were 
discharged on primary or secondary cardiovascular prevention drugs with nearly 3/4 on aspirin. 
When demographic and selected clinical characteristics of patients with single AMI are 
compared to those with "non" single AMI, patients in the single AMI group had a higher 
proportion of ST elevation (47 vs. 10 %, p <0.001) and ST depression (30 vs. 9 %, p <0.001) on 
the presenting ECG Table 5 -1. Therefore 23% of patients in the single AMI group had no 
evidence of ST deviation on the presenting ECG. 
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Table 5 -1: Demographic and clinical characteristics for whole population and by 





Non single AMI 













Diastolic BP 77.3 (12.8) 75.9 (12.8) 78.1 (12.8) 0.297 
BMI 26.9 (4.7) 26.9 (4.0) 27.0 (5.1) 0.865 
TThill risk score 2.6 (1.2) 3.5 (0.9) 2.1 (1.1) <0.001 
Time from pain to MRI, hrs 54.7 (32.0) 63.6 (22.8) 49.3 (35.4) 0.003 
Median (IQR) CR, IU /ml 172 (85 - 695) 736 (332 -2136) 111 (77 -188) <0.001 
Median (IQR) TnI, ng/ml 0.7 (0 -27.9) 29.8 (11.4 -64.9) 0 (0 -0) <0.001 
Cholesterol, mmol/l 5.6 (1.25) 5.6 (1.24) 5.6 (1.27) 0.963 
Median (IQR) glucose, 6.2 (5.3 -7.7) 7.0 (6.1 -8.9) 5.7 (5.2 -7.4) <0.001 
Median (IQR) urea, 5.4 (4.5 -6.5) 5.6 (4.7 -7.1) 5.2 (4.5 -6.3) 0.067 
Median (IQR) creatinine, 103 (84.5 -108) 104 (92.5 -111) 94.5 (82 -104) <0.001 
Categorical variables 
Sex, in 102 (66.6) 43 (75.4) 59 (61.5) 0.076 
Smoker 103 (67.3) 40 (70.2) 63 (65.6) 0.562 
Family history 70 (45.7) 22 (38.6) 48 (50) 0.171 
Diabetes 19 (12.4) 5 (8.8) 14 (14.6) 0.292 
Hypertension 53 (34.6) 21 (36.8) 32 (33.3) 0.659 
Hyp erc ho le s tern lae m i a 33 (21.6) 11 (19.3) 22 (22.3) 0.599 
Admission ECG: 
ST elevation 37 (24.2) 27 (47.4) 10 (10.4) <0.001 
ST depression 26 (17.0) 17 (29.8) 9 (9.4) <0.001 
Q waves 6 (3.9) 0 (0) 6 (6.3) 0.054 
Discharge Drugs: 
Aspirin 112 (73.4) 57 (100) 58 (60.2) <0.001 
Beta blocker 90 (58.9) 49 (86.4) 43 (45.0) <0.001 
ACE inhibitor 49 (32.3) 35 (61.4) 16 (16.7) <0.001 
Statin 85 (55.6) 55 (97.7) 32 (33.3) <0.001 
Admission cor. angio: 
Performed 78 (51.8) 41 (71.9) 37 (38.5) <0.001 
Sig. stenosis 58 (38.0) 37 (64.9) 21 (21.9) <0.001 
All available data used. Data presented as mean (SD) for continuous variables and number (%) for categorical 
variables, unless otherwise stated. Comparisons made between the 2 groups single AMI and non single AMI. 
Two sample t-test used for continuous variables and chi - squared test, categorical. The Mann -Whitney test was 
used for nm- normal data. Significant coronary artery stenosis defined as >70% in major coronary vessel. 
BP, blood pressure; BMI, body mass index, TIMI, thrombolysis in myocardial infarction; CKMB, creative 
kinase MB; Tnl, troporrin I, MRI, magnetic resonance imaging; ECG, electrocardiogram, ACE, angiotensin 
converting enzyme 
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Patients in the single AMI group had higher TnI (median 30 vs. 0.0 g, p <0.001) and CI{ 
(median 736 vs. 111 IU /ml, p <0.001) levels and higher TIMI risk scores (mean 3.5 vs. 2.1, 
p <0.001). A coronary angiogram was more likely to be performed as an inpatient (72 vs. 39 %, 
p <0.001) and there was a greater proportion with a significant stenosis (37/41 (90 %) vs. 21/37 
(57 %), p <0.001). There was a longer interval from onset of chest pain until the initial ceMRI 
study was performed (64 vs. 49 h, p= 0.003). Patients with single AMI had a higher admission 
glucose (7.0 vs. 5.7 mmol /L, p <0.001). A random blood glucose of 7.0 mmol /L (126 mg /L 
equivalent) is above normal but not within the range of "pre- diabetes" (140 -200 mg /L) (167). 
Patients with a single AMI had a higher serum creatinine (104 vs. 95 .tmol /L, p<0.001) the 
significance of which is uncertain as both are within normal limits. In the single AMI group 
aspirin, beta blocker and statin use were high ( >85% for each) but ACE inhibitor prescription 
less (61 %) and in all cases greater than the non - single AMI group. 
Final study population divided by dischage diagnosis based on a combination of TnI 
and ceMRI. 
Of the 153 patients that met study inclusion criteria, 80 (52 %) were TnI positive (TnI +), 
Figure 5 -4. Within this group, 71 (89 %) were also DE positive (DE +). Of the 71 DE+ 
patients, 68 (96 %) had a subendocardial DE pattern (acute MI) and 3 (4 %) had the 
subendocardial sparing pattern (acute myocarditis). Of the 68 acute MI patients, 57 (84 %) had a 
single discrete region of DE (single Acute MI) and 11(16 %) had > 1 region. The assumption is 
that at least one of the regions in the latter group is due to a prior event (acute and prior M1). Of 
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the 80 TnI+ patients coronary angiography was performed in 59 (73 %) and significant stenosis 
was seen in 49 (61 %). Nine (11 %) patients were Tnl+ but DE negative (DE -) and were 
classified as minimal myocyte necrosis (168). 


































4 . Chest pain, other 
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Figure 5 -4: Study patients divided by discharge diagnosis based on TnI and ceMRI 
Of the 153 patients that met study inclusion criteria, 73 (48 %) were TnI negative (TnI ), 
Figure 5 -4. Fourteen of these (19 %) were positive for DE (DE +); 9 patients (64 %) had 
subendocardial DE (priorMI) and 5 (36 %) had subendocardial sparing of DE (prior non - 
ischaemicfibrosis). Fifty nine (81 %) of the TnI negative patients were DE negative (DE-). In this 
group, 11 (19 %) had a diagnosis of unstable angina and 48 (81 %) had a diagnosis of "chest pain, 
other'. Coronary angiography was performed in 20 (27 %) and significant stenosis was seen in 8 
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(11 %), all eight were part of the unstable angina group. In total eighty five (56 %) of patients 
had hyperenhancement on ceMRI (DE +). 
Left ventricular structure and function in the final study population 
Six month follow up scans were performed in 103 patients (67 %) from the total population; 38 
(67 %) of the single AMI group and 65 (68 %) of the non -single AMI group, Table 5 -2. 
Table 5 -2: Baseline and follow up left ventricular structure and function by ceMRI 
Total 
Scan 1, n =153; 
Scan 3, n =103 
Single Alvfi 
Scan 1, n =57 
Scan 3, n =38 
Non single AlvII 
Scan 1, n =96 
Scan 3, n =65 p value 
L V ssuuctum arad fiincáion 
LVEF, %. Visit 1 60.8 (11.6) 55.9 (10.9) 63.7 (11.1) <0.001 
LVEF, %. Visit 3 61.5 (12.4) 54.8 (13.0) 65.4 (10.3) <0.001 
LVESV, ml. Visit 1 56.9 (38.0) 63.2 (25.3) 53.2 (43.4) 0.076 
LVESV, ml. Visit 3 64.6 (48.9) 86.0 (54.8) 51.9 (39.9) <0.001 
LVEDV, ml. Visit 1 138.6 (45.5) 140.9 (37.6) 137.2 (49.7) 0.607 
LVEDV, ml. Visit 3 156.1 (56.2) 181.1 (59.1) 141.1 (49.3) <0.001 
Remodeller by LVEDV 29 (18.9) 15 (26.3) 14 (14.6) 0.073 
LV mass, g. Visit 1 127.7 (43.0) 130.4 (38.3) 126.1 (45.7) 0.535 
LV mass, g. Visit 3 138.5 (43.3) 138.3 (42.1) 134.8 (46.7) 0.174 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (%) for categorical variables unless otherwise stated. Comparisons made 
between the 2 groups single AMI and non single AMI. Two sample t-test used to compare continuous 
variables and chi -squared test for categorical. Remodeller defined as an increase from baseline of >20%. 
LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVEDV, left 
ventricular end diastolic volume. 
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LVEF was significantly lower in the single AMI group both at baseline (56 vs. 64 %, p <0.001) 
and at 6 months (55 vs. 65 %, p <0.001). At baseline the individual LV dimensions measured 
were similar although there was a trend towards a larger LVESV in the single AMI group 
(mean 63 vs. 53 ml, p= 0.076). 
At follow up 6 months later both LVESV (mean 86 vs. 52 ml, p <0.001) and LVEDV (mean 
181 vs. 141 ml, p <0.001) were significantly greater in the single AMI group and there was a 
trend towards LV remodelling ( >10% increase) (26 vs. 15 %, p= 0.07). The inhomogeneity of 
the non - single AMI group will have contributed to this lack of difference in remodelling; the 
14 patients that remodel from this group included those with dilated cardiomyopathy and prior 
MI on admission. There was no difference in LV mass either at baseline or at follow up. 
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5.3 ST- segment deviation analysis of the admission 12 -Lead 
ECG as an aid to early diagnosis of AMI with a ceMRI gold 
standard 
This section describes the results from the sub study population consisting of 116 patients 
after 35 were excluded because of confounding factors on the admission ECG. 
Table 5 -3 presents the baseline demographic and clinical characteristics of this study 
population divided into AMI (n = 58) and non -AMI (n = 58) groups. Eight patients with 
multiple infarcts are included in this study. Patients in the AMI group were older (mean 59 vs. 
53 years, p = 0.0077) and there was a shorter duration of time from the onset of chest pain to 
the ECG (median 2.7 vs. 7.4 h, p = 0.02). There was a longer interval until the initial ceMRI 
study (median 64 vs. 33 hours, p = 0.0001) in the AMI group. Slightly more than one half 
(54 %) of the AMI group and few (5 %) of the non -AMI group received reperfusion therapy. 
Any reference to reperfusion therapy is based on the GUSTO ECG criteria as dictated by the 
local protocol. All STEMI patients received thrombolysis, except 2 who underwent primary 
percutaneous intervention. 
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Table 5-3: Demographic and clinical characteristics according to ceMRI diagnosis of 
AMI 
AMI Positive by 
ceMv1RI 
(n =58) 
AMI Negative by 
ceMRI 
(n =58) p value 
Continuous variables 
Median (IQR) zkivn size, g 27.1 (13.9 -45.4) - 
Median (IQR) AMI size, % LV 
mass 
23.8 (12.4 -38.8) 
Age, yrs* 59.1 (13.2) 52.8 (11.7) 0.0077 
Median (IQR) time to ECG, 
hourst 
2.7 (1.8 -9.6) 7.4 (2.3 -20.5) 0.020 
Median (IQR) time to Iva' scan, 
hourst 
63.6 (45.3 -85.0) 32.6 (26.0 -58.2) <0.0001 
Weight, kg* 79.6 (17.1) 81.8 (15.9) 0.46 
BP systolic, mmHg* 121.6 (17.9) 127.3 (19.7) 0.11 
BP diastolic, mmHg* 73.4 (10.7) 79.6 (14.2) 0.0084 
Heart rate, beats/ min* 53.7 (11.1) 58.0 (11.8) 0.049 
LVEF, u%* 57.0 (10.5) 64.4 (9.0) <0.0001 
Median (IQR) Tnl, ng/mLt 43.1 (12.7 -64.9) 0 (0 -0) <0.0001 
Median (IQR) peak CK, IU /mLt 733 (383 -1942) 102 (74 -162) <0.0001 
Median (IQR) peak CK1v1B, 56.0 (14.0- 111.0) 1.0 (0.5 -1.6) <0.0001 
IU /mlt 
Median (IQR) CRP, mg /It 36.0 (14.0 -91.0) 60 (0 -11.0) <0.0001 
Categorical variables 
Male* 39 (67.2) 36 (62.1) 0.56 
Smoking* 40 (72.7) 39 (68.4) 0.62 
Reperfusion Therapy* 31 (54.4) 3 (5.2) <0.0001 
Infarct location: 
Anterior 13 (22.4) - - 
Inferior 20 (34.5) 
Lateral 11 (19.0) 
Inferior and Lateral 6 (10.3) 
Multiple 8 (13.8) - - 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (%) for categorical variables unless otherwise stated. 
*Two -sample t-test used to compare continuous variables and chi - squared test for categorical. lWilcoxonrank 
sum test used for non -normal data. 
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There were 10 patients that were falsely positive by ECG and /or troponin I for AMI 
considering ceMRl as the gold standard Table 5 -4. In the 8 patients falsely positive by 
troponin I, the peak value was 4.4 ng /ml and the mean (SD) was 1.44 (1.38) ng /ml. In the 2 
falsely positive patients by ECG alone, 1 had a clinical diagnosis of pericarditis and the other 
had neither clinical nor angiographie evidence of cardiac disease. Eight of these 10 patients 
could be considered to have had minimal mvocyte necrosis or "necrosette" (i.e., an extremely 
small MI with a low peak troponin I) (169). 
Table 5 -4: False positives by Troponin I and/ or ECG criteria 
Patient Group TnI 
(ng /nil) 
ECG Coronae uniography Clinical diagnosis 
By TnI 
19 Negative Normal Minimal myocyte necrosis 
1.3 Negative NA Minimal myocyte necrosis 
0.3 Negative Normal Minimal myocyte necrosis 
0.3 Negative 95% stenosis LCx Minimal myocyte necrosis 
0.4 Negative 95% stenosis RCA Minimal myocyte necrosis 
0.9 Negative NA Minimal myocyte necrosis 
By ECG 
< 0.2 ACC/ ESC STELE NA Pericarditis 
<0.2 STEIVC equivalent Normal Non -cardiac chest pain 
By both TAI anti ECG 
4.4 ACC/ ESC STEMI Normal Takotsubo 
2 STEMI equivalent 95% stenosis RCA Minimal myocyte necrosis 
ECG criteria as described in text, table indicates by which criteria patient was falsely positive 
ACC / ESC, American College of Cardiology/ European Society of Cardiology; NA, not applicable (coronary angiogrephy 
not p erfonned); STEM, ST elevation myocardial infarction 
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The performances of the GUSTO and ACC /ESC STEMI criteria are almost identical, with 
only a single patient in both the AMI and non -AMI groups being classified differently. 
Therefore, for the remainder of the data analysis, only the more recently published STEMI 
criteria (ACC /ESC) are considered. Only 50% (29 of 58) of the AMI group are identified by 
the ACC /ESC STEMI criteria, but an additional 34 °/e (49 of 58) are identified by the STEMI- 
equivalent ST- segment depression criteria increased the sensitivity from 50% to 84% (p = 
0.0001) and reduced the specificity from 97 °/e and 93 °.%o (p = 0.50). Positive and negative 
predictive values are also shown and have been calculated with an infarct prevalence of 50% in 
this population Table 5 -5. 
Table 5 -5: Comparison of ECG criteria with ceMRI scan 
AMI detected by ECG NII detected by celdR.I Sensitivity Specificity Positive Negative 
guidelines (95% CI) (95% CI) predictive value predictive value 
Yes No 
(n =58) (n =58) 
GUSTO Yes 28 
STEIvII criteria No 30 57 0.48 (0 35,0 62) 0.98 (0.91.1 00) 0.96 0.65 
ACC/ESC Yes 29 
STEM" criteria No 29 56 0 50 (0.37,0.63) 0.97 (0.88,1.00) 0.94 0.66 
ACC/ESC 
STEMI and 
STEMI Yes 49 4 0.84 (0.73,0.93) 0.93 (0.83,0.98) 0.92 0.85 
equivalent No 9 54 
criteria 
CI = confidence interval. other abbreviations as in Table 5.21 and 5.2 
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Table 5 -6 presents the characteristics of the ceMRI- positive patients stratified according to 
detection by the ACC /ESC STEMI criteria (n = 29) and by the STEM1- equivalent ST- 
segment depression criteria only (n = 20). There is markedly longer delay from time of 
symptom onset until the initial ECG in the STEMI -equivalent group (median 5.5 h) than in 
the STEMI group (median 2.2 h [p = 0.00751). 
The AMI sizes estimated by the various biochemical markers are similar between the 2 ECG 
detection groups. There was a tendency toward lower LVEF in those detected by the STEMI 
criteria (54 %) than in those detected by the STEMI -equivalent criteria only (59 %) (p = 0.14), 
but it should be noted that both these values are within normal limits. However, as indicated, 
most (86 %) in the STEMI group but few (26 %) in the STEMI -equivalent group received 
reperfusion therapy. There was no significant difference in the presence or absence of MVO 
or transmurality or presence of multiple infarcts between the 2 groups. There was also no 
significant difference in the distribution of infarct locations between the 2 groups. 
- 71 - 
Table 5 -6: Comparison of demographic and clinical characteristics of ceMRI verified 
myocardial infarctions present by ST deviation ACC /ESC criteria 
CelvMR1 verified A.M2 
detected by 
ACC /ESC STEIvf 
criteria (n=29) 
CeIviRl verified MII 
detected by STEIvII 
equivalent criteria 
only (n =20) p value 
t1 uous variables 
Median (IQR) Infarct size, g* 
Median (IQR) Infarct size, °A LV 
mass* 
Age, years* 
Median (IQR) time to admission 
ECG, ht 
Median (IQR) time to ceMRI 
scan, h* 
31.2 (17.0 -44.6) 
23.8 (13.9 -36.3) 
55.7 (12.7) 
2.2 (1.3 -3.8) 
67.1 (50.1 -89.1) 
27.9 (16.4 -463) 
26.1 (14.5 -38.8) 
58.9 (13.0) 
5.5 (2.2 -17.1) 






Weight, kg 80.3 (16.5) 79.7 (17.9) 0.91 
Systolic BP, mm Hg 120.0 (16.9) 122.4(19.6) 0.65 
Diastolic BP, mm Hg 72.6 (10.4) 75.1 (11.3) 0.43 
Heart rate, beats/ min 54.2 (13.4) 53.4 (9.6) 0.81 
LVEF, % 54.0 (10.3) 58.6 (9.9) 0.14 
Median (IQR) peak Tnl, ng /mLt 43.8 (25.8 -68.5) 43.7 (12.4 -56.0) 0.34 
Median (IQR) peak CIÇ IU/mLt 746 (496 -2057) 989 (342 -1850) 0.78 
Median (IQR) peak CKMB, 55.1 (15.6 -172.1) 61.2 (12.3 -118.5) 0.88 
IU /mlt 
Median (IQR) CRP, mg /lt 48.5 (16.0- 107.0) 35.0 (11.0 -85.0) 0.61 
Categrrcal variables 
/vale 21 (72.4) 14 (70.0) 0.85 
Smokingt 20 (74.1) 14(73.7) 1.00 
Reperfusion Therapy 25 (86.2) 5 (263) <0.0001 
MUG 10 (37.0) 6 (31.6) 0.70 
Transmuralityr 21 (75.0) 12 (70.6) 0.74 
Infarct locationt 
Anterior 5 (18.5) 4 (20.0) 0.22- 
Inferior 14 (51.8) 5 (25.0) - 
Posterior 4 (14.8) 5 (25.0) - 
Inferior and Posterior 1 (3.7) 3 (15.0) - 
Multiple 3 (11.1) 3 (15.0) - 
All available data used; n is the maximum number in each group. Data are presented as mean @D) for 
continuous variables and number (°l°) for categorical variables unless otherwise stated. 
*Two -sample t-test used to compare continuous variables and chi- squared test (or Fisher Exact test as 
appropriate) for categorical. 1Wilcoxon rank sum test used for non- normal data. 
BP, blood pressure; ECG, electrocardiogram; CK, creatine kinase; CKMB, creatine kinase MB isoenzyme; 
CRP, C reactive protein; LVEF, left ventricular ejection fraction; MRl= magnetic resonance imaging; TnI, 
troponin I. 'Multiple category not included in test. 
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The comparative ceMRI- determined AMI sizes in the 2 ECG diagnostic groups are similar 
(median 31 vs. 28 g or 24% vs. 26% of the LV mass), Figure 5 -5. This result is in contrast to 
the trend (p = 0.29, Kruskal -Wallis test) to smaller AMI sizes in the group of 9 patients in 
whom even the STEMI equivalent criteria were not present. 
ECG criteria 
Comparative acute myocardial infarction (AMI) sizes (g) with median and interquartile ranges for 3 groups 
divided according to American College of Cardiologyt European Society of Cardiology (ACC/ ESC) criteria: 
detected by ST- segment elevation myocardial infarction (STEMI) criteria only (open triangles); detected by 
STEMI -equivalent criteria only (x); and AMI missed by both criteria (open circles). ECG = 
electrocardiographic. 
Figure 5 -5: Comparative AMI sizes with ECG Criteria 
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5.4 Validation of ECG and biochemical estimates of first AMI 
size using a ceMRI gold standard 
Thirty three (58 %) of the 57 patients with a single AMI received emergency reperfusion 
therapy Table 5 -7, a group that is synonymous with "STEMI ". Patients in the reperfused 
group were younger (mean 57 vs. 64 years, p= 0.047), had higher systolic (130 vs. 118, p =0.02) 
and diastolic (80 vs. 73, p =0.04) blood pressures than the non -reperfused group (that is 
synonymous with "NSTEMI"). AMI sizes by both biomarkers (CK -MB, TnI) and ECG 
(Selvester score) were larger in the reperfused group. The incidence of ST elevation (STE) was 
higher (73 vs. 13 %, p <0.001) and ST depression lower (18 vs. 46 %, p= 0.02). 
Aspirin, beta blocker and statin prescribing rates were similar for both groups and all over 
80 %. More patients in the reperfused group were discharged on an ACE inhibitor (77% vs. 
39 %, p= 0.01). Males made up over 75% of the population and patients in both groups had a 
similar risk factor profile with over 65% being current smokers. 
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Table 5 -7: Demographic and clinical characteristics for single AMI population and 






(n =24) p value 
Continuous variables 
Age, years 59.8 (12.5) 57.0 (13.0) 63.7 (11.0) 0.047 
Systolic BP 123.3 (18.6) 118.4 (16.4) 130.0 (19.7) 0.02 
Diastolic BP 75.9 (12.8) 72.9 (11.9) 79.9 (13.2) 0.04 
BMI 26.9 (4.0) 26.9 (4.3) 26.8 (3.6) 0.91 
TUvE risk score 3.5 (0.9) 3.5 (0.7) 3.5 (1.1) 0.85 
Time from pain to MRI 63.6 (22.8) 62.6 (21.4) 65.0 (25.1) 0.70 
Median (IQR) CKIVM, IUtml 68 96 40 0.04 
(19 - 131) (42 - 226) (15 - 100) 
Median (IQR) TnI, ng/ml 29.8 46.4 14.5 0.001 
(11.4 -64.9) (23.5 - 116.7) (10.2 - 32.4) 
Median (IQR) Selvester score 3 (1 -6) 4 (2 - 7.25) 3 (0 -5) 0.04 
Categorical variables 
Sex, male 43 (75.4) 25 (75.7) 18(75) 0.71 
Smoker 40 (70.2) 24 (72.7) 16 (66.6) 0.62 
Family history 22 (38.6) 12 (36.3) 10 (41.7) 0.68 
Diabetes 10 (17.5) 7 (21.2) 3 (12.5) 0.53 
Hypertension 21 (36.8) 11 (33.3) 10 (41.7) 0.52 
Hyp erc h o le s tero lae mi a 11 (19.3) 5 (15.1) 6 (25.0) 0.35 
Admission ECG: 
ST elevation 27 (47.4) 24 (72.7) 3 (12.5) <0.001 
ST depression 17 (29.8) 6 (18.2) 11 (45.8) 0.02 
Discharge Drugs: 
Aspirin 57 (100) 33 (100) 24 (100) 
Beta blocker 49 (86.4) 28 (84.6) 19 (88.9) 0.69 
ACE inhibitor 35 (61.4) 25 (76.9) 10 (38.9) 0.01 
Statin 55 (97.7) 32 (96.1) 24 (100) 0.4 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (%) for categorical variables unless otherwise stated. Comparisons made 
between the 2 groups reperfusion and non reperfusion. Two sample t-test used to compare continuous 
variables and chi -squared test for categorical. Wilcoxon rank sum test used for non -normal data. 
BP, blood pressure; BMI, body mass index, TIMI, thrombolysis in myocardial infarction; CKMB, creatine 
kinase MB isoenryme; TnI, troponin I, MRI, magnetic resonance imaging; ECG, electrocardiogram, ACE, 
angiotensin converting enzyme 
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By ceMRI, patients with a single AMI that had received emergency reperfusion therapy had 
significantly larger infarct sizes both on admission (mean 44g vs. 21g, p= 0.001) and at mean of 
38 days follow up (mean 31g vs. 13g, p= 0.004) Table 5 -8. This size difference was consistent 
in all dimensions of acute infarct size. A higher than expected proportion of patients had a 
transmural infarct; over three quarters (77 %) of the total population had a least one segment 
with an infarct transmurality that was over 50% of the wall thickness (mean = 3.5/4). 
Table 5 -8: Baseline and follow up infarct characteristics and left ventricular structure 
and function by cardiac ceMRI 
Total 
(Scan 1, n =57 
2, n=43 
3, n =38) 
Reperfused 




(Scan 1, n =24 
2, n= 17 
3, n =13) 
p value 
Infrari chrrmciteiisiics 
Infarct size, g. Visit 1 














Transrnurality score 3.5 (0.8) 3.7 (0.7) 3.1 (0.9) 0.02 
Transmurality ? 3 44 (77.2) 29 (88.1) 15 (62.2) 0.02 
Number of slices 6.3 (2.4) 7.1 (2.0) 5.2 (2.5) 0.002 
Number of segments 5.4 (2.7) 6.4 (2.5) 4.1 (2.5) 0.001 
Early MVO 35 (61.4) 24 (72.7) 11 (45.8) 0.04 
Late MVO 22 (38.6) 17 (51.5) 5 (20.8) 0.02 
LV structrae and function 
LVEF, %. Visit 1 55.9 (10.9) 53.8 (11.9) 58.7 (8.9) 0.09 
LVEF, Vo. Visit 3 54.8 (13.0) 51.4 (12.2) 61.3 (12.4) 0.02 
LVESV, ml. Visit 1 63.2 (25.3) 67.6 (26.4) 57.0 (23.4) 0.125 
LVESV, ml. Visit 3 86.0 (54.8) 95.7 (61.9) 67.8 (35.5) 0.08 
LVEDV, ml. Visit 1 140.9 (37.6) 144.6 (36.4) 135.7 (39.4) 0.38 
LVEDV, ml. Visit 3 181.1 (59.1) 186.3 (66.1) 171.0 (43.2) 0.45 
LV mass, g. Visit 1 130.4 (38.3) 132.1 (37.8) 127.9 (39.5) 0.68 
LV mass, g. Visit 3 138.3 (42.1) 137.5 (41.5) 140.0 (44.9) 0.86 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (Qlo) for categorical variables unless otherwise stated. Comparisons made 
between the 2 groups reperfusion and non reperfusion. Two sample t -test used to compare continuous 
variables and chi -squared test for categorical. Wilcoxon rank sum test used for non - normal data. 
IVIVO, microvascular obstruction; LVEF, left ventricular ejection fraction; LVESV, left ventricular end 
systolic volume; LVEDV, left ventricular end diastolic volume. 
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The total incidence of MVO was higher in the reperfused group, a result that would be in 
keeping with the larger infarct sizes. In both groups early MVO was detected more frequently 
than late MVO (reperfused, 73 vs. 52% and non -reperfused, 46 vs. 21 %). The proportion of 
MVO defined as late MVO was higher in the reperfused group than in the non -reperfused 
group (17/24 (71 %) vs. 5/11 (45 %), p <0.001). 
There were significant reductions in infarct size between admission and mean 38 days: by 30 
in the total population (p <0.001); by 30% (p <0.001) in the reperfused group; and by 37% 
(p= 0.001) in the non -reperfused group. 
There was no difference in LVEF between the groups on admission although there was a 
trend to a lower LVEF in the reperfused group (54 vs. 59 %, p= 0.09). By mean 203 days the 
difference in LVEF was significant (51 vs. 61 %, p= 0.02). LVEF remained stable between 
admission and mean 203 days when considering the whole group. 
Both the Selvester score and biomarkers correlate moderately well with acute infarct size by 
ceMRI in all cases and the correlation coefficient is better in the reperfused group Table 5 -9, 
Figure 5 -6. In the non -reperfused group TnI (r =0.43, p =0.05) and CKMB (r =0.54, p =0.02) 
correlated with infarct size. The Selvester score has a significant albeit weak correlation with 
TnI in reperfused infarcts only (r =0.5, p= 0.01). 
When correlations are made with final infarct size (at 38 days) there is an improvement in most 
r values: Selvester score (all: r =0.59 up to 0.69, p =0.47; reperfused: r =0.61 up to 0.72, p =0.5; 
non -reperfused: 0.31 up to 0.67, p =NA (sample size too small)); TnI (all: r =0.69 up to 0.75, 
p =0.93; non -reperfused: r =0.43 up to 0.78, p= 0.09). The contrary was found regarding the 
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correlation between TnI and infarct size in the reperfused group where the r value fell from 0.7 
to 0.59, p =0.5 between admission and mean 38 days. 
Table 5 -9: Correlation between selected measures of acute and final infarct size by 
acute reperfusion status 
Comparisons All cases Reperfusion No reperfusion 
r p r p r p 
Acute Inthirt size 
Infarct size, g. v Selvester 0.59 <0.001 0.61 <0.001 0.31 0.23 
(n=47) (n=30) (n=17) 
Infarct size, g. v TnI (ng /ml) 0.69 <0.001 0.7 <0.001 0.43 0.05 
(n=47) (n=26) (n=21) 
Infarct size, P. v CK1V11, (IU /ml) 0.60 <0.001 0.62 0.001 0.54 0.02 
(n=45) (n=27) (n=18) 
Selvester v TaI (ng /mi) 0.514 0.001 0.5 0.01 0.33 0.25 
(n=39) (n=25) (n=14) 
FmlIn rrtsize 
Infarct size, g. v Selvester 0.69 <0.001 0.72 <0.001 0.67 0.03 
(n =33) (n =23) (n =10) 
Infarct size, g v TaI (ng /ml) 0.75 <0.001 0.59 0.004 0.78 0.001 
(n =36) (n =22) (n =14) 
All available data used. Data are presented by number (n) suitable for analysis, Spearman's rank correlation 
coefficient (r) and significance (p). 
Tal, troponin I; CKA +IB, creatine kinase muscle brain isoenzyme; LVEF, left ventricular ejection fraction 
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Troponin I Selvester Score Selvester score 
Figure 5 -6: Individual correlations between ceMRI infarct size and Selvester score 
and TnI for the total population 
To investigate if the combination of Tnl and Selvester score improved the correlation with 
ceMRI derived infarct size a multiple linear regression model was formed. This included TnI 
first then the Selvester score was added Table 5 -10. 
Table 5 -10: The association between TnI alone and in combination with Selvester 
score with ceMRI derived admission and final infarct sizes 
All Reperfused Non reperfused 
R F change R F change R F change 




TnI plus Selvester 0.80 <0.001 0.82 0.003 0.43 0.25 
TnI 0.60 0.01 0.55 0.009 0.58 0.17 
Final infarct size 
TnI plus Selvester 0.80 <0.001 0.77 0.002 0.82 0.11 
All available data used. Data are presented as R, Pearson correlation and the significance of F change model 1 from control and model 2 with 
addition of Selvester to Tnl. 
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For the admission infarct size the Pearson correlation is seen to improve for the total 
population from 0.71 to 0.8, F change <0.001. There is improvement in both subgroups but 
only in the reperfused group is the addition of Selvester score to TnI significant 0.72 to 0.82, F 
change = 0.003). 
A similar pattern is seen when TnI and Selvester are used to predict final infarct size at mean 
38 days. For the total population the correlation rises from 0.6 to 0.8, F change <0.001. There 
was improvement in both subgroups but only in the reperfused group is the addition of 
Selvester score to TnI significant 0.55 to 0.77, F change = 0.002. 
The numbers are small when looking at the subgroups so no further comment can be made 
other than that the trend is consistent for improved correlation using the combined model. 
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5.5 The detection of myocardial scar by ceMRI in patients with 
TnI positive chest pain and minimal angiographic coronary 
artery disease 
CeMRI is able to both identify myocardial damage and describe its pattern. The aim of this 
analysis was to investigate the presence and pattern of DE in TnI positive patients with normal 
coronary arteries. 
Of the 153 patients that entered the study, 80 (52 %) were TnI positive. Of these TnI positive 
patients, 40 (50 %) were diagnosed as STEMI and received prompt reperfusion therapy with 
IV thrombolysis. Forty (50 %) were diagnosed with NSTEMI once the troponin result was 
available at 8 -12 hours. Coronary angiography was performed at the discretion of the physician 
in charge of the patient's care and reported by the operator, independent to the study. 
Coronary angiography was performed in 59/80 (74 %) of all troponin positive patients which 
accounts for 32 (80 %) of the STEMI group and 27 (68 %) of NSTEMI group. No significant 
stenosis was detected in a total of 8 (14 %) of angiograms performed (1 STEMI and 7 
NSTEMI). 
Of these 8 patients, mean (SD) 46 (12) years, 7 (88 %) had evidence of DE. Four had the 
standard ischaemic distribution of DE involving the subendocardium (2 inferior, 1 lateral and 
1 anterior). The infarct sizes were not trivial, median (IQR) infarct size was 8 (2.5 -21) g and 
TnI was 22 (11 - 34) ng /ml. 
Figure 6 -7 shows ceMRI images from three patients that had a normal coronary angiogram 
but were DE +. The left panel shows a SA image from a 54 year old female; the peak TnI was 
14.5ng /ml, DE mass was 13g (13% LV mass) and LVEF was 49 %. There was inferior DE 
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that is transmural with an associated regional wall motion abnormality. The admission ECG 
showed 2 mm inferior ST depression and the coronary arteries were entirely normal and 
treatment prescribed was aspirin and statin. 
The middle panel shows a ceMRI from a 66 year old male, peak TnI 29.3ng /ml, DE mass was 
3.1 g (3% LV mass) and LVEF was 73 %. Image shown is an adjusted LVOT view to 
incorporate the apical DE. Admission ECG showed significant ST depression and T wave 
inversion in leads V1 - V6 and III and aVF. Coronary angiography showed only plaque disease 
in the mid LAD (small vessel). There was a large dominant LCx and the RCA was a small 
vessel. Treatment was with aspirin, beta blocker, ACE inhibitor and statin. No embolic source 
identified at ceMRI. The most likely explanation was plaque rupture however this patient had 
had a MACE (stroke) by one year follow up. 
The right panel shows a SA slice from a 31 year old male, peak TnI 49 ng /ml, DE mass 45.5 g 
(33% LV mass). The LVEF was 65% with lateral hypokinesia. There is transmural DE in the 
lateral position with MVO. Admission ECG showed deep anterior ST depression and the 
patient was thrombolysed at 102 minutes following onset of chest pain. Coronary angiography 
showed a 25 -49% stenosis in the first obtuse marginal branch of the LCx, which is the likely 
culprit. No intervention was performed. Treatment was with aspirin, beta blocker, statin and 
ACE inhibitor. No MACE at three year follow up. 
Three (2 male) patients had subendocardial sparing pattern of DE and were diagnosed with 
acute myocarditis. All three had normal coronary arteries. One patient was negative for DE 
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and had a TnI of 4.4 ng /ml and a final diagnosis of Takotsubo cardiomyopathv was made by 
the characteristic LV cinematographic images, 5.9 below. 
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5.6 Serial assessment of MI size and characteristics using 
ceMRI 
Fifty seven patients with first presentation single AMI defined by history, ECG, TnI and 
ceMRI were included in this study. Forty five (79 %) attended for at least 2 studies, 35 (61 %) 
for at least 3 studies and 25 (44 %) for all 4. 
Study 1 was performed at mean (SD) 2.6 (0.9) days, study 2 at 38 (16) days, study 3 at 203 (34) 
days and study 4 at 387 (33) days. The follow up scans were performed as near as possible to 
the predefined time points but tended to be later than the planned date. The standard 
deviations indicate that the actual scan dates are within 2 weeks at visit 2 and within a month at 
visits 3 and 4. 
The clinical and angiographic characteristics of the study population are shown in Table 5 -11. 
The majority of patients presented within 8 hours (upper IQR = 8.5 hours). Just over a half 
(58 %) of infarcts were treated with IV thrombolysis at presentation. A further 19% had ST 
depression so would have been diagnosed based by STEMI equivalent criteria. Twenty three 
percent of patients had no ST deviation on the presenting ECG. 
The clinical protocol at the time of the study did not include routine inpatient coronary 
angiography for post AMI patients, so it was only performed in 72 %. If patients were clinically 
stable they could be discharged to have this performed as an outpatient. Subacute 
percutaneous intervention (PCI) is therefore defined as within 40 days of AMI and performed 
in 31 (54 %) patients. 
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Age, years 60 (12) 
BIv1I 26.9 (4) 
TIIAII risk score 3.5 (0.9) 
Time from pain to IvIRI, hrs 63.6 (22.8) 
Time from symptoms to admission, hrs 2.5 (1.6 - 8.5) 
CRP, mg/di, 28.6 (10.2 - 57.4) 
CK, N /ml 736 (332 - 2136) 
TnI, ng /ml 29.8 (11.4 - 64.9) 
NtBNP 1, ng/L 1276(740 -2117) 
NtBNP 3, AWL 253 (131 - 540) 
Presenting ECG total ST deviation, mm 10.3 (8.4) 
Selvester score 1 3.9 (3.4) 
Selvester score 2 4.2 (3.6) 
Categorical variables 
Sex, male 43 (75) 
Smoker 40 (70) 
Family history 22 (39) 
Diabetes 10 (18) 
Hypertension 21 (37) 
Hyp erc ho le s tero lae mi a 11 (19) 
Presenting ECG 
ST elevation 27 (47) 
ST depression 17 (30) 
Acute reperfusion 33 (58) 
Cardiac catheterisation 
Performed, n (o /o) 41 (72) 
. Subacute PCI 31 (54) 
Discharge Drugs 
Aspirin 57 (100) 
Beta blocker 49 (86) 
ACE inhibitor 35 (61) 
Statin 55 (98) 
Data are presented as mean (SD) or median (IQR) for continuous variables and number (°) for categorical. 
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Table 5 -12 shows the change in infarct size, characteristics and LV dimensions over 1 year. 
Mean infarct size and geometry all reduced over the time period and the greatest change 
occurred between visit 1 and visit 2. The most common infarct location seen at scan 1 was 
inferior in 27 (47 %) patients. Anterior was seen in 17 (30 %) patients and lateral in 13 (23 %). At 
the follow up scans the distribution was more balanced. 









Time chest pain to scan, days 2.6 (0.9) 38 (16) 203 (34) 387 (33) 
Infarct cha acteiis/ies 
Infarct size, g 34.6 (28.1) 24.9 (21.2) 26.9 (24.6) 24.8 (25.8) 
Endocardial extent, ° 92.3 (42.3) 82.7 (44.6) 80.2 (41.1) 63.9 (43.5) 
Transmurality score 3.5 (0.8) 3.1 (0.8) 3.1 (0.8) 2.8 (0.9) 
MVO early 
0 25 (44) 39 (93) 35 (95) 29 (97) 
1 32 (66) 4 (9.5) 3 (8) 1 (3) 
Size, g 9.2 (7.7) 4.0 (3.1) 2.2 (1.7) 5.7 
MVO late 
0 36 (63) 40 (93) 37 (100) 30 (100) 
1 21 (47) 3 (7) 0 0 
Size, g 9.4 (6.7) 2.3 (1.3) - - 
Infarct location 
Anterior 17 (30) 16 (38) 13 (35) 12 (40) 
Inferior 27 (47) 16 (38) 16 (43) 12 (40) 
Lateral 13 (23) 10 (24) 8 (22) 6 (20) 
LV dantensions 
LVEF, % 55.9 (10.9) 56.9 (11.8) 54.8 (13.0) 57.6 (14.3) 
LVEDV, ml 140.9 (37.6) 167.0 (50.9) 181.1 (59.1) 163.7 (55.8) 
LVESV, ml 63.1 (25.5) 75.5 (40.8) 86.2 (55.4) 72.4 (48.1) 
LV mass, g 130.4 (38.3) 145.2 (36.0) 138.3 (42.1) 150.6 (43.9) 
Data expressed as mean (SD) oz number (%) if categorical 
Early MVO was present more frequently than late MVO (66 vs. 47 %, p <0.0001). When late 
MVO is present there was always early MVO and 11 (20 %) patients have early MVO only. The 
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mean (SD) values for early (18 (8) %) and late (16 (9) %) MVO size were also similar when 
expressed as a percentage of the infarct size. Passive diffusion of some contrast agent may 
reduce the MVO area during the excess time of > 8 minutes, particularly as in some patients 
early MVO has resolved altogether by 10 minutes. There was a marked drop off in the 
incidence of both early and late MVO between scan 1 and scan 2. However, in a minority of 
patients the MVO persisted Figure 6 -8. 
There were 25 patients with a complete set of data at all 4 time points. The mean (SD) infarct 
sizes in this group was 42 (36), 27 (25), 27 (28) and 25 (27) g at each respective time point. This 
represented a mean (SD) reduction of 15 (16) g (36 %) between visits 1 and 2, 15 (14) g (36 %) 
between visit 1 and visit 3 and 17 (16) g (40 %) between visits 1 and visit 4. There was a greater 
absolute reduction in mean (SD) infarct size between visits 1 and 2 in those patients with late 
MVO, 23 (17) g, than those without, 6 (8) g, p= 0.004. 
When the whole group was considered using paired samples, there was a significant fall in 
infarct size between visits 1 and visit 2 and then the infarct sizes reached a plateau from visit 2 
onwards (p <0.0001) Table 5 -13. This reduction was consistent in transmurality. Hoever 
endocardial extent seemed to contiune to reduce over the four visits: -10" between visit 1 and 
2; -16" between visits 1 and 3; and -30" between visits 1 and 4. These differential patterns in 
change in infarct dimensions may merit further investigation in future studies. 
The LVEF showed a trend to improving between visit 1 and visit 4 (p= 0.07). The structural 
measurements, LVEDV and LVESV, peaked at 6 months. At 1 year there was a reduction 
back towards the baseline measurements. This may have been due to the beneficial effects of 
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secondary prevention (beta blocker and ACE I) as the doses are uptitrated and anti- 
remodelling occurs. 
LV mass returned almost to baseline at visit 3 and then compensatory hypertrophy may be 
seen at visit 4. 





dV4 - V1 
(95% CI) P 
Infarct characteristics 
Infarct size, g 
Endocardial extent, ° 
-12.7 ( -16.1, -9.3) 
-10.2 ( -19.1, -1.4) 
-13.0 ( -16.5, -9.4) 
-16.5 ( -26.0, -7.0) 
-14.1 ( -18.0, -10.2) 
-30.8 ( -41.1, -20.5) 
<0.0001 
<0. 0001 
Transmurality score -0.3 ( -0.6, -0.05) -0.4 ( -0.7, -0.1) -0.7 ( -1.0, -0.4) <0.0001 
LV dimensions 
LVEF, 2.1 ( -0.3, 4.4) 1.2 ( -1.3, 3.7) 3.5 (0.8,6.2) 0.07 
LVEDV, ml 23.0 (12.5, 33.4) 30.8 (19.9, 41.8) 18.8 (6.8, 30.7) <0.0001 
LVEDV, ml 10.0 (2.1, 17.9) 15.9 (7.6, 24.2) 5.3 ( -3.7, 14.3) 0.0019 
LV mass, g 11.4(4.4, 18.3) 0.6 ( -6.7, 7.9) 15.2 (7.3, 23.2) 0.00011 
Date expressed as mean difference and confidence intervals. Visit 1 is the baseline and used as the reference. 
V, visit. 
In order to investigate potential factors involved in different healing rates, MVO (early and 
late), acute reperfusion status and subacute PCI were assessed Table 5 -14 and Figure 5 -7. 
There was no difference in rate of reduction in infarct size between the 2 subacute PCI groups. 
This result is likely to be related to the large variation in time points at which PCI was 
performed between visit 1 and visit 2. The data is expressed as mean difference with 95% 
confidence intervals between the groups (data not shown). 
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Table 5 -14: The influence of MVO and acute reperfusion status on the healing rates 
of myocardial infarction 
AV2 -V]. 
(95°b CI) 
AV3 - Vi 
(95% CI) 
OV4 - Vi 
(95% CI) p 
Infarct size AVIVO early 
MVO late 
-11.9 ( -18.4, -5.3) 
-15.7(21.8, -9.7) 
-8.2 ( -152, -1.3) 
-12.1 ( -18.3, -5.8) 
-9.2 ( -17.1, -1.4) 
-15.0 (-21.8, -8.2) 
0.0036 
<0.0001 
Reperfirsion -5.5 (- 12.2,1.3) -5.5 (12.7, 1.8) -9.6 (17.4, -1.8) 0.095 
LIEF MVO early. -3.01 (-7.8, 1.7) -4.0 ( -9.1, 1.1) -6.3 ( -12.0, -0.6) 0.15 
MVO late -2.2 (-7.0. 2.5) -4.2 ( -9.1, 0.8) -6.0 ( -11.3, -0.6) 0.14 
Reperfusion -3.4 (-8.1, 1.4) -4.8 ( -9.9, 0.3) 0.43 ( -5.1, 6.0) 0.16 
LIEDI' MVO early 9.1 (- 12.24, 30.5) 5.2 ( -17.6, 28.0) 1.8 ( -24.0, 27,7) 0.85 
MVO late 22.4 (1.8. 42_.9 ) 30.8 (9.4, 52.2) 26.8 (3.6, 50.1) 0.022 
Reperfusion 6.81 ( -14.7, 28.3) 9.0 ( -14.0, 32.1) 11.2 ( -13.7, 36.1) 0.79 
LVESI' MVO early 10.5 ( -5.5, 26.4) 13.8 ( -3.2, 30.8) 12.8 ( -6.5, 32.1) 0.34 
MVO late 17.3 (2.1, 32.6) 27.6 (11.8, 43.5) 25.9 (8.6, 43.1) 0.0029 
Reperfusion 12.68 ( -3.4, 28.7) 17.0 ( -0.15, 34.2) 10.6 ( -7.9, 29.2) 0.22 
Li.' mass MVO earl- 3.8 ( -10.2, 17.8) -13.5 ( -28.4, 1.5) -7.7 ( -24.7, 9.2) 0.13 
AOVO late 0.13 ( -14.0, 14.2) -12.0 ( -26.7, 2.7) 1.0 ( -15.0, 17) 0.29 
Reperfusion -9.6 ( -23.9, 4.7) -1.6 ( -16.9, 13.8) -7.7 (-24.3, -1.8) 0.53 
Data expressed as mean difference between groups with confidence intervals. 
The rate of change in infarct size is greater in those patients with both early (p= 0.0036) and 
late (p <0.0001) MVO than those without. There is a trend to a greater reduction in infarct size 
in the reperfusion vs. non reperfusion groups (p= 0.095). Patients with late MVO demonstrate 
significant increases in LV dimensions; LVEDV (mean gain 27m1, p= 0.022) and LVESV 
(mean gain 26m1, p= 0.0029) than those without late MVO. 
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Figure 5 -7: Change in infarct size over time 
Figure 5 -7 illustrates the different gradients for reduction of infarct size between visit 1 and 
visit 2 for the total group and for each of the subgroups. In all cases the group with the larger 
infarcts had a steeper gradient. 
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5.7 Usefulness of CRP in detecting higher risk patterns of AMI 
defined by ceMRI 
This section uses ceMRI to describe the role of inflammation in ACS as measured by CRP. 
The diagnostic ability of CRP in patients admitted to hospital to rule out MI is tested and then 
correlated with infarct size. The ceMRI findings at the previously investigated CRP cut off 
levels, >3 and >10 mg /L, shown to be associated with adverse outcome are described. Finally 
the potential role of CRP in the detection of infarcts associated with microvascular obstruction 
is assessed and a new cut off level presented. 
Seventy one (46 %) of the patients admitted to rule out AMI had CRP > 10mg /L Table 5 -15 
and they had a higher mean WCC (10.5 vs. 7.3 x 109/L, p <0.001). Patients with a high CRP 
were older (mean 58 vs. 54 years, p =0.05) and had lower systolic (mean 122 vs. 129 mmHg, 
p =0.03) and diastolic (mean 74 vs. 81 mmHg, p <0.001) blood pressures. They had a larger 
median AMI size by CK, TnI and ceMRI. LVEF was lower during admission (57 vs. 65 %, 
p <0.001) and at 6 months follow up (56 vs. 66 %, p <0.001). More patients had ST elevation 
(38 vs. 11 %, p <0.001) and ST depression (25 vs. 10 %, p =0.01) on the presenting ECG. More 
patients had DE (80 vs. 35 %, p<0.001). The prescription rates of secondary prevention drugs 
reflected the higher rate of AMI with more patients receiving a beta blocker, ACE inhibitor 
and statin in the high CRP group. Amongst those patients with CRP <10mg /L a greater 
proportion had unstable angina (24 vs. 4 %, p= 0.044) and non cardiac chest pain (36 vs. 11 %, 
p <0.001). Patients with a low CRP were more likely to have either a family history of 
cardiovascular disease or a past medical history of hypercholesterolaemia. 
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Table 5 -15: Demographic and clinical characteristics for whole population and 






(n=71) p value 
Continuous variables 
Age, years 56.3 (12.8) 54.3 (12.0) 58.4 (13.4) 0.05 
Systolic BP 125.6 (19.7) 129.0 (19.4) 122.1 (19.8) 0.03 
Diastolic BP 77 (12.8) 80.8 (12.4) 73.6 (12.4) <0.001 
BMI 27.0 (4.7) 26.4 (4.3) 27.6 (5.1) 0.107 
TIM" risk score 2.6 (1.2) 2.1 (1.2) 3.2 (1.2) <0.001 
Time from pain to MRI, hrs 54.7 (32.0) 50.7 (37.3) 59 (24.6) 0.108 
Median (IQR) infarct size, g 0 (0 -6.1) 27 (1 -46.1) <0.001 
Median (IQR) CRP, mg/dL 7.3 (1.8 -36.4) 2.0 (1.1 -4.2) 38.0 (23.3 -83.8) <0.001 
Median (IQR) WCC, x 109/1 8.6 (7.1 -11.2) 7.3 (6.5 -9.0) 10.5 (8.3 -13.7) <0.001 
Median (IQR) CK, IU/ml 117 (77 -203) 504 (165 -2057) <0.001 
Median (IQR) TnI, ng/ml 0 (0 -0.85) 23 6 (2.2 -60) <0.001 
LVEF 1,% 60.8 (11.6) 64.5 (8.6) 56.5 (13 0) <0.001 
LVEF 3, % 61.5 (12.4) 66.1 (7.9) 56.4 (14.2) <0.001 
Categorical variables 
Smoker 103 (67) 50 (62.5) 51 (71.8) 0.22 
Family history 70 (46) 43 (53.7) 25 (35.2) 0.02 
Diabetes 38 (25) 21 (26.2) 17 (23.9) 046 
Hypertension 53 (35) 24 (30.0) 28 (39.4) 0.22 
Hypercholesterolaemia 33 (22) 22 (27.5) 10 (14.0) 0.04 
Admission ECG: 
ST elevation 37 (24) 9 (11.3) 27 (38.0) <0.001 
ST depression 26 (17) 8 (10.0) 18 (25.3) 0.01 
Discharge diagnosis 
DE + 85 (56) 28 (35.0) 57 (80.3) <0.001 
Single acute MI 57 (37) 14 (17.5) 43 (60.1) <0.001 
Acute and prior MI 11(7.1) 3 (3.8) 7 (9.9) 0.19 
Minimal myocyte necrosis 9 (5) 6 (7.5) 3 (4.2) 0.40 
Unstable angina 11(7) 9 (11.4) 2 (3.1) 0.044 
Acute myocarditis 3 (2) 1 (1.3) 2 (2.8) 0.60 
Prior non -ischaemic fibrosis 5 (3) 3 (3.8) 2 (2.8) 0.75 
Prior MI 9 (5.8) 7 (8.8) 2 (2.8) 0.174 
Chest pain, other 48 (31.3) 39 (48.8) 9 (12.7) <0.001 
Discharge Drugs: 
Aspirin 91 (59) 43 (53.8) 47 (66.2) 0.12 
Beta blocker 91 (48.0) 32 (40.0) 41 (57.7) 0.03 
ACE inhibitor 40 (26.3) 11 (13.8) 29 (40.8) <0.001 
Statin 69 (45.2) 26 (36.3) 42 (59.2) 0.001 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (%) for categorical variables unless otherwise stated. Comparisons macle 
between the 2 groups reperfasion and non reperfusion. Two sample t-test used to compare continuous 
variables and chi -squared test for categorical. Wilcoxon rank sum or Mann -Whitney U test used for non - 
normal data. Data from 2 patients is omitted from the total population clue to missing CRP values. 
ACE, angiotensin converting enzyme; BMI, body mass index; CRP, C- reactive protein; DE +, ceMRl positive 
for delayed hyperenhancement; TIMI, thrombolysis in myocardial infarction; WCC, white cell count. 
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To test the ability of CRP to diagnose AMI using a ceMRI gold standard for infarct presence, 
Receiver Operator Characteristics (ROC) were assessed in all 153 patients. The area under the 
curve (AUC) (95% CI) for CRP was 0.8 (0.73, 0.87), p <0.001 Figure 5 -8. For reference, the 
ROC curves for TnI (AUC 0.98 (0.96, 1.00)) and CK (AUC 0.86 (0.79, 0.93)) are also shown. 
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Figure 5 -8: Receiver Operator Characteristics for CRP, TnI and CK using ceMRI 
gold standard 
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Of the 57 patients with single AMI, 43 (75 %) had a CRP >10 but there was no difference in 
WCC (11.4 vs. 9.6, p= 0.109) Table 5 -16. 
These patients had significantly larger infarct sizes by ceMRI both acutely (median 40 vs. 14 g, 
p= 0.001) and at follow up (28.0 vs. 7.7 g, p= 0.009). The endocardial extent was greater (99" vs. 
66", p =0.02) but there was no difference in transmurality. 
They showed a trend to reduced mean LV ejection fraction during admission (54 vs. 61 %, 
p =0.07) that reached significance at 6 months (53 vs. 63 %, p= 0.001). The admission LVESV 
was higher (67 vs. 51 ml, p= 0.005) but this difference was no longer significant at 6 months. 
ST deviation occurred more frequently on the admission ECG in the high CRP group but this 
difference did not reach significance. 
The prevalence of late MVO in the total population is just over a quarter at 26 %. Patients with 
a high CRP had a greater proportion of early MVO (70% vs. 29 %, p= 0.011) and late MVO 
(47% vs. 7 %, p= 0.01). 
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Table 5 -16: CeMRI, biochemical and electrocardiographic characteristics in patients 










Median (IQR) Acute 
infarct size, g 
31.2 (14.4 -48.2) 14.2 (7.7 -25.7) 40.1 (21.8 -67.2) 0.001 
Median (IQR) Final 
infarct size, g 
22.2 (6.3 -38.8) 7.7 (4.0 - 22.2) 28.0 (15.6 -40.6) 0.009 
Transmurality score 3.5 (0.8) 3.1 (1.0) 3.6 (0.73) 0.15 
Endocardial extent 90.7 (43.9) 66.4 (36.6) 98.9 (43.5) 0.02 
Categorical variables 
MVO early 35 (61) 4 (29) 30 (70) 0.011 
MVO late 22 (39) 1 (7) 20 (47) 0.01 
Transmurality ? 3 44 (77) 9 (64) 35 (81) 0.185 
LV structure and 
function 
LVEF 1,% 55.9 (10.9) 60.5 (7.5)) 54.4 (11.5) 0.07 
LVEF 3, % 54.8 (13.0) 63.4 (3.9) 52.8 (13.5) 0.001 
LVEDV 1, ml 140.9 (37.6) 130.4 (28.2) 144.3 ( 39.9) 0.234 
LVEDV 3, ml 181.1 (59.1) 152.7 (39.3) 187.5 (61 4) 0.16 
LVESV 1, ml 63.2 (25.3) 51.3 (12.7) 67.0 (27.5) 0.005 
LVESV 3,m1 (54.8) 93.1 (59.0) 0.106 
LV mass 1, g 130.4 (38.3) 119.7 (37.3) 133.8 (38.4) 0.23 
LV mass 3, g 138.3 (42.1) 117.5 (25.5) 143.1 (43.9) 0.15 
Biochemical markers 
Median (IQR)WCC,x109/1 10.9 (8.7 -13.8) 9.6 (8.7 -11.6) 11.4 (8.7 -14.0) 0.109 
Median (IQR) TnI, ng/ml 29.8 (11.4 -64.9) 11.3 (4.4 -36.2) 41.7 (20.2 -29.0) 0.005 
Admission ECG 
ST elevation 27 (47) 5 (36) 22 (51) 0.32 
ST depression 17 (30) 4 (29) 13 (30) 0.91 
All available data used; n is the maximum number in each group. Data are presented as mean (SD) for 
continuous variables and number (9'0) for categorical variables unless otherwise stated. Two sample t-test used 
to compare continuous variables and chi - squared test for categorical. Wilcoxon rank sum test used for non - 
normal data. Infarct size represents planimetered delayed enhancement (DE) mass 
Abbreviations as previous tables. 
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Having established that the diagnostic ability of CRP compares favourably with standard 
biomarkers the correlation of CRP with infarct size was assessed Figure 5 -9 and Table 5 -17. 
All single acute ischemic necrosis Acute reperfusion No acute reperfusion 
Figure 5 -9: Correlations CRP and infarct size by ceMRI for all infarcts and by 
reperfusion status 
There is a moderate correlation of CRP with infarct size in the total group (r =0.57, p <0.001), 
in the reperfused group (r =0.6, p <0.001) and in the non -reperfused group (r =0.56, p= 0.004). 
When CRP was compared to final infarct size (mean 38 days) in the non- reperfused group 
there was a significant increase in the correlation (r =0.56 up to 0.87, p= 0.04). 
The WCC mildly correlates with infarct size (r =0.37, p= 0.004) in the total population. In 
contrast to the standard biomarkers (CK, Tnl) WCC correlates better with non -reperfused 
acute myocardial infarct size (r =0.55 vs. r =0.20, p= 0.14). Similarly, only in the non -reperfused 
group did CRP correlate with TnI (r =0.73, p <0.001). 
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There was a modest correlation between CRP and acute LVEF in the reperfused group 
(r= -0.49, p= 0.004) which improved when compared to the 6 month LVEF (r= -0.67, 
p <0.001). 
Table 5 -17: Selected correlations with CRP by acute reperfusion status 
Comparisons il cases Reperfusion No reperfusion 
r p r p r p 
Acute Irbrct 
CRP y Infarct size, g. 0.57 <0.001 0.60 <0.001 0.56 0.004 
(n =57) (n =33) (n =24 
TnI y Infarct size, g 0.69 <0.001 0.70 <0.001 0.43 0.05 
(n =47) (n =26) (n =21) 
1CC y infarct size, g 0.37 0..004 0.20 0.27 0.55 0.006 
(n =57) (n =33) (n =24) 
CRP y TnI (ng/m1) 0.41 <0.001 0.23 0.25 0.73 <0.001 
(n =47) (n =26) (n =21) 
CRP y LVEF, % -0.28 <0.001 -0.49 0.004 -0.12 0.96 
(n =57) (n =33) (n =24) 
Chronic /r/act 
CRP y Infarct size, g 0.56 <0.001 0.40 0.05 0.87 <0.001 
(n =43) (n =26) (n =17) 
CRP v LVEF, -0.63 <0.001 -0.67 <0.001 -0.40 0.17 
(n =38) (n =25) (n =13) 
All available data used. Data are presented by number (n) suitable for analysis, Spearman's rank correlation 
coefficient (r) and significance (p). 
CRP, C- Reactive Protein; Tn!, tsoponin I; WCC, white cell count; LVEF, left ventricular ejection fraction. 
The diagnostic abilities of the available biochemical and bioelectrical markers to determine 
presence of late MVO were then tested and the ROC curve is shown Figure 5 -10. The ROC 
curves for early MVO were similar although AUC reduced for each parameter, not shown. 
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Figure 5 -10: Receiver Operator Characteristics for CRP, Troponin, CK and the 
Selvester score for the prediction of late MVO 
Surprisingly the "old fashioned" CK comes out on top with an AUC of 0.93 (0.87 - 0.99) with 
the Selvester score next, AUC 0.88 (0.79 - 0.96). Troponin (0.79 (0.69 - 0.9)) and CRP (0.79 
(0.68 - 0.9)) are very similar Table 5 -18 and Figure 5 -10. 
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Table 5 -18: Area under the curve and ROC determined optimum sensitivity and 
specificity of routine biochemical and bioelectrical markers of myocardial infarction 
in the diagnosis of late MVO 
ALTC (95% CI) Cut off Sens. (95% CI) Spec. (95% CI) PPV NPV LR 
CRP 0.79 (0.68 -0.9) <0.0001 > 26 0.85 (0.76 -0.95) 0.66 (0.56 -0.75) 0.47 0.92 2.5 
TnI 0.79 (0.69 -0.9) <0.0001 > 25 0.85 (0.76-0.95) 0.62 (0.53 -0.72) 0.45 0.92 2.3 
CK 0.93 (0.87 -0.99) <0.0001 > 850 0.90 (0.80 -1.0) 0.80 (0.70 -0.89) 0.61 0.96 4.4 
ECG 0.88 (0.79-0.96) <0.0001 > 3.5 0.75 (0.64 -0.86) 0.80 (0.69 -0.91) 0.63 0.88 3.8 
(SS) 
The cut off values are the optimum from the coordinates of the ROC curve. 
AUC, Area under the curve: CI, confidence interval; ECG, represents the Selvester score; PPV, positive 
predictive value: NPV, negative predictive value; LR, likelihood ratio. Prevalence of late MVO in the 
population is 0.26. 
Using the coordinates of the ROC curve the cut off points with optimum sensitivity and 
specificity in the diagnosis of late MVO were defined. A CRP of >26 mg /L has a sensitivity 
and specificity of 0.85 and 0.66 respectively, with a likelihood ratio of 2.5. A similar result is 
obtained using a TnI cut off of >25ng /nil. The ECG derived Selvester score as a measure of 
infarct size has a cut off of >3.5 points. The sensitivity is 0.75 and specificity 0.8 and likelihood 
ratio of 3.8. 
The most useful test in determining presence/ absence of MVO in this population is CK with 
a sensitivity of 0.9 and specificity of 0.8 at a cutoff point of >850 IU/ ml (peak value out of 3 
(admission, 12 hours and mean 2.6 days)). 
A model was constructed using logistic regression, (method: forward stepwise (likelihood 
ratio)) to look for the best parameters in the detection of late MVO. In addition to the above 4 
biomarkers, the model included age and time from chest pain to presentation. 
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Table 5 -19: Logistic regression to predict presence of late MVO 
Wald p Exp B (95% CI) 
Step 1 CK 18.5 <0.0001 1.002 (1.001 -1.003) 
Step 2 CRP 6.70 0.01 1.013 (1.003- 1.024) 
CK 14.8 <0.0001 1.002 (1.001- 1.004) 
Step 3 CRP 6.3 0.012 1.014 (1.003 -1.025) 
CK 9.1 0.003 1.002 (1.001 -1.003) 
Selvester 3.3 0.07 1.4 (0.97 -2.021) 
Variables entered on step 1, CK, step 2, CRP, step 3, Selvester Variables not in the equation: TnI, age, 
time from chest pain to admission 
The only 3 variables left in the model were CK, CRP and Selvester Table 5 -19. CK was the 
strongest predictor with overall 86°,/o of late MVO correctly predicted, rising to 88.1°/0 with the 
addition of CRP and 90% when all 3 are present. 
It is slightly surprising that TnI does not feature but it may be that CK provides enough 
information about necrotic myocytes and the additional information from CRP relates to an 
additional inflammatory response that may be associated with MVO. 
To investigate reasons why CRP infers increased risk, the ability to predict MVO at each 
routinely used CRP cut off was tested for both early and late MVO in TnI positive patients. 
The sensitivities and specificities of CRP to detect early MVO were: CRP >3 =0.97 (0.86, 1.0) 
and 0.25 (0.14, 0.36), LR 1.3; CRP >10 =0.87 (0.76, 0.98) and 0.45 (0.34, 0.56), LR 1.6; and 
CRP >26 =0.67 (0.56, 0.78) and 0.7 (0.59, 0.81), LR 2.2. 
Table 5 -20 shows the results for late MVO. There were no patients with late MVO that had a 
CRP <3 and only 1 patient <10 mg /L. This is reflected in the high sensitivity but low 
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specificity. The lower limit of the confidence interval for specificity is >0.5 for early and late 
MVO at a CRP of >26mg /L. 
Table 5 -20: Sensitivity and specificity of CRP in the diagnosis of late MVO by ceMRI 
in TnI positive patients 

















Yes 21 47 
CRP >3 (n =6 8) 1 O (0 9 -1 0) 0.19 (0.09 -0.29) 0.3 1.0 1.2 
No 0 11 
(n =11) 
Yes 20 35 
CRP >I0 (n =55) O 95 (0 85 -1 0) 0.40 (0.30 -0.49) 0.36 0 96 1.6 
No 1 23 
(n =241 
Yes 18 20 
CRP >26 (n_38) 0 86 (0 76 -0.95) 0.66 (0.56 -0 75) 0 47 0.92 2.5 
No _ 38 
(n=41) 
There were 3 patients with late MVO but CRP <26 mg /L (CRP values 7.33 (male, age 54), 
13.38 (male, age 31) and 16.0 (female, age 40); in all cases the CK was >850, the TnI > 25 and 
all were transmural (score 4). Two were thrombolysed and the Selvester score was 5 in both. 
Figure 6 -9 shows a SA slice from each patient demonstrating late MVO. 
On the left is a patient that had a lateral infarct (36g), 12% of which was MVO. 
The patient with the anterior MI (46g) had an admission LVEF of 48 %, 10% of which was 
MVO, middle panel. 
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The 31 year old had 45g of lateral infarction, 10% of which was MVO, a normal LVEF and 
Selvester score of 1, right panel. He had minimal coronan disease at angiographv so plague 
rupture was thought to be the aetiology (Intravascular Ultrasound (TVUS) was not performed). 
There is no obvious explanation as to why these patients had late MVO and lower CRP 
although the ratio of MVO/ infarct size for all three is in the lower half (the median ratio 
being 13 %). 
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5.8 MMP -1 promoter polymorphisms and changes in LV 
volume following AMI 
Changes in LV volumes in patients with differing MMP -1 genotypes are listed in Table 5 -21. 
In comparison with patients with the G/G genotype, patients possessing a single GG allele 
exhibited no difference in volume changes after AMI. 




(n = 42) 
G/G Genotype 
(n = 11) 
G /GG 
Genotype 
(n = 25) 
GG /GG 
Genotype 
(n = 6) p Volue 
Age (yrs) 60 (45 -67) 63 (52 -70) 61 (45 -66) 52 (42 -71) 0.66 
Men 34 (81 %) 10 (91 %) 18 (72) 6 (100%) 0.18 
Hypertension 15 (36%) 4 (36 %) 9 (36%) 2 (33 %) 0,97 
Diabetes mellitus 4 (10 %) - 3 (12i,) 1 (17 %) 0.63 
Hypercholesterolem is * 24 (57%) 6 (55 %) 13 (52 %) 5 (83%) 0 37 
Current smoker 33 (79%) 8 (73 %) 21 (84 %) 4 (67%) 0.95 
Anterior myocardial infarctions 13 (31 %) 6 (55 %) 7 (28 %) - 0.08 
Inferior /lateral myocardial infarctions 26 (62 %) 5 (45 %) 15 (60%) 6 (100 %) 0.08 
ST-elevation myocardial infarction 19 (45 %) 4 (36 %) 12 (48 %) 3 (50 %) 0.79 
12 -h cardiac troponin I (ng /ml) 46 (9 -78) 38 (10 -86) 55 (7 -94) 30 (1 -72) 0.72 
Revascularization during study period* 23 (55%) 7 (64%) 12 (48 %) 4 (67 %) 0.56 
Discharge medication 
ACE inhibitor or ARB 28 (67 %) 8 (72 %) 16 (64 %) 4 (67 %) 0.88 
ß blocker 34 (81 %) 9 (82%) 19 (76 %) 6 (100 %) 0.40 
MRI measurements of baseline 
LV end -systolic volume (ml) 61 (49 -79) 75 (56 -94) 60 (48 -76) 54 (32 -65) 0.16 
LV end - diastolic volume (ml) 146 (120 -174) 154 (140 -197) 145 (120 -170) 122 (103 -155) 0.19 
LV ejection fraction ( %) 58 (49 -65) 54 (39 -60) 59 (50 -65) 62 (46 -67) 0.52 
Infarct size (g) 30 (8-46) 24 (6-70) 30 (11-47) 31 (6 -66) 0.98 
MRI measurements of 6 mo 
LV end -systolic volume (ml) 72 (52 -100) 73 (63 -108) 68 (36 -101) 71 (48 -100) 0.72 
LV end -diastolic volume (ml) 166 (132 -205) 165 (143 -204) 166 (127 -205) 176 (140 -236) 0.84 
LV ejection fraction (%) 58 (49 -65) 55 (46 -62) 57 (52 -69) 64 (46 -68) 0.35 
Changes in LV volumes 
Change in end -systolic volume (ml) 8 ( -7 to 21) 7 ( -6 to 14) 3 ( -15 to 24) 16 (12 -42) 0.16 
Change in end -diastolic volume (ml) 20 ( -10 to 51) 7 ( -13 to 32) 10 (-11 to 54) 52 (35 -85) 0.07 
% change in end -systolic volume 14 ( -17 to 41) 13 ( -8 to 19) 4 ( -23 to 42) 45 (23 -70) 0.05 
% change in end -diastolic volume 11 ( -8 to 39) 4 ( -10 to 18) 8 ( -9 to 37) 41 (28 -70) 0.03 
Results shown are medians (interquartile ronges) or absolute values (percentages). 
`History of hypercholesterolemia or random cholesterol >5.5 mmol /L (212 mg /dl) on admission. 
in 3 cases, the site of infarction could not be accurately defined. 
*Seventeen during index admission, 6 during subsequent 6 months. 
ACE = angiotensin converting enzyme; ARB = angiotensin -ii receptor antagonist. 
Similarly, there was no difference in allele frequency in patients exhibiting a <_ 10% or > 10% 
increase in LV volumes Table 5 -22. However, patients possessing the GG /GG MMP -1 
- 103 - 
genotype were significantly more likely to experience a >10% increase in LV end -systolic vol- 
ume (p = 0.02, relative risk 1.4, 95% CI 1.1 to 1.8) or LV end -diastolic volume (p = 0.009, 
relative risk 1.4, 95% CI 1.1 to 1.9) compared with those with the G/G or G /GG genotype. 
Table 5 -22: MMP -1 Allele frequencies in patients exhibiting < 10% or > 10% 
increase in LV volumes after an AMI 
G Allele GG Allele Relative Risk (95% CI) p Value 
5:-10% increase in LVESV 24 14 
>10% increase in LVESV 23 23 1.26 (0.87 -1.84) 0.27 
....510% increase in LVEDV 27 15 
>10% increase in LVEDV 20 22 1.35 (0.91 -1.99) 0.19 
Ci = confidence interval; LVEDV = LV end - diastolic volume; LVESV = LV end -systolic volume. 
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5.9 Additional ceMRI findings in patients with first hospital 
admission for chest pain to rule out MI 
This section describes additional findings in patients admitted to rule out MI and is based on 
the diagnostic category Figure 5 -4. The chapter also includes a description of patients from 
the whole population with right ventricular infarction or LV thrombus 
Acute Myocarditis 
Three patients were diagnosed with acute myocarditis based on a rise and fall of TnI, normal 
coronary angiography and a subendocardial pattern of DE that did not adhere to a particular 
coronary artery territory. 
Table 5 -23: Selected clinical features of patients with discharge diagnosis of acute 
myocarditis 
No. Age Sex ECG TnI CRP WCC Nt- 
ENP 
I?E, LVEF TR+ri 
37 34 M Inf. 70.9 107 10.3 2454 74.7 53 3 
STE 
70 37 F Norm 0.4 1.5 8.6 333 6.3 61 2 
229 42 F Lat. 29.3 259 16.5 4225 36.5 46 3 
STE 
No., patient number; DE, Delayed enhancement; Ait. BNP, N terminal Brain Natriuretic Peptide; STE, ST 
segment elevation 
Two patients presented with ST elevation and were considered for acute reperfusion therapy. 
One (number 37) received thrombolysis Figure 6 -10 and the intention for the other was 
primary PCI. 
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The 3rd patient's presenting ECG was normal. The biomarkers of myocardial necrosis (TnI, 
CK) and inflammatory markers (CRP, WCC) levels were variable and greater in the two 
patients with largest DE mass. The TIMI score was low or low /moderate risk in all. Points 
were scored for chest pain, positive biomarkers and ECG changes. None of the patients had 
>3 traditional risk factors and only one smoked. All 3 patients underwent diagnostic coronary 
angiography and no significant stenosis was identified. The working clinical diagnosis was, 
"coronary embolus/ spasm" until ceMRI was performed. Delayed hyperenhancement that 
spares the subendocardium and does not match a coronary artery territory is demonstrated 
(Figure 6 -10, upper left: 4 chamber and upper right: mid ventricular SA). 
It was possible to planimeter the regions of hyperenhancement in all patients and the % LV 
mass was variable. No regional wall motion abnormality was detected and all were reported as 
having normal LV function by echo. By ceMRl the LV ejection fraction varied between 46 and 
61 %. By 28 days the LVEF was >60% in all three cases and remained so out to one year. Two 
patients (numbers 37 and 70) attended for one year follow up and the DE mass was reduced 
(74.7g to 48.9g and 6.3g to 2.3g). The third patient only attended for 28 day follow up and 
again DE mass was reduced (36.5g to 6.3g). 
One patient (number 37) was treated with ACE inhibitor, aspirin and B blocker whilst the 
other two were maintained on aspirin only. NtBNP was elevated in all three patients during 
admission (2454, 333 and 4225) falling to near normal levels (305, 23.2 and 339) by 28 days. 
Values were within normal limits in the two patients that attended for 1 year follow up (18 and 
26). Figure 6 -11 shows the SA and 4 chamber views at each follow up scan of the index 
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patient illustrating the persistence of, but reduction in, area of DE over time (scan 1, 74.7g; 
scan 2, 70g; scan 3, 45.7g; and scan 4, 48.9g). 
Prior myocardial infarction 
Twenty (13 %) patients had evidence of previous myocardial infarction when examined using 
ceMRI; 11 were TnI positive and nine were TnI negative. 
Troponin I positive patients 
Eleven patients with a mean (SD) age 62 (13) years, 7 (64 %) of whom were male were TnI 
positive (median (IQR) 10 (7 -25)) with an ischaemic pattern of DE in ?2 coronary artery 
territories and/ or evidence of prior myocardial infarction on the presenting ECG (Q waves) 
Figure 6 -12. 
Three patients presented with ST elevation and were thrombolysed; two had significant ST 
depression. Mean (SD) LVEF was 56.6 (11.3) % and similar to the acute single MI group. 
Three patients had prior infarction by ECG criteria but single region of DE suggesting that the 
time period from infarct to patient presentation was longer than represented by the patient's 
symptoms, but within 2 weeks as TnI was still detectable. The location of the Q waves 
matched the DE location by ceMRT (two inferior and one anterior) in three out of four cases. 
Seven (64 %) patients had a mean transmurality score of >_ 3. 
Early MVO resolves with time in the majority of cases so its presence may help to differentiate 
between acute and prior MI. Four patients had early MVO in 1 of the infarct areas. Two 
patients (numbers 149, 296) had ST deviation on the ECG and the MVO was related to the 
culprit lesion at coronary angiography; the 3rd had multi vessel PCI; and the 4th was not 
investigated further. 
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Table 5 -24: Selected clinical characteristics of patients with a discharge diagnosis of 
acute and prior myocardial infarction 








34 76 F Inf.. STE 19.2 64.4 53.11 Ant, Inf 
89 75 M Normal 8.4 15.9 43 05 Ant Lateral 
95 64 M Lateral ST 112 30.5 55.53 Ant. Lateral 3vd 
Dep. 
104 51 M Ant. Q 
waves 
7.9 32.3 39.3 Ant Inf. LCx 
110 73 F Amt. Q 
waves 
6.2 7.7 80.14 Inf. 
117 53 M Inf.. Q 
waves 
1.6 5.1 58.12 Inf. 2vd 
149 50 M Inf STE 34.4 21.4 53.12 Ant. Inf. LAD 
201 65 M Normal 9.7 8.4 69.75 Inf Lateral 3vd 
218 78 F Ant Q 
waves 
5.8 12.0 59.68 Ant 
272 40 F Inf. STE 12.7 12.0 58.98 Ant. Lateral 3vd 
296 58 M Inf. ST 30.8 40.1 51.9 Ant. Inf. RCA 
Dep 
No., patient study number, M, male, F, female; DE, delayed hyperethancement; loc., location, STE, ST elevation; P, p, depression; Ant., anterior; Inf., inferior; 2 or 
3vd, 2 or 3 vessel disease at coronary angiography (>70% stenosis). 
Patient example 1: Acute and prior Ml, patient number 149 
There is MVO associated with the inferior but the not anterior MI Figure 6 -13. This is 
possibly due to difference in size and transmurality, but acuteness may contribute. The 
admission ECG showed inferior ST elevation and thrombolysis was administered. At inpatient 
coronary angiography the culprit artery was a distal LAD occlusion with residual clot, no PCI 
was possible. It is possible that the culprit lesion was actually more proximal and there was 
embolisation into a diagonal branch (causing the basal anterior DE) and into the distal part of 
a "wrap- around" LAD (infero- apical DE). 
Patient example 2: Acute and prior MI, patient number 34 
A 76 year old female presented within 2 hours of chest pain and inferior ST elevation on ECG. 
She was thrombolysed and successfully reperfused by 90 minute ECG criteria resolution. 
- 108 - 
Coronary angiography was not performed. Routine echo contained no mention of LV 
aneurysm and concluded, "There is mild/ moderate LV dysfunction, infero- posterior segment 
thinned and hypokinetic. LV dilated distally." At ceMRI there was a localised aneurysmal 
segment in the mid lateral wall with significant thinning Figure 6 -14. LVEF was 53 %, the 
patient did not return for follow up scans but she had not experienced a MACE at 3 years. 
Troponin I negative patients 
Nine patients with a mean (SD) age of 64 (11) years, 6 (67 %) of whom were male had evidence 
of prior myocardial infarction by ceMRI but negative TnI Table 5 -25. Cardiovascular risk 
profile: current smoker (n =5); hypertension (n =4); hypercholesterolaemia (n =1); positive 
family history (n =4); and diabetes (n =1). The highest TIMI score was 4 (two patients). 
Table 5 -25: Selected clinical characteristics of patients with a final discharge 
diagnosis of prior (silent) myocardial infarction 
No. Age, 
yrs 










69 60 M Normal 191 1 3.2 Inf. 54 3vd 
115 81 M LVH 113 3 5.6 Lateral 74 
118 44 M Ant. S.L.E. 270 2 3.0 Lateral 72 - 
124 67 F LVH 65 3 0.9 Ant. 71 
147 74 M If Q waves 132 4 8.2 Inf. 50 - 
221 70 F Normal 65 3 6.7 Lateral 66 - 
231 55 M LBBB 84 3 7.6 Ant 12 Normal 
240 58 M Inf. TWI 102 1 6.4 Ill 52 RCA 
293 71 F Inf. ST dep. 159 4 9.3 Itif. 65 
LBBB, left bundle branch block; TWI, T wave inversion; dep., depression. 
Only one patient was correctly identified as "old infarction" by the ECG core lab (inferior Q 
waves). ECG core lab findings in the remainder: normal (n =2); LBBB (n =1); subendocardial 
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ischaemia (n =1); T wave inversion (n =1); LVH (n =2); and acute anterior MI (n =1). 
Three patients had diagnostic coronary angiography with the following diagnoses and 
treatment: normal arteries (n =1); 3 vessel disease (n =1), referred for CABG; significant RCA 
disease (n =1), follow on PCI. Infarct size by ceMRI varied from 0.9 - 9.3g. 
Infarct location was inferior or lateral in 7/9 (78 %): inferior (n =4); lateral (n =3); and anterior 
(n =2). Three patients (33 %) were discharged on secondary prevention therapy (aspirin, ACE 
inhibitor, beta blocker and statin). One patient was started on aspirin alone. LV ejection 
fraction was above 50% in six patients. 
Patient example 3: Prior myocardial infarction, patient number 221 
A 70 year old female smoker presented with chest pain described as a, "discomfort ". She had 
a past medical history of hypertension and a positive family history. TIMI risk score of 3, 
normal ECG, TnI negative and peak CK 65 IU /ml. CeMRI was performed 25 hours from 
onset of pain and showed DE in basal lateral segments and infarct size of 6.1 g (8% LV) 
Figure 6 -15. 
Infarct size was similar at 28 days (6.8g) and 6 months (6.8g). LVEF was 65% during 
admission and 67% at 6 months with no regional wall motion abnormality. The patient was 
discharged on aspirin alone and there was no MACE up to 3 years. 
Patient example 4: Prior myocardial infarction, patient 231 
A 55 year old male, with no standard cardiovascular risk factors presented with chest pain as 
primary symptom. He denied significant dyspnoea and was NYHA functional class 2. His 
alcohol consumption was >50 units per week. ECG showed LBBB with QRS duration 167ms 
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and a chest X ray showed cardiomegaly with clear lung fields. Cardiac catheterisation revealed 
smooth epicardial arteries, an LV end diastolic pressure of 4 mmHg and mean pulmonary 
artery wedge pressure of 7 mmHg. The official report of both the LV -gram and echo state that 
there is a possibility of LV thrombus. CeMRI was performed at 74 hours following onset of 
chest pain (Figure 6 -16). 
CeMRI revealed a dilated LV with severely impaired systolic function (LVEF 12 %, LVEDV 
442 ml, LVESV 389m1 and LV mass 275g). Early MVO was seen at one minute (upper right) 
in a similar location to the thin rim of anterior subendocardial DE (lower right). Mean 
transmurality score was 1.2 and endocardial extent 60 °. No thrombus was seen. He was started 
on aspirin, ACE I, beta blocker, statin. Frusemide was reduced to 40mg because of low filling 
pressures and he was advised to abstain from alcohol altogether. 
Follow up ceMRI scans were performed at 35, 176 and 361 days (Figure 6 -17). LVEF and 
dimensions improved up to one year (LVEF 11, 19 and 32 %; LVEDV 436, 392 and 200m1; 
LVESV 388, 317 and 136m1); most change occurred between six months and a year. There 
was also a change of cardiac axis between 6 month and 1 year scans. There was a minor change 
in LV mass over the same time period (LV mass 236, 210 and 204g). 
Minimal myocyte necrosis 
Nine patients with a mean (SD) age 55 (9) years, 7 (78 %) of whom were male had a positive 
TnI (median (IQR) 1.3 (0.7 -2)) but no evidence of DE on ceMRI. 
Table 5 -26: Selected clinical characteristics in patients with a discharge diagnosis of 
minimal myocyte necrosis 










13 58 M Normal 0.3 208 75.62 2 3vd 
61 60 F Normal 1.3 99 63.81 2 - 
78 51 M LVH 1.8 111 61.84 4 LCX 
80 53 M Inf. Q 
waves 
4.4 841 74.56 4 minimal 
83 46 M Norrnal 0.5 172 73.32 2 LCX 
97 63 M LVH 2.3 749 37.39 4 2vd 
109 40 F Normal 0.7 121 68.04 3 RCA 
193 67 M Inf. ST 
dep. 
2 111 66.8 5 RCA 
211 60 M Normal 0.9 168 53.8 2 - 
LVH, left ventricular hypertrophy, minimal, indicates <25% stenosis (for this patient in the RCA). Remainder 
of abbreviations as in previous tables. 
The median (IQR) peak creatine kinase value was 168 (111 -208) IU /l. The highest TnI value 
was 4.4ng /ml and in this patient the diagnosis of Takotsubo cardiomyopathy was made by 
ceMRI. The next TnI value was just under half that (2.3 ng /ml). The diagnoses by ECG were: 
normal (n =5); LVH (n =3); and subendocardial ischaemia (n =1). TIMI risk score ranged from 
low/ moderate to high risk in 1 patient. LVEF was normal in the majority of patients (mean 
(SD), 64 (12) %). Diagnostic coronary angiography was performed in seven and significant 
disease was seen in six. Five were suitable for inpatient PCI and the sixth underwent CABG. 
Patient example 5: Minimal myocyte necrosis, patient number 80 
A 53 year old male was admitted with 90 minutes of significant chest pain and ECG showed 
widespread deep T wave inversion with borderline anterior ST elevation Figure 5 -11. The 
QTc was elevated at 474ms. 
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Figure 5 -11: Presenting ECG in patient with final discharge diagnosis of Takotsubo 
cardiomyopathy 
Due to a recent history of upper gastrointestinal bleeding it was decided to perform emergency 
cardiac catheterisation with a view to primary angioplasty. At angiography there was plaque 
disease at most in the mid LAD. An LV gram was performed and reported as showing, 
"hypokinetic apical segments of the anterior wall ". Subsequent troponin was elevated at 4.4 
and CK 841. Risk factors included smoking, positive family history for premature 
cardiovascular disease and treated hypertension. The TTMI score was 4. CeMRI was 
performed 25 hours after the onset of chest pain. On the SSFP images there is obvious apical 
ballooning, best seen in the LV outflow tract views (Figure 6 -18). Upper panels, left shows 
end diastole and right shows end systole. 
The corresponding DE imaging was negative and LV ejection fraction was 75 %, LV mass 
elevated at 175 g, LVEDV (120 ml) and LVESV (27m1) were within normal limits. The patient 
returned for follow up scan 58 days later. LV dimensions were similar (LVEF 80 %, LV mass 
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173g, LVEDV 104m1 and LVESV 21mí). The apical ballooning had resolved leaving no 
regional wall motion abnormality and again there was no evidence of DE. 
The diagnosis is in keeping with Takotsubo cardiomyopathy and shows that there was no 
irreversible damage and that the regional wall motion abnormality had resolved by 2 months. 
The TnI level (4.4ng /1) is the highest value at which DE was not detected and is almost twice 
the next value in this series of patients (2.3ng /1). 
Prior non -ischaemic fibrosis 
Five patients with a mean (SD) age of 54.8 (12.7) years 4 of whom (80 %) were male presented 
with chest pain, normal TnI and subendocardial sparing pattern of DE Table 5 -27. 
Table 5 -27: Selected clinical characteristics of patients with a discharge diagnosis of 
prior non -ischaemic fibrosis 
No. Age, Sex ECG CIL, Creat., DE, g DE loc. LVEF, LVM, 
yrs Mil mmolfl % g 
29 54 F Inf. Q waves 82 112 13.1 Lateral 78.28 109.28 
77 35 M Normal 137 95 1.2 Lat 52.59 122.41 
112 55 M Normal 150 94 1.5 Lat 65.26 150.02 
230 60 ltii Normal 449 81 24.5 Lat 82.87 245.37 
255 70 M Pericarditis 103 104 5.6 Lat 67.4 141.27 
Creat., creatinine; LVM, left ventricular mass 
The ECG was normal in three, showed features of an old inferior MI in one and widespread 
saddle shaped ST elevation with a CRP of 142 in keeping with pericarditis in another. All 
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patients were low risk by TIMI scoring. Coronary angiography was performed in one patient 
and showed no significant disease. 
All had subendocardial sparing on ceMRI and all were in the basal lateral location (Figure 6- 
19). It was possible to planimeter the regions of DE and the size varied from 1.2 to 24.5 g. 
LVEF was over 50% in all cases and there were no regional wall motion abnormalities. The 
LV mass was normal in four patients and markedly elevated in the fifth (see example below). 
The aetiology of hyperenhancement in the four patients with normal LV mass is not clear. 
There are a number other conditions described that have been associated with DE 
(myocarditis (21), sarcoidosis (28), amyloidosis (29), dilated cardiomyopathy (30), hypertrophic 
cardiomyopathy (31) and chronic renal failure (32)). None of these patients had a history in 
keeping with these diagnoses and renal function was normal. 
Patient example 6: Prior non -ischaemic fibrosis, patient 230 
A 60 year old male with a past history of treated hypertension and type II diabetes presented 
with ischaemic chest pain. Admission ECG was normal. CeMRI demonstrated marked left 
ventricular hypertrophy (LV mass 245 g) and LV systolic function was hyperdynamic (LVEF 
83 %). LVEDV was elevated at 180m1 and the LVESV was low at 30m1 (Figure 6 -20). There 
is patchy DE that is localised to the basal lateral segment (upper panels). There is concentric 
LVH and with LV cavity obliteration in systole (lower right). At TTE the gradient across the 
aortic valve was 13 mmHg and the aortic valve was not calcified. NtBNP was 319 during 
admission and 191 at 6 months. 
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Unstable angina 
Eleven patients with a mean (SD) age of 56(14) years, 4 (36 %) of whom were male presented 
with chest pain, were TnI negative and had no evidence DE on ceMRI Table 5 -28. The 
additional qualifying factors for unstable angina included either significant ST segment 
depression or significant coronary disease at inpatient angiography or positive exercise 
tolerance test (Full Bruce Protocol). 














52 47 F Normal 91 1 10.9 71.29 Minimal 
101 52 F Normal 45 1 371 62.51 RCA 
125 46 F Normal 204 1 238 63.94 LAD 
126 48 M SEI 126 2 18 59.8 RCA 
M Ant Q waves 153 2 89.5 75.55 - 
166 34 M Normal 59 1 48.8 64.01 LCX 
204 55 F Normal 67 2 158 78 - 
237 69 F SEI 84 3 175 61.44 
249 49 M LB BB 112 1 187 44.38 - 
256 82 F Normal 96 2 769 80.62 2vd 
261 77 F Normal 30 2 141 75.99 RCA 
SEI, sub endocardialischaemia 
ECG diagnosis: Normal (n =7); LBBB (n =1); old anterior (n =1); subendocardial ischaemia 
(n =2). All patients, except one (TIMI score =3), had a low risk TIMI score. Seven underwent 
coronary angiography: one patient had minimal disease but severe coronary spasm; one patient 
had multi vessel disease and the remaining five had single vessel disease; LAD (one), LCx (one) 
and RCA (three). All patients were suitable for follow on angioplasty and stenting. One patient 
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(patient number 204) had a normal presentation ECG but went on to have a positive exercise 
test. Coronary angiography was not performed and she was treated medically. 
Chest pain, other 
Forty eight patients with a mean (SD) age of 51 (11) years 30 (63 %) of whom were male were 
admitted with chest pain and subsequently had a negative TnI and no DE. The discharge 
diagnosis was taken from the patients discharge letter and was determined by the Consultant 
Physician (Cardiology or General Internal Medicine) Table 5 -29. 
Table 5 -29: Selected clinical features of patients in the "chest pain, other" diagnostic 






Smoker FH BP Chol. 
Presenting ECG 








Chest pain. 30 16 53.4 18 15 13 10 26 3 1 0 66.4 1 
?cause (53) (10.7) (60) (50) (43) (33) (87) (10) (3) (0) (8.3) (1.5 -2) 
Musculoskeletal 7 5 47.8 5 5 1 0 4 2 0 1 62.2 2 
(71) (17.1) (71) (71) (14) (0) (57) (28) (0) (14) (5.9) (1.5-2) 
CORD 7 6 44.8 7 5 2 1 7 0 0 0 67.3 1 
(86) (5.3) (100) (71) (28) (14) (100) (0) (0) (0) (8.3) (I-1) 
Pericarditis 2 2 45 and 0 0 0 0 1 1 0 0 66.8 and 1 and 1 
59 59.2 
PAF 1 1 43 1 0 0 0 0 0 0 1 64.8 2 
LRTI 1 0 44 1 1 0 0 1 0 0 0 71 I 
AU available data use n is the maximum number of patients in each group. 
Data are presented as mean (SD) for continuous variables (median (IQR) for TIMI score) and number (96) for categorical variables When the number of patients in a 
diagnostic group < 7 individual cases are presented. 
FH, family history cardiovascular disease; BP, treated hypertension; Chol., treated hypercholesterolaemia; LVH, left ventricular hypertrophy, LBBB, left bundle 
branch block; ST dev., ST segment devirlion; LVEF, left ventricular ejection fraction; TIMI, Thrombolyses In Myocardial Infarction risk score (0 -7); GORD, gastro- 
oesophageal reflux disease; PAF, paroxysmal atrial fibrillation; LRTI, lower respiratory tract infection. 
All patients had a low TIMI risk score with normal LV systolic function. The ECG 
characteristics were: normal (n =45), LVH (n =2), LBBB (n =1). Thirty (62.5 %) patients 
received the label "chest pain, unknown cause ", indicating all basic investigations were normal. 
Seven out of forty eight (15 %) patients had a diagnosis of musculoskeletal chest pain and 7/48 
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(15 %) were labeled Gastro- oesophageal Reflux Disease based on the nature of chest pain and 
upper GI endoscopy if performed. 
The diagnosis of pericarditis was made in 2 patients based on history alone. A further patient 
had atrial fibrillation and rate related ST depression on the presenting ECG. She reverted to 
sinus rhythm spontaneously and subsequent coronary angiography was normal. One patient 
developed consolidation on her chest X -ray so discharge diagnosis was of bronchopneumonia. 
Out of the 48 patients, two patients had reached an end point of MACE/ death at 3 years. 
One patient underwent elective percutaneous intervention and the other was dead (murdered). 
One of the patients with LVH met the ST elevation criteria and was thrombolysed 
inappropriately and there were no evolving electrocardiographic changes. The patient with 
LBBB went on to have a normal coronary angiogram. On further inspection of the 48 ceMRI 
scans, 47 were entirely normal. One patient (number 164) had a dilated aortic measuring 41 
mm at the sino- tubular junction in the LVOT view root (Figure 6 -21). This patient attended 
for all four follow up visits and there was no change in the dimensions over this time. A 
central jet of mild aortic regurgitation is seen as a flow void. None of these patients had 
evidence for ischaemic heart disease. 
Right ventricular infarction 
Twelve patients with a mean (SD) age 59 (14) years and 10 (83 %) of whom were male had 
evidence of RV infarction by ceMRI Figure 6 -22. These 12 patients comprised 15% of all TnI 
positive patients and 11/33 (33 %) of all inferior infarcts. In only 2 patients (17 %) was RV 
involvement suspected at transthoracic echocardiography. The mean (SD) RV infarct size was 
25.6 (20.5) g on admission and by visit 2 had fallen to 12.1 (14.3) g, a reduction of 53 %. The 
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mean (SD) RV infarct size comprised 40 (17) % of the total (RV + LV) infarct burden. By 
presenting ECG, 5 had ST elevation, 4 had ST depression and 3 were normal. Eight patients 
received thrombolysis. 
LV thrombus 
Five patients with a mean (SD) age of 65 (10) year and 4 (80 %) of whom were male had 
evidence of LV thrombus by ceMRI, which comprises just over 6% of all troponin positive 
patients Figure 6 -23. All had TTE and in no patients was LV thrombus detected. All were 
started on warfarin following the results of ceMRI and thrombus was not visible in any scans 
at 6 months. Four presented with anterior ST elevation and were thrombolysed. The fifth 
presented with significant ST depression. By ceMRI the infarct location was anterior in 4 and 
anterior plus inferior (acute and prior infarctions) in the fifth, all involved basal segments. 
LV thrombus therefore complicated 4/21 (19 %) of anterior myocardial infarctions in this 
population. The mean (SD) infarct size was 68 (34) g or 47 (26) % of LV mass and TnI was 
155 (169). By visit 2 the infarct size had fallen to 46 (18) g a mean reduction of 32 %. Three 
patients had late MVO and 4 had the maximum mean transmurality score of 4. The fifth 
patient had a smaller infarction of 32g that was neither transmural nor had MVO. There was a 
localised aneurysmal segment in the apex that contained thrombus. The mean (SD) LVEF was 
39 (8) % on admission rising to 42 (11) % at 6 months. A proximal occlusion was confirmed at 
coronary angiography in 3 patients. In 2, the culprit vessel was the proximal LAD and in the 
third it was the LCx. 
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6 Illustrations - ceMRI 
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Figure 6 -1: CeMRI mid left ventricular SA slices showing early MVO (left) and 
corresponding DE image with no late MVO (right) 
Figure 6 -2: Series of DE images illustrating DE area planimetry in the same patient 
at 2, 38, 260 and 380 days post AMI (left to right) 
Upper panels, SA view. Lower panels, 2 chamber view 
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Figure 6 -3: SA stacks showing infarct planimetry in the same patient from base to 
apex (left to right) for 3 separate visits 
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Figure 6 -4: Short and long axis images of the three infarct locations 
Left - anterior; middle - inferior; and right - lateral 
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Figure 6 -5: SA scans showing 2 patterns of MVO in 2 patients 
Early MVO only (upper) and early plus late MVO (lower) 
Figure 6 -6: Series of mid ventricular SA images from admission to 1 year in the same 
patient illustrating infarct planimetry and calculation of endocardial extent. 
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Figure 6 -7: DE in three patients with positive TnI but normal coronary arteries 
Figure 6 -8: Persistence of early MVO in the anterior region out to 1 year (upper) 
Persistence of late MVO in the lateral region out to 28 days, resolving by 6 months 
(lower) 
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Figure 6 -9: Three patients with late MVO and CRP < 26 mg /L 
Figure 6 -10: Acute myocarditis 
4 chamber (left) and SA (right) DE images during admission showing 
subendocardial sparing (upper) 
Presenting 12 -lead ECG showing acute inferior ST elevation (lower) 
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Figure 6 -11: Evolution of acute myocarditis by ceMRI at 3, 31, 155 and 368 days 
SA (upper) and 4 chamber (lower) 
Figure 6 -12: Two chamber view of multiple infarcts by ceMRI 
Small anterior (mid ventricle) and larger inferior (mid ventricle) 
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Figure 6 -13: Multiple infarcts by ceMRI 
SA views showing small basal anterior (left) and larger apical inferior (centre) 
2 chamber view showing both infarcts (right) 
Figure 6 -14: Multiple infarcts by ceMRI 
SA and 4 chamber DE (left) showing septal and lateral infarcts 
Corresponding SA and 4 chamber SSFP end diastolic stills (right) showing a 
localised thinned and aneurysmal segment of the mid lateral wall 
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Figure 6 -15: Prior (silent) MI by ceMRI showing DE in the basal lateral segments 
SA (left) and LV outflow tract (right) 
Figure 6 -16: Prior (silent) MI by ceMRI showing a thin strip of subendocardial DE in 
the basal and mid anterior segments 
2 chamber DE image (left) 
SA views post Gd -DTPA at identical slice positions (right) showing early MVO only 
at 1 o'clock (upper) 
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Figure 6 -17: SSFP images showing reduction in LV dimensions with medical therapy 
in a patient with DCM at 3, 35, 176 and 361 days (left to right) 
2 chamber (upper), 4 chamber (middle) and LV outflow tract (lower) 
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Figure 6 -18: Takotsubo cardiomyopathy by ceMRI at 1 day (upper) and 58 days 
(lower) showing resolution of apical ballooning 
SSFP LV outflow tract views at end diastole (left) and end systole (right) 
Figure 6 -19: Prior non -ischaemic fibrosis by ceMRI 
There is inferolateral subendocardial sparing of DE at 5 o'clock in 2 contiguous SA 
slices (left and middle) that is confirmed in the 2- chamber view (right) 
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Figure 6 -20: Prior non -ischaemic fibrosis by ceMRI 
DE images (upper), SA view shows subendocardial sparing of DE at 5 o'clock (left) 
that is confirmed in the LV outflow tract view (right) 
SSFP images (lower) of the LV outflow tract in end diastole (left) and end systole 
(right) showing mid- and apical ventricular cavity obliteration 
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Figure 6 -21: Dilated aortic root and mild aortic regurgitation by ceMRI at 5, 31, 185 
and 366 days following admission with chest pain (left to right) 
SSFP LV outflow tract images at end diastole showing a dilated aortic root and a flow 
void at the aortic valve indicating aortic regurgitation 
Figure 6 -22: Acute right ventricular myocardial infarction by ceMRI 
SA (left) and 4 chamber (right) views showing DE in the inferior LV wall (with late 
MVO) that extends into the RV 
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Figure 6 -23: Apical LV thrombus in AMI by ceMRI 
DE 4 chamber view showing an extensive anterior mid and apical transmural MI 
with late MVO and apical LV thrombus 
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7 Discussi®n 
CeMRI is superior to any other available noninvasive imaging technique for identification, 
localisation and quantification of myocardial infarction in both its acutely necrotic and 
chronically fibrotic states (31;33;109;170). In addition, it is possible to discern certain 
characteristics of the myocardial scar such as microvascular obstruction. 
Over a 9 month period between August 2002 and May 2003, all patients admitted to the 
Western Infirmary, Glasgow with their first presentation of chest pain to rule out myocardial 
infarction were considered for this study. The final study population consisted of 153 
consecutive patients that did not meet any of the exclusion criteria. This represents 12 % of 
the total population that underwent an "MI screen" and 54% of those presenting for the first 
time. Patients were included on the basis of history and collaboration with case records to 
confirm initial presentation. The reasons for exclusion fell into 6 broad categories: past medical 
history; comorbidity; consent; contraindications to ceMRI; geography and other. The most 
frequent contraindication was a past medical history of chest pain or confirmed ischaemic 
heart disease comprising 65% of the screened population. 
The aim of this thesis was to study the role of ceMRI in two important diagnostic areas of the 
chest pain syndrome; the correct identification and then accurate quantification of myocardial 
infarction. 
Early correct identification of myocardial infarction was investigated using ceMRI to determine 
the sensitivity and specificity of first ST elevation, then ST deviation on the presenting ECG. 
Improved final diagnosis was investigated by performing ceMRI in broad population of 
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patients and the additional findings in patients with first historical hospital admission with an 
acute chest pain syndrome are presented. 
To investigate the routinely available biochemical (8 -12 hour TnI level) and bioelectrical (ECG 
at discharge, by Selvester score) means of estimating (reperfused and non -reperfused) infarct 
sizes, correlations with planimetered regions of subendocardial DE were made both 
individually and in combination with planimetered regions of subendocardial DE. For the 
measurement of infarct size it became apparent that it would be necessary to confirm that 
there was indeed a single acute MI using a combination of ceMRI, ECG and TnI. The 57 
patients with "single AMI" comprised the largest diagnostic group seen in Figure 5 -4. These 
patients had larger infarct sizes, reduced LV systolic function, increased LV dimensions and 
were at moderate risk by mean TIMI score. They were more likely to have diagnostic coronary 
angiography and > 1 significant stenosis and there was a longer time to first ceMRI scan. The 
ceMRI findings in patients that were TnI positive but had a normal coronary angiogram are 
also described. The remaining patients are referred to as "non - single AMP' and described in 
section on additional findings by ceMRI. 
Using measurements at 4 planned time points (admission, 28 days, 6 months and 1 year) the 
natural history of infarct size and characteristics was documented and reasons for different 
rates of change explored. These time points were also chosen to investigate LV remodelling 
and the hypothesis was that the genotype of the MMP -1 promoter sequence would have an 
influence. Finally, as part of investigations into the ACS, the role of inflammation was 
investigated by demonstrating both the correlation of CRP with infarct size and the its ability 
to predict infarct characteristics. 
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7.1 ST segment deviation analysis of the admission 12 -lead 
ECG as an aid to early diagnosis of AMI 
The biochemical methods for detection of AMI have become so sensitive that it is necessary 
to develop clinically relevant subgroups. The 1999 ESC /ACC consensus conference produced 
such a broad definition, on the basis of historical information and biochemical marker data, 
that any ECG criteria were rendered superfluous for making the final diagnosis (171). The 
current availability of aggressive emergency therapies for establishing myocardial reperfusion 
requires a method for establishing a rapid working diagnosis of thrombotic AMI at the time of 
initial pre -hospital or emergency department presentation. The performance of such a method 
can be determined by observing outcomes that range from aborted infarction to hemorrhagic 
complications due to inappropriate therapy(33;48;161). An immediately available clinical test 
with high sensitivity and specificity for thrombotic AMI is required, and neither the history nor 
the biochemical markers achieve this goal at present. ST- segment elevation has such high 
specificity for AMI that the currently accepted name of this patient subgroup is "ST- segment 
elevation MI," conveniently termed "STEMI." Indeed, the multiple randomised clinical trials 
in patients with ACS have either STEMI or Non -STEMI inclusion criteria. 
This study highlights that, in patients with acute chest pain, ST- segment depression is often 
indicative of AMI, but does not aim to make any recommendations about treatment strategies. 
Use of this method to confirm the high specificity and to determine the sensitivity of the 
existing ECG criteria requires the study of the broad population of consecutive patients 
admitted to a single medical centre with symptoms compatible with ACS. The present study 
was designed and implemented for this purpose. 
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Thirty -five (23 %) out of 153 patients were excluded on the basis of ECG confounding factors. 
The removal of confounders, so often characterised by the early repolarisation that mimics the 
ST- segment deviation of acute transmural ischemia led to, for example, a surprising infarction 
rate by ceMRI of 29 of the 31 patients (94 %) meeting the ACC /ESC ST segment elevation 
threshold(60). When considering the total population without exclusions, infarct by ceMRI 
was present in 32 of the 40 (80 %) patients meeting the ST- segment elevation threshold. In 
addition, the sensitivity rose from 44°/o in the ACC /ESC STEMI group to 71% in the STEMI 
equivalent group with a reduction in specificity from 91% to 86 %. As expected, these values 
demonstrate a reduced diagnostic accuracy both overall and between groups, but interestingly 
there is very little difference in the positive predictive values (83% vs. 82 %). 
The prevalence of infarction in this study population was high at 50% meaning positive 
predictive values for ACC /ECC STEMI and STEMI -equivalent criteria were 94% and 92 %. 
Considering the lower AMI prevalence of 20% that is more typical of the population 
presenting to the Accident and Emergency; the PPV falls to 85% and 75% respectively. This 
extrapolation requires further investigation, if the results are to be applied more widely. 
Eight patients were considered to have had multiple infarcts, 3 of whom had 3- vessel disease 
(one with critical left main stem stenosis); one had proximal and distal lesions in a dominant 
RCA; one had distal left anterior descending disease; one had normal coronaries; and for the 
final 2 patients coronary angiography was not clinically indicated. The distribution of 
STEMI /NSTEMI was equal, and all had a rise and fall in cardiac enzymes in keeping with 
AMI. It is possible that the patients with 3- vessel disease had multiple "hot plaques," but it is 
more likely that there were chronic infarcts. Because there were no well -validated ceMRI 
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sequences for differentiating age of infarct at the time of recruitment, absence of either 
historical or ECG suggestion of infarct was required for study inclusion together with a rise 
and fall of troponin and /or CK -MB. 
Consideration of presenting STEMI or STEMI equivalent criteria as "falsely positive" would 
be in error when the prompt administration of reperfusion therapy sufficiently aborts the AMI 
so that it is not detected by ceMRI. Fourteen patients presented to hospital within 1 h; 8 had 
an AMI by both ECG and ceMRI. None of the remaining 6 had significant ST- segment 
deviation, and the largest initial CK value was 134. Aborted AMI is therefore unlikely to be a 
significant confounder in this study. 
There were no patients with a troponin I > 4.4 ng /ml who did not have DE, and the mean 
TnI for these 8 patients was 1.44 Table 5 -4. This might indicate the upper limit of troponin 
that suggests a "necrosette," and further studies on the significance of this change range using 
ceMRI in this lower -risk group might help in future risk stratification (172). 
The similarity in infarct size by ceMRI between the STEMI and STEMI -equivalent groups 
highlights that significant infarcts are being missed by the ECG criteria used in typical clinical 
practice. It should be noted, however, that the naturally occurring AMI sizes of many of the 31 
of 58 in the ceMRI-positive group who received reperfusion therapy would have been higher. 
This is further illustrated by the significantly lower time to presentation in the STEMI group 
(difference in median 3.3 hours), suggesting that this group had more severe symptoms. 
Myocardial infarcts that are missed altogether by the ECG are smaller, although the difference 
does not reach statistical significance (p = 0.29, Kruskal -Wallis test) Figure 5 -5. 
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The additional diagnostic information provided by the STEMI -equivalent criteria resulted in 
increased detection in the anterior location from 38% (5 of 13) to 69% (9 of 13), in the inferior 
location from 70% (14 of 20) to 95% (19 of 20), in the posterolateral location from 36% (4 of 
11) to 82% (9 of 11), and in the inferior and posterolateral location from 17% (1 of 6) to 67% 
(4 of 6). 
In the present study, when maximal ST- segment deviation appeared as depression in V1, V2, 
or V3, 7 of the 9 patients had ceMRI- determined infarction in the posterolateral region of the 
LV; the remaining 2 did not but had 3- vessel disease. This maximal ST- segment deviation 
direction was falsely positive for infarction in none of the individuals. The basal region of the 
LV is superiorly oriented in the thorax, directly opposite the inferior or diaphragmatic region. 
When ST- segment depression in "inferior leads" accompanies ST- segment elevation maximal 
in V2 to V4, extension of the anterior infarction into the basal region has been documented, 
due to occlusion of the proximal LAD(173). In the present study, when maximal ST- segment 
deviation appeared as depression in II, III, and aVF, 4 of the 5 patients had ceMRI- 
documented infarction in the basal region of the LV. This maximal ST- segment deviation 
direction was only falsely positive in 1 individual with a body mass index of 33 who 
subsequently had a normal coronary angiogram. The term "ST- segment deviation MI" could 
be adapted with designation of the direction of the lead with the maximum either ST- segment 
elevation or ST- segment depression. The negative leads are as "real" as the positive leads, and 
indeed lead " -aVR" replaced +aVR in Sweden 30 years ago(174). With either alternative, the 
identification of the spatial direction of the ST- segment as indicated by the lead with the 
maximal deviation would be required. This study has documented that in patients admitted to 
- 140 - 
hospital with chest pain and no historical or ECG evidence for previous AMI only 50% of the 
AMI group are identified by the ACC /ESC STEMI criteria, but an additional 34% are 
identified by the STEMI -equivalent ST- segment depression criteria with ceMRI as the gold 
standard. 
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7.2 Validation of ECG and biochemical estimates of index acute 
and final MI sizes 
The validation of different biochemical and electrical clinical indices of myocardial infarct size 
have so far been limited by deficiencies in the gold standards to delineate regions of acute 
myocardial necrosis and/ or chronic scar in vivo. Infarct size is accurately and reproducibly 
measured using ceMRI in both acute and chronic phases of myocardial infarction providing an 
ideal living autopsy (175;176). Using ceMRI to confirm there was a single infarct together with 
the rise and fall of troponin to confirm acuteness meant that it was possible to precisely define 
a population with single acute MI. The routinely available biochemical and bioelectrical 
markers of myocardial infarction both individually and in combination were correlated with 
the planimetered regions of DE. The treatment with most influence on final infarct size is 
currently reperfusion therapy based on the presenting ECG, so patients were compared using 
these subgroups. 
Troponin levels are widely available and now accepted as the biomarker of choice in the 
diagnosis of ACS. Troponin was routinely only measured once at 8 -12 hours following onset 
of chest pain and its primary use is to dichotomise patients into high and low risk. This is 
illustrated by the TIMI risk scoring system according a single point for positive biomarkers 
regardless of the value. Troponin is exclusively released from necrotic myocytes so an infarct 
size derived from troponin levels should not include infarct penumbra such as oedema. 
Troponin release is a dynamic process over 2 weeks post infarction and the optimum sample 
timing point is yet to be determined so this study tests the use of the single sample point 
already in clinical use. The troponin level is likely to be important as an indicator of infarct size 
and so further aid in risk stratification of patients and therefore clinical decision making. 
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The standard ECG has been used to detect and estimate MI size for many decades. The 
Selvester score is a 31 point scoring system based on specific patterns in the QRS complex and 
provides a simple, economical means of risk stratification at discharge (177). Whilst the 
Selvester score is straightforward to perform by expert analysts, it is not yet part of routine 
clinical practice. All the information is available and contained within the ECG and most ECG 
machines could be adapted to use an algorithm that will provide an automated score. 
Acute myocardial injury not only encompasses myocvte damage but also the effects of an acute 
inflammatory response including oedema. It was thought that ceMRI during the acute phase 
led to over estimation of infarct size(178) but this has subsequently been demonstrated not to 
be the case using TTC staining (179;180). It is clear then that the region of DE and TTC are 
the same but this still does not exclude the likelihood that the distance between necrotic 
myocytes is expanded in the acute phase due to oedema. 
Infarct size has been shown to reduce between the acute and chronic phases of healing by 
around 30% (181). Of the 57 patients with single AMI, 43 have a scan at visit 1 and visit 2. In 
these patients the mean reduction in infarct size is from 37 (30) g to 14(14) g or 35 %. This 
early reduction accounts for most of the reduction to a year (40 %). Infarct size at 38 days was 
therefore chosen to represent "final infarct size ", with additional benefit that there were less 
patients lost to follow up than at later time points. It was hypothesised that there would be a 
better correlation with infarct size once the acute inflammatory response to injury has settled 
down. 
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Patients who received reperfusion therapy had a lower systolic and diastolic blood pressure at 
the time of ceMRI scan. The trend towards a lower ejection fraction and a difference in 
secondary prevention prescription may have contributed, although only the rate of ACE 
inhibitor use was significantly higher (77 vs. 399/o). 
Nearly 3/4 of patients who received reperfusion therapy had ST elevation on the presenting 
ECG and just under a fifth had ST depression Table 5 -7. A further 12 % of patients 
developed ST elevation on repeat ECG testing. The diagnosis of evolving STEMI was missed 
in 13 % of patients that were not reperfused when the strict ST deviation criteria were applied 
by the ECG core lab, 4.4 above. There may also have been better pattern recognition by the 
core lab than that of the junior doctor assessing the patient in an emergency setting. Of those 
that were not reperfused, 46% had significant ST depression on the presenting ECG and 
would be classified as STEMI equivalent. 
The patients that were reperfused had larger acute infarct sizes by CIüVIB, TnI and Selvester 
score. Infarct sizes were larger by ceMRI measures including total DE area, transmurality and 
endocardial extent. Patients who received reperfusion therapy also had larger final infarct sizes 
by ceMRT at a mean of 38 days Table 5 -8. There was a significant reduction in mean infarct 
size for both reperfused and non -reperfused infarcts, -15.4 g and -9.6 g respectively. The 
greater absolute reduction may be due to resolution of oedema and haemorrhage in reperfused 
infarcts rather than improved healing of an area of infarction subtended by an open artery. 
The non -reperfused infarcts more closely reflect the natural history of coronary occlusion and 
so will not be subject to the same degree of reperfusion injury. 
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The correlation between a single TnI and area of DE was strong for all infarcts, particularly 
those that received reperfusion therapy (r =0.7, p <0.001). 
In non -reperfused patients, it has already been shown that TnI correlates poorly with acute 
infarct size (182), a result that was confirmed in this study. But when TnI is compared to final 
infarct size in the non -reperfused group the correlation improved from r =0.43 to r =0.78 
Table 5 -9. A similar improvement was seen between Selvester score and acute then final 
infarct size, r =0.31 to r =0.67 in the non -reperfused patients. 
In the reperfused group the trend towards improved correlation between admission 
biochemical or bioelectrical markers and final infarct size by DE applies to the Selvester score 
but not TnI. It is not clear why this might be the case. 
When considering all infarcts; the correlation between admission TnI and admission DE 
(r =0.70) improves when admission TnI is correlated with final DE (r= 0.75). 
The improvements in correlation were tested by means of a Z test but due to the small study 
numbers none of the improvements reached significance. The improved correlation between 
TnI and acute then final infarct size in the non -reperfused group was nearly significant, 
p =0.09. Correlations between TnI and geometrical measures of infarct size such as endocardial 
extent (r =0.42, p= 0.004), number of segments (r =0.52, p <0.001) and number of slices 
(r =0.53, p <0.001) were significant but no better than the total infarct mass. 
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The rationale for investigating both acute and final infarct sizes by ceMRI is that the area of 
DE planimetered will be influenced by the timing of the first ceMRI scan, 5.6 above. The final 
infarct size at 38 days allows any confounders such as oedema to settle down. 
The poor correlation between Selvester score and acute non -reperfused infarct size by ceMRJ 
was surprising (r =0.31) as this score was originally designed in the pre -reperfusion era. 
However, its use was to estimate chronic infarct size; equivalent to the 10 patients in Table 
5 -9 (r =0.67, p= 0.03). Previous investigators into the Selvester score and chronic infarct size by 
ceMRI have found the best relationships in basal anterior infarcts (183;184) likely due to the 
limited location of the 6 anterior chest leads and 4 limb leads and infarcts in other locations 
"hiding" from the ECG. Infarct location was not investigated as a variable in this study due to 
the small numbers of anterior infarcts and the indiscriminate nature of Tnl release. The 
Selvester score is based on points derived from the QRS complex but the extent of 
transmurality did not correlate with the Selvester score. 
Multiple linear regression was performed to investigate if the 2 readily available measures of 
infarct size, TnI and ECG, would improve correlation with ceMRT derived infarct size when 
used in combination. This hypothesis was based on the premise that TnI indicates the amount 
of necrotic myocytes and the ECG will account for any additional effects of the infarct 
process. In the total population the Pearson correlation coefficient increased from r =0.71 to 
r =0.80 (p <0.001). The main contributor was the reperfused group (r =0.72 to r =0.82, 
p= 0.003). In the non -reperfused group the correlation did improve from r =0.28 to r =0.43 but 
did not reach significance. Therefore the combination of Selvester and Tnl provides an 
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improved estimate of infarct size in acute reperfused infarcts and again the results are not 
consistent within the non -reperfused infarct group. 
It is not clear why the acute reperfusion strategy should influence the correlation of TnI or 
Selvester with acute infarct size and is complicated by evidence that reperfusion is itself 
associated with injury. The kinetics and release ratio of troponins are not well defined and are 
likely to be affected by reperfusion(24). It has been shown that troponin at 72 and 96 hours 
correlates well with scintigraphically defined infarct size regardless of reperfusion status (15;16) 
so it may be that 8 -12 hours is too early a sample point. It is unlikely to be too late as troponin 
levels remain elevated for up to 2 weeks following myocardial injury. The inhomogeneity of 
the non -reperfused group may contribute and illustrates why studies to investigate the early 
treatment of patients without ST elevation have been unsuccessful thus far. 
In conclusion both biochemical and bioelectrical markers of myocardial infarction provide an 
estimate of acute infarct size when all infarcts are considered; this correlation is largely driven 
by the reperfused or STEMI group. Tnl measured 8 -12 hours post chest pain and Selvester 
score at mean 64 hours correlate with acute STEMI infarct size by ceMRI and this correlation 
improves when they are used in combination; but only CKMB correlates with NSTEMI size. 
When considering the non- reperfused group these markers correlate better with final infarct 
size. Improved correlation of standard biomarkers with final infarct size suggests that the 
optimal time for acquiring ceMRI images may be once the acute injury process has settled 
down. 
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7.3 The detection of myocardial scar by ceMRI in patients with 
TnI positive chest pain and minimal angiographic coronary 
artery disease 
International guidelines recommend early coronary angiography (CA) and revascularisation in 
all patients diagnosed with acute myocardial infarction. Normal CA does not exclude AMI but 
makes the final diagnosis less accurate. Christiansen et al. looked at the detection of myocardial 
scar by ceMRI in patients with TnI positive chest pain and minimal angiographic coronary 
artery disease in a (non -prospective) group of 23 patients who were referred for ceMRI by 
their physician, 7 (30 %) of which had evidence of DE (185). In this prospective study, 8 (10 %) 
patients with a positive TnI had a normal coronary angiogram and in contrast, 7 (88 %) had 
evidence of DE. The single patient negative for DE had a TnI of 4.4 ng /ml and a final 
diagnosis (by ceMRI) of Takotsubo cardiomyopathy 5.9 above. Four out of 7 patients had an 
ischaemic distribution of DE (2 inferior, 1 lateral and 1 anterior), median TnI of 22 ng /ml and 
DE mass of 8 g. The remaining 3 had a subendocardial sparing pattern of DE with median 
TnI 29 ng /ml and DE mass 36.5 g. Therefore the diagnosis of acute myocarditis was made in 
43% of patients with positive TnI and normal coronary arteries (cf. 14.2% in the study by 
Christiansen et al.). Only one patient out of eight (12.5 %) had a MACE (stroke) recorded at 3 
years and he was from the ischaemic DE group. 
It is well recognised that angiographically normal coronary arteries do not exclude coronary 
artery disease or myocardial infarction, for example recanalisation of an acute thrombotic 
occlusion or an embolic event. In this group of patients, comprising 10% of all troponin 
positive patients meeting the inclusion criteria, ceMRI has definitely improved diagnostic 
certainty. Four (50 %) patients were confirmed as a Non STEMI with attendant implications 
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for prognosis, need for secondary prevention, psychological well being and subsequent 
occupational and health insurance assessments. Four (50 %) patients were spared this label; 
three with a diagnosis of acute myocarditis and one with Takotsubo cardiomyopathy. These 
findings require further investigation but illustrate the potential of ceMRI for improving the 
accuracy of the label (acute) myocardial infarction. 
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7.4 Serial assessment of MI size and characteristics using 
ceMRI 
The natural course of myocardial infarction by ceMRI at 4 time points over 1 year in both 
reperfused and non -reperfused infarcts (STEMI and NSTEMI) has not been previously 
documented. Pathological studies are necessarily limited to a single time point per patient but a 
large autopsy series has shown the histopathological evolution of myocardial infarction in 
different patients(186) Figure 7 -1. 
14 21 28 
TIME (Days) 
Figure 7 -1: Course of time for histopathologic changes in myocardial infarction in 
man. Ordinate indicates relative severity of histopathologic changes. Reproduced 
from Fishbein, Chest 1978; 73(6):843 -849 
During the first 3 -4 days there is infarct expansion due to myocyte necrosis with haemorrhage, 
oedema and infiltration of leucocytes. At the time of study design the aim was to image the 
infarct as soon as possible after initial injury so a mean time to scan from chest pain of 2.3 days 
was acceptable given that there was a reluctance to allow patients with an STEMI out of the 
coronary care unit to attend a research study for 48 hours post admission, regardless of clinical 
status. 
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By 4 -6 weeks these changes have largely settled and necrotic cells are no longer detectable, 
there is functional vascular proliferation, fibroblast infiltration and collagen deposition. The 
aim of planning scan 2 at 28 days was to correspond with this time point and that which is 
frequently used in clinical trials. 
At 6 months and beyond the acute injury process is complete and myofibroblast activity 
persists, nourished by the neo vascularure Table 7 -1. Scans 3 and 4 were planned for 6 
months and 1 year to assess the dynamics of infarct healing during this period and to 
correspond with 2 further time points frequently used in clinical trials. In addition, 4 time 
points over a year is more than has been used in previous studies and provides a reasonably 
smooth curve. 
Table 7 -1: Relation of age of infarct to vascular and cellular changes 
Age of 
infarct Necrosis 
Intercellular Haemorrhage Vascular Neutrophils Fibroblasts Collagen 
(days) 
oedema proliferation 
3 + ++ ++ ++ O + ++ 0 0 
28 + + + + ++ 0 ++ + ++ 
180 0 0 0 ++ 0 ++ + ++ 
All changes graded for severity as follows: 0 absent + mild; ++ moderate; +-H- severe 
CeMRI visualises the net effects of factors causing early infarct expansion and subsequent 
infarct resorption, in a similar way that serial TTC staining on histopathological specimens 
would. The contrast agent Gd -DTPA is non -specific and remains in the extracellular 
compartment. Delayed hyperenhancement imaging with ceMRI relies on the different rates of 
wash in and wash out of GdDTPA between normal and damaged myocardium. In the acute 
phase of myocardial injury, hyperenhancement is due to loss of cell sarcolemmal integrity. In 
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the chronic phase the volume of distribution is increased due to the increased interstitial space 
in collagen. There is therefore no reason why acute and chronic infarcts should appear the 
same on DE imaging. Figure 6 -2 shows 4 ceMRI scans over 1 year in the same patient with 
an extensive anterior MI. The reduction in infarct size can be seen but also the clarity of the 
infarct border improves greatly between scan 1 and scan 2. This is particularly evident on the 2 
chamber views (lower panels left and 211`i from left). 
When considering the 25 patients with single AMI and a complete set of 4 scans the mean 
reduction in infarct size is 15 (16) g or 36% by 38 days and 17 (16) g or 40% by 1 year. The 
other measures of infarct geometry in this study, endocardial extent and transmurality, are also 
significantly reduced by 1 year confirming that infarct size reduction occurs in all dimensions. 
This pattern is seen in all infarcts whether reperfused or not meaning that final infarct size is 
essentially achieved by 38 days. This suggests that final infarct size is achieved outwith the 
chest pain to scan time of 4 days that encompassed 95% of patients. Imaging for infarct size 
should not be done during the first week, at least if ceMRI is to be used as a gold standard to 
test therapies that reduce final infarct size. 
MVO, defined by a hypoenhanced core surrounded by hyperenhancement, has been 
investigated on both early and delayed images. One of the aims of this study was to document 
the relative incidence of both early and late MVO and its change over time. 
When late MVO is present there is always early MVO indicating that they are measuring the 
same phenomenon. Early MVO is seen more frequently than late MVO (66 vs. 47 %, 
p <0.001). This incidence is higher than the 35% seen with no reflow despite TIMI 3 flow 
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following priman PCI using intracoronary myocardial contrast echocardiography (187). The 
size of MVC) (9.2 vs. 9.4 g) and percent of infarct size (15 vs. 19 %) are similar for early and late 
MVO respectively. Previous studies have documented MVO resolution by between 6- 
9months (67). In this patient population, MVO has largely settled by mean 38 days and in the 
small number of patients in which it persists the extent is significantly reduced. No patients 
have late MVO after visit 2 so this information may be used to rule in a recent infarct if 
biomarkers are normal or determine the culprit infarct site if there are multiple. 
The reduction in infarct size was greatest if MVO (early or late) was present on the admission 
scan. It was anticipated that a reduced blood supply at the microvascular level would impair 
healing but it is likely that the net effect in infarct resolution as measured by ceMRI is 
reduction in oedema. It may that in there is more inflammation and "infarct expansion" 
associated with MVO so that there is a greater rate of regression to the mean by 28 days. 
There was a trend to increased rate of reduction in infarct size in reperfused vs. non - 
reperfused infarcts but again these infarct sizes were significantly larger and the increased rate 
of change may be due to resolution of the effects of reperfusion injury or haemorrhage into 
the infarct that caused over estimation during the first week. 
In the population of patients with single AMI the mean LV ejection fraction improved by 
1.7% at 1 year. There was a significant increase in both LVEDV and LVESV with the main 
increase between visit 1 and visit 2, continuing at a reduced rate to visit 3. Between visits 3 and 
4 there was a general reduction in LV dimension. Overall the mean increase in LVEDV was 
23ml (16 %) and LVESV 9ml (14 %). In the group with late MVO the LVEF remained static 
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over 1 year but those without late MVO showed a mean increase in LVEF of 5.7 %. In the late 
MVO group, mean LVEDV increased by 38m1s (26 ° %0) and LVESV by 24ml (32 %) whereas in 
those patients without late MVO, mean LVEDV increased by 8 ml (6 %) and LVESV 
decreased by 7m1 (13 %). 
The mean increase in LV mass was 20g (15 %) indicating that there was compensatory 
hypertrophy as normal myocardium made up for loss of functioning myocardium 
The main limitation of this study is the small patient numbers that completed all 4 scans. Due 
to patient drop outs the complete set of all 4 scans is only available in 25 (44 %) patients. The 
serial analysis did account for this by using the baseline scan as the reference in paired analysis. 
This study documents the natural evolution of both reperfused and non -reperfused infarcts at 
4 time points over 1 year. The reasons for the patterns of the the rates of change in infarct size 
over 38 days are not known although it seems to be related to infarct size and associated 
oedema. Further mechanistic studies to investigate whether there are any therapeutic 
implications, for example varying ariythmogenic properties of oedema vs. infarct. Larger 
studies would be required to investigate the prognostic and therapeutic significance of the 
change and rate of change of infarct size. 
If ceMRI is to be used as a gold standard for infarct size estimation in trials of infarct 
regeneration such as stem cell therapy it may be more reliable and certainly more practical to 
measure baseline infarct size at least 2 weeks following AMI and probably at 1 month. The 
planimetered DE area is unaffected by other factors such as hibernation, stunning or loading 
conditions and the high spatial resolution means that trials can be adequately powered with 
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fewer patients. CeMRI is particularly attractive for serial measurements due to the lack of 
radiation exposure. 
The results of this analysis will be of use in providing a "normal range" of infarct evolution 
against which future therapies that aim to alter infarct size both prospectively and 
retrospectively may be tested. The study also indicates that the timing of the ceMRI scan will 
be of great importance in study design. 
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7.5 CRP in the detection of higher risk patterns of AMI 
There is an acute inflammatory response to myocardial injury but the precise trigger is as yet 
unknown(188). CRP is a non -specific inflammatory marker that appears to be a strong 
predictor of cardiovascular risk (189), including in patients with ACS (132). It is currently 
unclear whether inflammatory markers measurable in the peripheral blood can be clinically 
useful tools for risk assessment and whether intervention to reduce inflammation will influence 
risk (190). Further information on the association of CRP with acute myocardial necrosis may 
help to guide future therapeutic trials. CeMRI was used to investigate the relationship between 
CRP and the diagnosis and prediction of infarct size. In the investigation into whether the 
measurement of CRP in troponin positive patients can predict the presence of MVO 
comparisons were made with the standard diagnostic armoury. 
In this study a single CRP was checked at the time of the first ceMRI scan at a mean (SD) of 
55 (32) hours, the time point when CRP will have peaked and reached a plateau. ROC analysis 
of the total population showed that measuring CRP at this time has a diagnostic accuracy close 
to CK (AUC 0.8 vs. 0.86, Figure 5 -8). The AUC for TnI is shown for comparison and is near 
perfect at 0.98. 
An elevated CRP is a sensitive but not specific test for myocardial damage that becomes more 
discriminating as the value increases. The higher of the previously investigated CRP cut offs 
was used in the analysis. In addition the 10mg /L cut off point chosen for the initial analysis 
has been shown to be associated with hard end points and approximates the median 
(7.3mg/L) of this study population. A CRP of 10 >_ mg /L in this study population provided a 
sensitivity of 0.74 and specificity of 0.63 for the diagnosis of myocardial infarction. This does 
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not suggest that CRP should be used as an alternative to current biomarkers in the diagnosis of 
acute myocardial damage but demonstrates that CRP release is triggered by infarction. Patients 
with a high CRP have larger infarcts by TnI and DE planimetry and greater endocardial extent 
but no difference in transmurality. 
Patients with a high CRP showed a trend towards a lower mean acute ejection fraction (54 °,i° 
vs. 60.5 %) that reaches significance at 6 months (53% vs. 63 %, p= 0.001). The mean change 
in LVEF during the remodelling process showed opposite polarity in the high CRP group (- 
1.6%) to the low CRP group ( +2.9 %). In keeping with previous studies (191) there was a 
moderate negative correlation between CRP and acute left ventricular ejection fraction in 
reperfused infarcts (r= -0.49, p= 0.004). The correlation was better with LVEF at 6 months (r = 
-0.67, p <0.0001) which may explain the association with adverse outcome and improve 
identification of those higher risk patients that would benefit from intensification of 
asecondary prevention therapies. 
Using ceMRI as the gold standard for infarct size in patients with single AMI there is a 
moderate correlation with CRP in the total population (r =0.57, p <0.001), in reperfused (r =0.6, 
p <0.001) and in non -reperfused (r =0.56, p= 0.004) infarcts Figure 5 -9, Table 5 -17. 
The white cell count does not correlate with reperfused infarct size (r =0.2) but shows a 
modest but significant correlation with infarct size in the non -reperfused group (r= 0.55). The 
results in the non -reperfused infarct group are better with both markers of inflammation than 
between TnI and infarct size (r =0.39) but not significantly so (p =0.5). It appears that 
reperfusion therapy has an effect on the relationship between inflammation and myocyte 
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necrosis and a larger study group would be required to investigate whether CRP (or WCC) 
truly gives a better estimate of infarct size than TnI in the non -reperfused (NSTEMI) group of 
patients. 
The absolute reduction in median infarct size between admission and 38 days in patients with 
CRP >10mg /L was 12 g which was significantly greater than the median reduction in infarct 
size in the low CRP group, 6.5 g, p= 0.025. When the cutoff of 26 mg /L was used the 
difference in median reduction in infarct size was greater; 18.5 vs. 6 g, p= 0.013. These results 
are in keeping with the hypothesis that overestimation of infarct size in the acute phase of 
myocardial injury by ceMRI may be due to the associated inflammatory response. The early 
infarct expansion may be related to the inflammatory response in the myocardial tissue with 
oedema being the main contributor and will have settled by 38 days. The acute CRP levels 
were therefore correlated with final infarct size and there was a reduced correlation in the 
reperfused group (from r =0.6 to r= 0.4) but increased in the non -reperfused group (from 
r =0.56 to r= 0.87). It is not possible to say why this difference occurred but this polarisation 
may be influenced by different healing characteristics or inflammation associated with 
reperfusion injury. 
Seventy percent of patients with a high CRP have early MVO compared to 29 % with a low 
CRP, p= 0.011. Similarly, 47% patients with a high CRP have late MVO compared to 7% in 
the low CRP group, p =0.01. 
To investigate potential mechanisms for CRP determining cardiovascular risk in addition to 
that of TnI, the sensitivity and specificity of CRP in the diagnosis of MVO was assessed. The 
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AUC for early MVO is 0.69 and for late MVO is 0.75. Using a CRP cut off of 3 mg /L there is 
a similar sensitivity and specificity in the detection of early (0.97, 0.16) and late (1.0, 0.19) 
MVO. Using a CRP cut off of 10 mg /L there is again a similar sensitivity and specificity in the 
detection of early (0.87, 0.38) and late (0.95, 0.4) MVO. Overall there is minor loss of 
sensitivity but greatly improved specificity when using the higher cut point of 10 mg /L. It 
seems likely that use of late MVO is more robust than early MVO although they are part of the 
same spectrum of no reflow. Late MVO was therefore used in the further analysis as indicates 
a more profound level of reduced tissue perfusion demonstrated by the 11 patients that have 
early MVO that fills in by 10 minutes. 
The most reliable biomarker in the detection of late MVO was CK at a cut off of 850 IU 
(sensitivity 0.9 and specificity 0.8). A patient with a CK >850 and ACS is more than 4 times as 
likely as not to have late MVO by ceMRT. 
The next best was the ECG derived Selvester score with a cut off of 3.5 (equivalent to infarct 
size >9% LV mass) which had sensitivity of 0.75 and specificity of 0.8. 
The optimum CRP was 26mg /L with a sensitivity of 0.85 and specificity 0.66. A patient with 
symptoms of ACS who is TnI positive and has a CRP >26 is more than twice as likely to have 
microvascular obstruction. A similar result was obtained with TnI (cut off 25 ng /ml) making it 
unlikely that the risk due to a high CRP over and above TnI is due to a different frequency of 
MVO. 
Logistic regression was then performed to assess which biomarkers were the best in the 
prediction of late MVO. The only 3 left in the model were CK, CRP and Selvester score. The 
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3 patients with CRP <26 and late MVO all had a CK of above 850 IU so the combination of 
the 2 would have meant the sensitivity was 1.0. Infarct size by ceMRI was not included as it 
would not be applicable to a broader clinical population without access to ceMRI. If it were 
included then it becomes the strongest predictor of presence of MVO. It is not possible to 
control for the effects of infarct size so it may be that this is simply what CRP is measuring. 
CRP is easily and inexpensively measured and standardised high sensitivity assays are available 
commercially. The measurement of CRP will not replace TnI or CK for the diagnosis of ACS 
but has been shown in large epidemiological studies to provide additive information. Using 
ceMRI as a gold standard for infarct presence, size and MVO; a CRP > 10mg /L corresponds 
with a higher risk group and has a sensitivity of 0.74 and specificity of 0.63 in the diagnosis of 
AMI. 
CRP correlates with recognised prognostic indicators such as LV structure, function and 
infarct size regardless of acute reperfusion status. A CRP of >26 mg /L means a patient with 
ACS is more than twice as likely to have MVO and in combination with CK will correctly 
identify 88% of patients. 
The association of MVO with infarct size is so strong that it was not possible to determine if 
MVO was associated with an additional inflammatory response. It may be that CRP is the 
bridge between infarct size and morphology. 
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7.6 MMP -1 promoter polymorphisms and changes in LV 
volume following AMI 
The present data suggest that there may be an association between the MMP -1 promoter 
genotype and the risk for remodelling after AMI. It is biologically plausible that MMP -1 
promoter polymorphisms might influence remodelling. The insertion of a G nucleotide in the 
promoter region of the MMP -1 gene determines the presence of an Ets binding site, which 
increases the transcription of MMP -1 in many cell types (156). MMP -1 is the most ubiquitous 
interstitial collagenase and plays a vital role in the degradation of fibrillar collagens. These are 
the predominant structural proteins in the human myocardium (150), and collagen degradation 
is a hallmark of early remodelling. This is associated with increased myocardial expression of 
MMP -1 and its messenger ribonucleic acid, plus increases in circulating levels (153 -155). In 
addition, in a murine model, the introduction of the human MMP -1 gene results in LV dilation 
and dysfunction (151). MMP -1 polymorphisms have also been implicated in the progression of 
other disease states, particularly cancer. For example, MMP -1 is found in multiple tumor cell 
types, and several studies have suggested that the GG allele is associated with an increased risk 
for malignancy and a greater risk for invasion and metastatic spread (192). 
Patients possessing 2 GG alleles seem to be at greatly increased risk for remodelling, whereas 
heterozygotes, possessing 1 G and 1 GG allele, appear at no increased risk. This is consistent 
with previous reports. These have demonstrated a particularly large incidence of GG 
homozygotes in many tumor cell lines (157), plus an association between GG /GG genotype 
and the invasiveness of malignant melanoma and increased risk for colorectal and renal 
carcinoma (193 -195). In addition, a significant association has been demonstrated between 
MMP -1 GG /GG genotype and lung carcinoma, even after adjustment for age, gender, and 
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smoking status (196). Interestingly, the excess risk was particularly pronounced in men with 
the GG /GG genotype(196), an observation that has also been made in patients with renal 
carcinoma (195). One potential explanation may be that MMP -1 activity is inhibited by ovarian 
steroids (197). This may also partly explain why the men in this cohort with GG /GG genotype 
exhibited such marked remodelling. 
There are a number of limitations in this study including the absence of any direct evidence 
that possession of the MMP -1 GG /GG polymorphism is associated with enhanced translation 
into functional MMP -1 or increased collagenolytic activity after AMI. Likewise, there is no data 
regarding the activity of other MMPs and tissue inhibitors of metalloproteinases in this setting. 
The use of ceMRT to define LV volumes greatly reduces sample size requirements (198) but 
the small number of patients, especially homozygotes for the GG allele, limits the conclusions 
that can be drawn. This is particularly true given the unexpected finding that patients with the 
GG /GG genotype experienced greater LV dilation despite an absence of anterior AMI in this 
subgroup. Further work is required to address these important limitations and confirm an 
association between homozygosity for the MMP -1 GG allele and LV remodelling. 
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7.7 Additional findings by ceMRI 
Myocardial infarction has proved to be one of the most frequently missed clinical diagnoses in 
comparison with autopsy findings (199;200). Small subendocardial scar detected by ceMRI is 
missed by nuclear scintigraphy (71), ECG, or segmental wall motion (60) on echocardiography. 
Histopathological studies give credence to the idea that any region of myocardial scarring has 
the potential to adversely affect prognosis either by heart failure or dysrhythmias (201). 
The current tools available to the clinician looking after a patient with chest pain syndrome 
include the history and examination, ECG, TnI, echocardiography and coronary angiography. 
These methods are not able to directly visualise myocardial damage, whilst ceMRI is. 
The presence of any DE may be a marker of the burden of coronary atherosclerosis (202) that 
is the predisposing cause of acute cardiac events from a post mortem series of sudden death 
victims without known heart disease (203;204). The majority of these cases have areas of 
healed myocardial necrosis (205) that could be identified on ceMRI. 
The presence of DE is the strongest multivariable predictor of MACE and cardiac mortality 
compared with common clinical measures such as ECG and LV function. A threshold was 
demonstrated and even a small myocardial scar ( <2% LV mass) was associated with a > 7 fold 
increase in MACE (206). Thus suggesting that DE provides, "complementary and incremental 
associations with MACE and cardiac mortality beyond the currently available to clinical tools 
on the assessment of a patient with chest pain ". 
Within a group of patients admitted with first episode of chest pain 37% had a single acute MI 
by a combination of ceMRI and biomarkers. The remaining patients are at lower risk by 
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conventional measures Table 5 -1. Delayed hyperenhancement was detected in a further 18 % 
of patients. 
Acute myocarditis 
Three patients (4% of TnI positive group) that may have been incorrectly diagnosed with ACS 
by conventional diagnostic tools have been correctly identified using ceMRI. Confidence in the 
pattern of distribution of mid wall DE may in future prevent the need for inpatient 
angiography in these patients. This small series suggests that the extent of DE does reduce 
with time but is seen to persist for at least one year. The recognition of the two distributions of 
DE is useful in differentiating ischaemic form non ischaemic myocardial damage. The 
subendocardial sparing of DE is non -specific and has been described in a number of 
conditions: myocarditis(160); sarcoidosis (72); amyloidosis (207) ; dilated cardiomyopathy(202); 
hypertrophic cardiomyopathy(208); and chronic renal failure(209). Additional clinical 
information is therefore required if ceMRI suggests that there is myocardial involvement. 
Prior myocardial infarction 
Twenty (13 %) patients had evidence of previous myocardial infarction when examined using 
ceMRI; 11 were TnI positive and nine were TnI negative. 
Only 4 (20 %) patients would have been identified as prior infarction by the presence of Q 
waves confirming the lack of sensitivity of this marker. The development of Q waves requires 
a critical extent of scar (114;221) and myocyte necrosis often exists without significant Q waves 
(60;222). The reverse is also true as Q waves are known to occur in conditions other than MI 
(223 -225). Two patients that were troponin negative and DE positive had a normal ECG and 
2 met criteria for LVH, the remaining 5 had suspicious ECG patterns. The opinion of an ECG 
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core laboratory represents a lower negative ECG rate than would be achieved by the general 
physician that looks after TnI negative patients in current clinical practice. Only 1 patient 
would have been identified as prior MI by the presence of Q waves confirming the lack of 
sensitivity of this marker. 
Troponin I positive patients 
Eleven patients (14 %) from the 80 that were TnI positive had evidence of previous myocardial 
infarction when examined using ceMRI. It should be noted that all patients recruited had what 
they report as first episode of chest pain, the implication in this population is that the infarcts 
were silent, which highlights the limitations of relying on the patient history that is necessarily 
subjective. Different ceMRI sequences may assist in determining infarct age but these were not 
clinically validated at the time of the study. It may be that the presence of early MVO can assist 
in the confirmation of an infarct being <28 days old which may be of clinical use, for example 
in deciding culprit vessel for percutaneous coronary intervention. In one case the improved 
spatial resolution of ceMRI over standard transthoracic echo has identified severely thinned 
and aneurysmal segment of LV myocardium that would merit long term follow up. 
Troponin I negative patients 
Nine patients (12 %) out of the 73 with a negative TnI had evidence of prior MI by ceMRI. 
Twenty five percent of these patients underwent diagnostic coronary angiography which is a 
significantly lower proportion than is currently recommended for patients with MI. This figure 
may even be artificially elevated due to the potential influence of the ceMRI result on clinician 
decision -making. 
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Only a third of these patients with a negative troponin in the presence of DE were discharged 
on adequate secondary prevention therapy. This result raises the possibility of a potential 
forgotten population when compared to the population with single AMI where secondary 
prevention was prescribed to over 85 %. 
The second patient example showed a small subendocardial rim of DE but normal coronaries 
in a patent with severe dilated cardiomyopathy. This pattern of DE has been previously 
described in patients with DCM but usually in the mid wall. It is possible there was previous 
plaque rupture or side branch occlusion that was not distinguishable on standard coronary 
angiography. The extent of DE was small so it remains likely that the aetiology of DCM in this 
patient was alcohol. 
Silent myocardial ischaemia is defined as objective documentation of myocardial ischaemia in 
the absence of angina or angina equivalents. Since its original description in the 1970s it had 
undergone extensive investigation and the clinical significance in now well established. If an 
exercise tolerance test is performed on an asymptomatic population up to 8 % will have 
abnormal ETT and 3 % will have significant coronary disease (210;211). Post MI, the reported 
frequency of silent ischaemia is 30 - 43% and ongoing ischaemia ( silent or not) is associated 
with an increased risk of infarction and death (212). The prognosis of patients with 
unrecognised MI is comparable or worse than recognised MI (213;214). The frequency of 
myocardial scars in the PIVUS (Prospective Investigation of the Vasculature in Uppsala 
Seniors) population by ceMRI was 29% (72/248) in Swedish 70 year olds. Twenty percent 
(49/248) had unrecognised MI, 5 % (12/248) had another pattern of DE and 4% (11/248) 
had a history of MI (215). 
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There were an additional 5 patients that were TnI negative had evidence of delayed 
hyperenhancement that spared the subendocardium Prior non- ischaemic fibrosis, below. 
Therefore the incidence of myocardial fibrosis that would only be detected by ceMRI was 
25/153 (16 %) of patients admitted to hospital to rule out myocardial infarction when 
presenting for the first time with chest pain. This myocardial fibrosis will presumably carry an 
adverse prognostic risk that would otherwise be unrecognised. 
Prior non -ischaemic fibrosis 
Five patients (7 %) out of 73 that were Tn1 negative had evidence of DE that spared the 
subendocardium. In all of these patients it was localised to the basal lateral segments. These 
patients had evidence of myocardial scarring that will carry an adverse prognostic risk. Further 
work is required to investigate the implications of an incidental discovery of "non- ischaemic" 
fibrosis. It was only possible to suggest aetiology in the patient example and that was severe 
LVH (illustrated in figure 6.20). This patient had experienced a sudden death at 3 -year case 
note review. 
Minimal myocyte necrosis 
Nine patients (11 %) out of 80 that were TnI positive had no evidence of DE on ceMRI. The 
threshold TnI value of 4.4 ng /ml may be useful in refining the term ACS. It has been shown 
as that any elevation of troponin is associated with adverse risk (216 -219) and that future risk 
does relate to extent of troponin release (220). Patients that are TnI positive but DE negative 
may be used to define the group of patients with minimal myocyte necrosis described by Fox 
et al. who used an arbitrary cut off troponin T value of 1.0 for the label, "ACS with minimal 
myocyte necrosis" (168). The term "necrosette" has been used to describe those patients that 
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are CK negative but troponin positive. The serum troponin levels are only elevated for at most 
2 weeks after the acute phase of myocardial injury so ceMRI will allow the detection of small 
myocardial scar caused by subclinical coronary events out with this window. 
Two patients in this group had a CK value greater than twice upper limit of normal. One had 
Takotsubo's cardiomyopathy and the other with severe LVH. It may follow that absence of 
visible scar is associated with reduced future risk, and so improve risk stratification. There are a 
number of potentially confounding reasons for the ceMRI being false negative for DE. These 
include: the interslice gap of 2mm, patient movement (e.g. during respiration), and scan quality 
e.g. myocardium inadequately "nulled ", and artifact. Ultimately presence or absence of DE in 
this study was determined by visual inspection so misinterpretation or human error may play a 
role. This could be improved by the use of pixel intensity threshold software, an option not 
available in the unit at the time of post processing. 
On reviewing the basic clinical data (including transthoracic echo) for the patient with 
Takotsubo's cardiomyopathy the diagnosis could have been made without the use of ceMRI. 
However, ceMRI confirmed that there was no visible scarring. This case also highlights the 
benefits to patients of being part of a clinical trial with the associated increased scrutiny of 
data. 
Unstable angina 
Eleven patients (15 %) patients out of the 73 who were admitted with ischaemic chest pain and 
a normal troponin were diagnosed with unstable angina. The diagnosis in this population 
required additional objective evidence for lack of MI (absent DE) and coronary disease 
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(dynamic ST segment deviation, significant stenosis at coronary angiography (or coronary 
spasm) or positive inpatient exercise test). 
Chest pain, other 
Forty eight patients (65 %) out of the 73 patients admitted with ischaemic chest pain and a 
normal troponin had no evidence of myocardial involvement when ceMRI is used in addition 
to standard diagnostic investigations. Thirty patients (41 %) were discharged without a specific 
diagnosis, i.e. "chest pain, unknown cause ". 
They were younger and there was a higher proportion of females when compared to single 
AMI. This figure was at the lower end of the previously described spectrum ranging from 40 
(226) to 70% (227) and may have been influenced in part by the increased sensitivity of 
ceMRI in providing additional diagnostic information. 
RV infarction 
RV infarction can complicate up to half of inferior myocardial infarctions (228). RV infarction 
syndrome covers a wide spectrum of presentations and defines a higher risk population of 
patients. The diagnosis of RV infarction is largely made clinically on based on the findings of 
hypotension, a raised JVP and clear lung fields in the context of an inferior STEMI. ST 
elevation on the right sided precordial leads of an ECG will be of use if performed early 
enough. The RV is not usually adequately visualised by TTE to identify regional wall motion 
abnormality. The treatment is quite specific and contrary to standard LV infarction 
management with mainstay being fluid loading if there are no revascularisation issues. In this 
population ceMRI identified 12 patients with RV infarction accounting for 33% of all inferior 
AMIs, both STEMI and NSTEMI. RV function was reported as normal in all standard TTEs 
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that were performed as part of the post AMI protocol. CeMRI has non invasively identified an 
important complication of inferior myocardial infarction that was not apparent on routine 
TTE. Even if the condition were subclinical, closer attention to fluid balance and more 
cautious introduction of hypotensive medication would be warranted. 
LV thrombus 
Studies from the pre- and early reperfusion eras reported that LV thrombus occurred in 15 - 
56% of anterior AMIs. Contemporary studies suggest a lower overall incidence in general of 
around 4% and within the anterior AMI subgroup the incidence approaches 10% (229 -232). In 
this study of patients first presentation of chest pain the incidence of LV thrombus is 6.25% of 
all troponin positive patients. Of those with an anterior AMI the incidence rises to 19 %. These 
patients were a group with large infarcts due to occlusion of the proximal LAD. They are 
therefore a high risk group and mean LVEF was <40 %. All 5 patients underwent routine TTE 
and although the potential substrate was identified there were no confirmed sightings of 
thrombus. There is debate as to the actual incidence of embolic events but it is difficult to 
ignore once seen. Formal anticoagulation is not part of routine clinical protocol unless 
thrombus is seen. In all 5 patients a short course of warfarin was commenced based on the 
ceMRI findings and at the 6 month follow up scan no thrombus was detected. 
- 170 - 
 Conclusions 
This study has demonstrated that it is possible to perform ceMRI on patients admitted with 
chest pain within one week of admission and that it is safe to do so. 
The presenting ECG in patients with no historical or ECG evidence for previous AMI detects 
only 50% of the AMIs using the ACC /ESC STEMI criteria, but an additional 34% are 
identified by the STEMI- equivalent ST- segment depression criteria with ceMRI as the gold 
standard. 
In patients diagnosed with myocardial infarction it is possible to estimate infarct size using 
either TnI measured at 8 -12 hours following onset of chest pain or the ECG using the 
Selvester score at discharge. The addition of Selvester score to TnI improves the correlation 
with ceMRl derived AMI size in reperfused infarcts (STEMI). 
The correlation of infarct size by TnI or Selvester score shows a trend to improvement when 
compared to ceMRI performed mean 38 days after AMI. This may be a more reliable time 
point at which to measure infarct size by planimetry if this is to be used as a surrogate end 
point in future studies. 
Ten percent of patients that were TnI positive had a normal coronary angiogram, 88% of 
whom had DE. 37% these patients with DE had subendocardial sparing suggesting acute 
myocarditis. 
A natural history of infarct evolution is described for patients that received urgent reperfusion 
therapy (S'l'EMI) and those who did not (NSTEMI). There is a mean reduction in infarct size 
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of 35 "'o that predominantly occurs between admission and a mean of 38 days. The rate of 
change in infarct size remains stable thereafter to 1 year and final reduction in infarct size is 
400 /o. The presence of late MVO is associated with a greater absolute reduction in infarct size 
and an increase in LV dimensions. 
CRP provides information that is comparable to CK in the diagnosis of AMI and has a 
moderate correlation with acute infarct size regardless of acute reperfusion status and with LV 
ejection fraction at 6 months. CRP has a modest sensitivity and specificity for the detection of 
MVO. A patient with ACS and a CRP of >26 mg /L is more than twice as likely to have MVO 
and in combination with CK of ? 850 IU /ml will correctly identify 88% of patients. 
Patients possessing 2 GG alleles in the MMP -1 promoter sequence were at increased risk for 
remodelling compared with homozygotes for the G allele and heterozygotes possessing 1 G 
and 1 GG allele. 
Thirty seven percent of patients with first hospital admission with chest pain had a single AMI 
by a combination of bioelectrical, biochemical and biomagnetic markers. A further 16% had 
evidence of previous myocardial scarring in the absence of prior significant, recognisable 
symptoms. Nine percent of TnI positive patients had no evidence of myocardial scar by 
ceMRI. Additional findings included RV infarction in 8 %, LV thrombus in 3% and acute 
myocarditis in 2 %. 
This thesis illustrates that advanced imaging of a broad population using ceMRI can improve 
the diagnostic yield of acute and prior myocardial scarring due to ischaemic or non ischaemic 
aetiology. Infarct size can be estimated using biomarkers of myocyte necrosis and 
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inflammation together with bioelectrical markers. In terms of infarct size the dichotomy 
between STEMI and NSTEMI is artificial and there is considerable overlap between the 2 
groups and Figure 8 -1 demonstrates that infarct size is a continuum. Further work is required 
to identify the characteristics of patients presenting with NSTEMI, such as ST deviation, who 
would derive similar benefit from an early reperfusion strategy rather than being treated 
conservatively with at most aspirin, clopidogrel and heparin on a medical ward. 
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Figure 8 -1: Ranked infarct sizes for each patient 
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9 Further studies 
The advocation of the routine use of ceMRI in patients admitted with chest pain should be 
further investigated with larger studies to identify the potential forgotten population of patients 
with missed prior or mis- labeled myocardial infarction that will provide both prognostic and 
cost effective information. 
To refine immediate risk stratification by the ECG on presentation the contribution of an 
increase in the number of leads and /or electrodes, T -wave changes, and ST- segment changes 
appearing in serial ECG recordings should be investigated. Addition of selected leads such as 
V4R, V7, or V8 (233) or multi -lead body surface maps (234) have been shown to increase 
sensitivity. However, the ability to increase sensitivity via additional electrodes must be 
confirmed when "ST- segment deviation" replaces "ST segment elevation" in AMI criteria for 
the standard 12 -lead ECG. 
The use of CRP in the detection of microvascular obstruction requires further investigation, in 
particular to investigate the role of inflammation in MVO and to test if anti -inflammatory 
therapies are effective. 
Further investigation into the international reproducibility of the DE image acquisition and 
analysis are ongoing. 
Continued work with biomarkers will include investigations into NtBNP and infarct size/ 
characteristics and LV remodeling. In addition the analysis of troponin degradation products 
will be assessed as a means of predicting hibernating or stunned myocardium and MVO (235). 
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10 Study Limitations 
This study is limited to the population of patients with their first episode of chest pain, who 
have been deemed to be at enough risk to merit hospital admission. The patients had to be 
clinically stable following initial treatment and motivated enough to participate in a study that 
involved an hour long ceMRI scan. The application to a broader population therefore needs to 
be assumed with consideration. 
Using single observer image analysis for the gold standard of infarct size was not ideal but 
necessary. Any subjective difficulties of image interpretation were settled by arbitration (BAG). 
A complete ceMRI assessment of a patient with ischaemic heart disease would require more 
information on viability and myocardial perfusion particularly in those patients that were 
delayed enhancement negative. 
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12.2 Information sheet for patients/ volunteers in clinical 
research project 
THIS SHEET HAS BEEN APPROVED BY THE WEST ETHICS COMMITTEE 
INFORMATION SHEET FOR PATIENTS /VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
Patient's Summary 
The Role of Cardiac magnetic Resonance Imaging (CMR) in ACS (ACS) 
We would like to invite you to take part in a study to assess the role of a special scan called Cardiac Magnetic 
Resonance Imaging (CMR) with an injection of dye (contrast) called gadolinium in the diagnosis of Acute 
Coronary Syndromes (ACS). ACS is a new term that includes a range of heart muscle damage from angina to a 
heart attack. You have been invited to take part in this study because it is the first time you have been admitted to 
hospital with chest pain, which is suspected to have come from the heart. 
CMR is a new type of scan that does not rely on radiation to create the pictures. The machine is shaped like a 
large tunnel and open at both ends. The scanner contains the magnet, which enables the images of your heart to 
be obtained. 5% of patients do not wish to enter the scan because they don't like confined spaces 
(claustrophobia). 
Gadolinium looks clear like water, is non -radioactive and is many times safer than the iodine type contrast used 
in X -Ray scans. After it is injected into a vein, gadolinium accumulates in the abnormal tissue and these areas 
become very bright (enhanced), it is then rapidly cleared from the body by the kidneys. A few side effects, such 
as headache, nausea, light headedness and local burning can occur. Ven rarely (less than one in a hundred 
thousand), patients are allergic to gadolinium when they develop a rash and/ or swollen lips. If this occurs you 
will be assessed by the doctor supervising the scan, or if you have left the hospital contact your GP. 
On arrival at the Clinical Research Initiative (CRI) a radiographer will go through a safety checklist and make 
sure that all magnetic have you 
asked to sign the consent form. Once you have changed into a hospital gown you will then be asked to lie flat 
on the bed that will move into the scanner. A small plastic cannula (similar to that used when putting up a drip) 
will be inserted into your vein to allow us to take a blood sample and give you the gadolinium. A doctor will 
insert the cannula and 30 mis of blood (about 3 tablespoonfuls) will be taken. This blood will be used to check 
your liver and kidney function and to detect the concentration of a substance called BNP (a measure of how 
well your heart pumps). You will need to wear a pair of headphones, allowing you to listen to music of your 
choice (you are welcome to bring your own CD) and to allow us to communicate with you throughout the scan. 
The headphones are also necessary because of the loud knocking noise that occurs when the pictures are being 
taken. You will be given an emergency buzzer and very quickly taken out of the scanner should it be necessary. 
During the scan you will asked to hold your breath for about 8 seconds, on separate occasions to improve the 
quality of the pictures. The scan will last approximately 45 minutes. 
You will be invited to return to the Western Infirmary on 3 further occasions. After 4 weeks, 6 months and 1 
year for a clinical assessment, repeat scan and further blood tests. Each visit will last approximately 1 hour and 
will take place in the (CRI) located on level 4 of the Western Infirmary, Glasgow. 
You are not obliged to take part in the current study but if you do decide to take part then you will be asked to 
give your written consent. If you do not wish to participate then your care will not be affected in any way. You 
may withdraw from the study at any time. Your GP will be informed of your participation in the study. If you 
are, or are likely to be, pregnant then we advise that you do not take part in the study. It should be noted that 
your participation may not be of direct benefit to you, but could help in the development of diagnostic tests and 
treatments for the benefit of future patients. We may from time to time wish to obtain information from your 
hospital medical notes and we therefore ask you to release this on the understanding that, like any other details, it 
will be kept confidential. If you have any questions or concerns about this study please contact Professor Dargie 
or Dr Thomas Martin at 0141 211 8527. 
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WEST ETHICS COMMITTEE 
FORM OF CONSENT FOR PATIENTS /VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
Title of Project: 
The Role of Cardiac magnetic Resonance Imaging (CMR) in ACS 
By signing this form you give consent to your participation in the project whose title is at the top of this page. 
You should have been given a complete explanation of the project to your satisfaction and have been given the 
opportunity to ask questions. You should have been given a copy of the patient information sheet approved by 
the West Ethics Committee to read and to keep. Even though you have agreed to take part in the research 
procedures you may withdraw this consent at any time without the need to explain why and without any 




give my consent to the research procedures above, the nature, purpose and possible consequences of which have 
been described to me 
by 
Patient's signature Date 
Doctor's signature 
- 199 - 
12.3 Personal Health Record 
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12.4 MRI safety Questionnaire 
CRI MRI UNIT 




Date of Birth: 
ti33SFt.rIR: 
Date of Scan: 
Referring Clinician: 
Location: 
Weight (kg): Heig.}d (gJc : 
SAFETY QUESTIONS 
Have they: 
A cardiac paaanoker 
An artificial heart valve 
An aneurysm clip 
A bladder implant 
An ear implant 
A pain relief implant 
A time release drug dispenser 
An eye prostheses 
Any other implants 
Have they eser: 
Done welding or grinding? 
Had metal enter their bodies 
Had heart trouble? 
Had on operation en their head? 
Had any artificial joints or screws or 
km or plates for broken bones? 




Any dentures or hearing aids? 
Any hai rclips and jewellery? 
Any tattoos or permanent makeup? 
Any body piercing? 
Any hairpieces? 
Removed their watch, credit cards and 
moo their pockets? 
Ladies only: 
Could you be pregnant or breast feeding' 
Have you been sterilised or have you 
2Lt IUD fitted ? 
Do you have asthma lygyfgm or any 
g gggtqsg that you know of? 
YES NO 
I oamfum that the answers to the above safety questions are coned 
I also confirm Brat I amas accept a contrast agent injection if oequixed. 
Signature of patiedig.glkar_t 
*Patient only ifose:1ó 
Dale I 
Signature of Authorised Scanning Staff Member 
If the patient is canatose, young or ggt,{i,gyi,;, 
(we you confirmed with the Supervising Radiologist that they are safe to image? (please ring) YES NO 
If the patient is unable to sign please state why. 
The Superveing Clinician should countersign hero if no clear history of implants or operations, can be obtained. 
Note the implant or operation here: 
The Supervising Clinician should sign here if they now 
consider the scan to be completely safe. 
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12.5 AHA/ ESC 17 segment model used to determine infarct 
location 
nrqtlrxar 








Short Axis (SA) 
- 203 - 
Apex 
Horizontal 




Long Axis (VLA) 
(2 Chamber) 
12.6 Abstracts from this thesis 
Infarct imaging in a single heart beat: Could LESS be more? 
\ larcin TN, Grocnning BA, Chung YC, Steedman T, Foster JE, Elliott iAT, Dargie HJ 
.-1m Coll Cardiol. 2003 Mar 19;41(6 Suppl B):450 
A single troponin I concentration measured 12 hours after onset of chest 
pain accurately reflects infarct size as measured by gadolinium -DTPA late 
enhancement magnetic resonance imaging 
Martin TN, Grocnning BA, Steedman T, Foster JE, Elliott AT, Dargie HJ. 
J .Am Coll Cardiol. 2003 Mar 19;41(6 Suppl B):380 -1 
Validation of the 12 -lead admission ECG in patients with acute chest pain 
for diagnosis of myocardial infarction by late contrast enhanced magnetic 
resonance imaging. 
Martin TN, Wagner GS, Steedman T, Foster JE, Elliott AT, Dargie HJ, Groenning BA. 
Eur Heart J 2003;8 (abstr.suppl.):92 
Validation of the ECG Selvester Score for assessment of infarct size by late 
contrast enhanced magnetic resonance imaging 
Thomas Martin, Bjoern Groenning, Galen Wagner, Tracey Steedman, John Foster, Alex 
Elliott, Henry Dargie 
Society of Cardiovascular Magnetic Resonance Imaging. J Cardiovasc Magn Res 2003 
- 204 - 
Usefulness of CRP in detecting higher risk patterns of myocardial 
infarction defined by contrast enhanced magnetic resonance imaging 
Thomas N. Martin, Navccd Sattar, Robin Weir, Simon Martin, Nirosha Gunitillake, Charles 
Maynard, _Andrew Flapan, Henry Dargic. 
:American College of Cardiology, March 2008. 
The detection of myocardial scar by ceMRI in patients with Tnl positive 
chest pain and minimal angiographic coronary artery disease 
Thomas N. Martin, Galen Wagner, Bjoern Groenning, Robin Weir, Andrew Flapan, Henry 
Dargic. 
Society of Cardiovasacular Magnetic Resonance imaging, eb 2008.3 Cardiovasc Magn Res 
2008 Feb 
Validation of electrocardiographic and biochemical estimates of first acute 
myocardial infarct size using cardiac magnetic resonance imaging 
Thomas N. Martin, Galen Wagner, Allan Pettigrew, Bjoern Groenning, Robin Weir, Charles 
Maynard, Andrew Flapan, Henry Dargie. 
British Cardiac Societe, )une 2008 
- 205 - 
12.7 Full publications from this thesis 
ST- deviation analysis of the admission 12 -lead ECG as an aid to early 
diagnosis of acute myocardial infarction using a cardiac magnetic 
resonance imaging gold standard 
Thomas N Martin, Bjoern .A Grocnning, Heather \1 Nlurray, Tracey Steedman, John E Foster, 
Alex T Elliot, Henry J Dargie Ron Selvester, 011e Pahlm, Galen Wagner . 
J ,Am Coll Cardiol. 2007 Sep 11;50 (11):1021 -8. 
Myocardial infarct quantification: is magnetic resonance imaging ready to 
serve as a gold standard for electrocardiography? 
Engblom H, ,Anceden H, Foster J 1, A fartin TN. 
J Electlocardiol. 2007 Ju1;40(3):243-5. 
Diagnosing Acute Myocarditis using Cardiac Magnetic Resonance Imaging 
Thomas N Martin, Bjoern Groenning and Henry] Dargie 
Eur Heart J.2006 Feb;27(4):468 
Matrix Metalloproteinase -1 Promoter Polymorphisms and changes in Left 
Ventricular Volume following Acute Myocardial Infarction 
Thomas N. Martin, Dawn E. Penney, Jamie A Smith, Bjoern À. Groenning, Henry] Dargie, 
Graham S. Hillis. 
Am J Cardiol. 2004 Oct 15;94(8):1044 -6 
- 206 - 
